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The purpose of this dissertation was to use the theory of planned behavior (TPB) 
to predict Texas pharmacists‘ intention to report serious adverse drug effects (ADEs) to 
the Food and Drug Administration (FDA). The study explored the utility of the TPB 
model constructs (attitude [A], subjective norm [SN], perceived behavioral control 
[PBC]), as well as past reporting behavior (PRB), and perceived moral obligation (PMO) 
to predict pharmacists‘ intention to report serious ADEs to the FDA. The study also 
determined if the pharmacists‘ A, SN and PBC were related to practice characteristics 
and demographic factors.  
A survey was developed based on two focus group interviews, pretested and 
mailed to 1,500 Texas practicing pharmacists. An overall response rate of 26.4 percent 
was obtained (n = 377 pharmacists). Overall, pharmacists intended to report serious 
ADEs, had a favorable attitude towards reporting, were somewhat influenced by social 
norms regarding reporting and perceived themselves to have some control over reporting 
 viii 
serious ADEs to the FDA. For direct measures, A and SN were significant predictors of 
intention to report serious ADEs, but PBC was not. The TPB constructs together 
accounted for 34.0 percent of the variance in intention to report serious ADEs to the 
FDA. Using indirect measures, A, SN and PBC were significant predictors of intention 
and together accounted for 28.8 percent of the variance in intention to report serious 
ADEs. PRB and PMO improved the explanatory power of the regression models (direct 
and indirect measures) over and above the TPB constructs. Unlike most other practice 
characteristics and demographic factors examined, knowledge was significantly related 
with the TPB constructs.   
In summary, A, SN, PBC (indirect measures), PRB, and PMO influence the 
formation of pharmacists‘ intention to report serious ADEs. The TPB has utility in 
predicting ADE reporting behavior. Pharmacy educators should explore pharmacists‘ 
attitudes, beliefs, and expectations of important others in designing educational programs. 
Strategies to help pharmacists report more serious ADEs should focus on altering their 
perception of social pressure towards reporting and addressing the barriers towards ADE 
reporting (e.g., lack of knowledge).  
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CHAPTER ONE: INTRODUCTION 
1.1 BACKGROUND  
Although patients expect positive health outcomes from the health system, 
healthcare interventions including medicines can also cause significant patient harm 
(Institute of Medicine Report, 2001). Medical practice is potentially dangerous and 
inherently unsafe (Chantler, 1999). Many people are unintentionally harmed by 
treatments and in the process of being treated (Institute of Medicine of the National 
Academies, 2007b; Sandars, 2007; Vincent et al., 2006).  Healthcare lags behind other 
high risk industries on safety. The use of medicines is associated with risks, hazards and 
adverse outcomes (adverse events) that compromise patient safety. These drug-related 
injuries occur for various reasons including lack of patient compliance, inadequate initial 
testing, poor postmarketing surveillance and prescribing errors (Moore, Psaty, & Furberg, 
1998).  
Drug-related injuries or adverse drug events (ADEs) are common and account for 
about 20 percent (range: 1.5% to 35%) of hazards related to the medication use process in 
hospitalized patients (Bates et al., 1995b; Brennan et al., 1991; Leape et al., 1991). The 
Food and Drug Administration (FDA) defines an ADE as any adverse event that is 
associated with the use of a drug whether or not that event is considered drug-related. 
Common ADEs include failure of expected pharmacologic action, drug abuse, drug 
withdrawal and overdoses (accidental or intentional) (Trontell, 2001). A serious adverse 
event is defined as any event that is fatal, life threatening, is permanently/significantly 
disabling, requires or prolongs hospitalization, causes a congenital anomaly and requires 
intervention to prevent permanent impairment or damage. In the United States (U.S.), 
about 1.5 million people are injured by prescription drugs annually (Institute of Medicine 
of the National Academies, 2007b). Some of these people are hospitalized and 
approximately 100,000 die as a result of these injuries (Institute of Medicine Report, 
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2001). In the U.S., ADEs are the 4
th
 leading cause of death; more people die from ADEs 
than from pulmonary disease, diabetes, AIDS, pneumonia, accidents and automobile 
deaths (FDA/Center for Drug Evaluation and Research, 2002). 
An important ADE is the adverse drug reaction (ADR) accounting for an 
estimated 7,000 deaths annually (Institute of Medicine, 2000). The incidence of ADRs is 
high among hospital patients, an estimated 6.7 percent of whom have serious ADRs 
(Lazarou, Pomeranz, & Corey, 1998). These figures do not include ADRs occurring in 
ambulatory settings and those occurring in nursing homes (over 300,000 annually) 
(Gurwitz et al., 2000).   
Drug-related injuries are the most frequent cause of procedure-related malpractice 
claims (National Association of Insurance Commissioners, 1980). An estimated three (3) 
to eight (8) percent of hospital admissions in internal medicine are related to ADEs 
(Einarson, 1993). ADEs compromise patient safety and are a considerable public health 
problem. ADEs are the most common threat to patient safety in secondary care (Sandars, 
2007). In addition, ADEs account for a significant part of healthcare expenditures and 
costs. In 1995, the cost of drug-related morbidity and mortality in the ambulatory care 
was estimated to be $76.6 (range: $30.1 – $136.6) billion annually in the U.S. (Johnson & 
Bootman, 1995). In 2001, the cost of drug-related morbidity and mortality was estimated 
to exceed $177.4 billion, more than double the 1995 estimate (Ernst & Grizzle, 2001). 
Many patients‘ hospital and doctor visits are attributable to ADEs (20%) (Leape et al., 
1991). ADEs also increase patients‘ hospital stay.   
Because of the significant health and economic costs associated with ADEs, 
regulatory authorities invest significantly (e.g., staff and resources) in evaluating the risks 
of treatments and in monitoring the safety of drugs throughout the lifetime of their use. 
This occurs mainly through pharmacovigilance and postmarketing surveillance (PMS). 
PMS, the continuous safety monitoring of all drugs, plays a critical role in drug safety 
and drug therapy decision-making. PMS monitors drug safety through collecting and 
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analyzing voluntary spontaneous reports submitted by healthcare professionals (HCPs), 
pharmaceutical companies and patients. HCPs are encouraged to voluntarily report ADEs 
(mostly suspected ADEs) to drug regulatory authorities or programs (Belton & The 
European Pharmacovigilance Research Group, 1997). Voluntary spontaneous reporting is 
the primary and most common method of pharmacovigilance or PMS (Ahmad, 2003; 
Lexchin, 2006; Rawlins, 1988a, 1988b; Strom, 2004; Wysowski & Swartz, 2005). 
Voluntary reporting of ADEs through spontaneous reporting systems (SRSs) is an 
important component of any comprehensive surveillance program of risks induced by 
drug use.  
Voluntary ADE reporting by HCPs is widely accepted and is considered standard 
practice in many countries. SRSs are simple to operate, relatively inexpensive, 
comprehensive (i.e., cover all drugs and entire patient population) and are not intrusive 
(Cosentino, Leoni, Banfi, Lecchini, & Frigo, 1997). SRSs are the best and most common 
method for identifying and highlighting new and rare ADEs and the factors predisposing 
patients to ADEs (Bates et al., 1997; Classen, Pestotnik, Evans, Lloyd, & Burke, 1997; 
Rawlins, 1988b). Data gathered through such schemes make a priceless contribution to 
patient safety and facilitate improved understanding of the benefits and risks of drugs. 
This information is valuable for drug manufacturers (useful in modifying product 
information, warnings, and the product or its use and withdrawing the product from the 
market), patients (identify risks and prompt discussion about these risks with their HCPs) 
and HCPs including pharmacists (make better clinical decisions). SRSs provide valuable 
feedback to manufacturers, practitioners and their patients on medicines that have 
problems (Edgar, Lee, & Cousins, 1994). Thus, ADE reporting helps minimize injury due 
to drugs, improves risk management and quality of care and informs prevention efforts 
(Barwick, 1996; Solberg, Moaser, & McDonald, 1997). Also, the existence of SRSs 
reinforces the importance of drug safety issues to HCPs. To date there is no real 
substitute for it. 
 4 
HCPs, including pharmacists, can play an important role in improving the safety 
of treatments through reporting ADEs. The success of pharmacovigilance programs 
requires the participation and support of pharmacists. Findings from previous studies 
show that HCPs have favorable beliefs and opinions concerning ADE reporting (Lawton 
& Parker, 2002; McArdle, Burns, & Ireland, 2003; Uribe, Schweikgart, Pathak, Marsch, 
& Fraley, 2002). In addition, subjective norm supporting ADE reporting and strong 
perceived behavioral control (PBC) may be positive and significant predictors of 
intention to report ADEs.  
 
1.2 ADE REPORTING IN THE U.S. AND STATEMENT OF THE PROBLEM 
Formal ADE reporting has a long history in the U.S., dating back to 1969. 
Pharmacovigilance in the U.S. is spearheaded by the FDA, an agency of the Department 
of Human and Health Services. In addition to approving drugs, the FDA‘s Center for 
Drug Evaluation and Research (CDER) is responsible for monitoring the safety of all 
marketed drugs. Physicians, pharmacists, dentists, nurses and consumers in the U.S. are 
encouraged to report serious ADEs they encounter to the FDA. The submitted reports are 
stored and analyzed in the adverse event reporting system (AERS) database. The AERS 
database is maintained by the CDER‘s Office of Surveillance and Epidemiology (OSE), 
formerly known as the Office of Drug Safety. The AERS is the cornerstone of the FDA‘s 
drug PMS activities. The database has over 2 million reports of ADEs and is the world‘s 
largest (Moore, Cohen, & Furberg, 2007). In 1993, the FDA‘s ADE reporting system was 
renamed MedWatch. MedWatch facilitates the reporting of serious ADEs, product 
quality problems (e.g., device malfunctions, labeling concerns, suspected counterfeit 
products, product contamination, poor packaging, and therapeutic failure) and medication 
and device use errors.  
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On average, the FDA receives approximately 250,000 reports of adverse events 
annually (Ahmad, 2003). Most (80%) of the HCPs‘ reports are submitted to the FDA 
through pharmaceutical companies and approximately 20 percent of the reports go 
directly to the FDA through MedWatch. Compared to other HCPs in the U.S., 
pharmacists submit the greatest number of reports to the FDA. In 2001, pharmacists 
submitted 41 percent of the reports made by individuals. The rest of the reports were 
made by physicians (11%), nurses (11%), other health care professionals (11%), 
unknown (18%), and consumers (8%) (Cobert, 2007; Office of Drug Safety, 2001).  
Notwithstanding the many advantages of ADE reporting, underreporting by 
HCPs, including pharmacists, is a major problem (Cullen et al., 1995; Lawton & Parker, 
2002), occurring at a rate of 50 to 96 percent annually in the U.S. (Barach & Smith, 
2000). It has also been estimated that less than 1 percent of serious adverse events are 
reported to the FDA (Scott et al., 1987). Underreporting reduces the effectiveness and 
benefits of SRSs (Fontanarosa, Rennie, & DeAngelis, 2004; Hazell & Shakir, 2006).  
There are many factors that affect the reporting of ADEs by HCPs (including 
pharmacists). These include reluctance to send reports based on mere suspicion, fear of 
personal repercussions, sense of professional responsibility, difficulty in accessing the 
means of reporting, lack of information, the type and nature of the ADE, attention drawn 
to a particular drug and ADE, beliefs and opinions and ‗lack of time‘ among others 
(Vallano et al., 2005; Wakefield et al., 1999). In addition, underreporting by pharmacists 
may be explained by their attitude toward ADE reporting.  
No known studies have evaluated the U.S. pharmacists‘ beliefs and attitudes 
concerning ADE reporting using a theoretical framework. Thus, little is known about 
pharmacists‘ attitudes or intentions to report serious ADEs.  
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1.3 PURPOSE OF THE STUDY 
The purpose of the study is to explore the predictive utility of the theory of 
planned behavior (TPB) in understanding Texas pharmacists‘ intentions to report serious 
ADEs.  The study also identifies and examines the factors affecting Texas pharmacists‘ 
beliefs (attitude, subjective norm and perceived behavioral control) toward reporting 
serious ADEs using the TPB model. 
 
1.4 THE THEORY OF PLANNED BEHAVIOR 
 The theory of planned behavior (TPB) is an extension of the theory of reasoned 
action (TRA) (Ajzen, 1991; Ajzen & Fishbein, 1980). The TPB is the most widely used 
social cognition theory for predicting human behavior (Hardeman et al., 2002). Over 600 
empirical studies have predicted behavior and behavioral change using the TPB in the 
past two decades (Francis et al., 2004). The theory stipulates that behavior is predicted by 
behavioral intention. Behavioral intention is in turn predicted by attitude, subjective norm 
and perceived behavioral control. The TPB has been successfully used to predict the 
intentions and behaviors of patients and healthcare professionals (Armitage & Conner, 
2001; Godin, Belanger-Gravel, Eccles, & Grimshaw, 2008; Sheppard, Hartwick, & 
Warshaw, 1988). Many studies found attitude, subjective norm and perceived behavioral 
control to be reliable predictors of intentions to perform health-related behaviors 
(Armitage & Conner, 2001; Godin et al., 2008; Godin & Kok, 1996). Many theory-
guided health interventions have been successfully implemented using the TPB 
framework (Valois, Turgeon, Godin, Blondeau, & Cote, 2001; Walker, Grimshaw, & 
Armstrong, 2001; Walker, Watson, Grimshaw, & Bond, 2004). 
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1.5 IMPORTANCE OF THE STUDY 
Pharmacists have the opportunity and responsibility to promote safe and effective 
use of medications. Their actions with respect to identifying and reporting serious ADEs 
is one way they can do so effectively.  The literature lacks information that addresses 
pharmacists‘ attitude, subjective norm and perceived behavioral control concerning ADE 
reporting. Policy makers, public health officials and regulatory agencies need this critical 
information in order to improve medication safety. In addition, continuing education 
(CE) programs need this information in order to better design and target their 
interventions to meet the needs of pharmacists, to increase their willingness to report 
serious ADEs, and thus better serve the community. 
Once the pharmacists‘ beliefs are identified, the next step is to use them to 
develop appropriate interventions. The long-term goal is to facilitate pharmacists‘ 
education and monitoring activities and to promote the safe and appropriate use of 
medications in Texas, U.S. 
Taken together, the findings of this study will contribute to the extant literature by 
identifying modifiable factors and processes for increasing the pharmacists‘ reporting of 
serious ADEs. This data can be used to inform strategies to improve the safety of 
treatments and the medication use processes. 
 
1.6 OVERVIEW OF THE STUDY 
This dissertation will consist of six chapters and appendices. This chapter 
provides an overview of the study: background, ADE reporting in the U.S., statement of 
the problem and the purpose and importance of the study.  Chapter Two will present a 
summary of the current literature on patient safety, pharmacovigilance, HCPs‘ 
perceptions about ADE reporting, and pharmacists‘ beliefs concerning ADE reporting. 
Chapter Three will discuss the research model to be used in the study as well as the study 
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hypotheses. The study will be based on the TPB model. Chapter Four will present the 
research methodology of the study and Chapter Five will detail the main study findings or 
results. The last chapter, Chapter Six, will present a discussion of the study findings, 
recommendations based on findings, limitations of the study and conclusions of the 
research. It will also provide the implications for future research.  
 
 9 
 CHAPTER TWO: LITERATURE REVIEW 
 
It may seem a strange principle to enunciate as the very first requirement in a hospital 
that it should do the sick no harm (Nightingale 1863). 
 
2.1 HEALTHCARE AND MEDICATION USE 
Medical care has grown in scope and complexity over the years. There has been a 
marked increase in the number and types of medical treatments (e.g., medicines and 
hospital beds) and diagnostic procedures. Healthcare interventions and procedures 
promote health by preventing, managing and treating diseases. When used appropriately, 
healthcare interventions and products (including pharmaceuticals) save lives and improve 
quality of life. Healthcare is an integral part of life and is the largest industry1 in the 
United States (U.S.), accounting for 16 percent of the Gross Domestic Product (GDP) 
(Borger et al., 2006; Zuvekas & Cohen, 2007).  
Drug therapy is one of the most widely used interventions in healthcare (Kohn, 
2001). About a third of the U.S. population takes at least five different medications in a 
day. More than 80 percent of U.S. adults take at least one medication, vitamin/mineral, or 
herbal supplement per week (Institute of Medicine of the National Academies, 2007b). 
Forty four percent (44%) of the U.S. population take at least one prescription drug in any 
given month (National Center for Health Statistics, 2004). Prescription drug use per 
capita is high and is expected to increase owing to the growing population, changing age 
structure of the population and increasing prevalence of chronic diseases, human 
immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) and other 
infectious diseases. According to the Henry J. Kaiser Family Foundation, an average 
                                                 
1 In 2006, total estimated spending on healthcare was $2.2 trillion. The share of the gross domestic product 
(GDP) accounted for by health is projected to rise to 20 percent in 2015 (Borger et al., 2006). 
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American took 12.6 prescriptions in 2007 (Lundy, 2008). In Texas, the per capita retail 
prescription drugs filled at pharmacies in 2008 was 10.8 (The Henry J. Kaiser Family 
Foundation, 2008). Other states have higher figures: West Virginia = 18.7 percent, 
Arkansas = 17.5 percent, South Carolina = 17.4 percent and Alabama = 17.2 percent (The 
Henry J. Kaiser Family Foundation, 2008).  
Pharmaceuticals contribute significantly towards the health and well-being of 
society. Vaccines have vanquished killer diseases like polio and measles. Medicines 
provide effective cures (e.g., antibiotics), stave off death, and relieve suffering (e.g., pain 
and disabilities) (Farley & Cohen, 2005) and have eliminated the need for surgery in 
some cases. Medicines have also eliminated or reduced the need for institutionalization 
for some patient populations (McKinnell & Kador, 2005). However, medical science—
characterized by constant change in knowledge and uncertainty of information—is far 
from being perfect. As a people-driven and people-centered business, healthcare is prone 
to human error (Al-Assaf, Bumpus, Carter, & Dixon, 2003) and all medical professionals 
are fallible (Esmail, 2006). As a consequence, medical practice is potentially dangerous 
and unsafe (Chantler, 1999).  
 
2.2 PATIENT AND DRUG SAFETY 
Health interventions should not only be effective, efficient, patient-centered, 
timely and affordable, but they should also be safe (Institute of Medicine Report, 2001). 
Although patients expect positive health outcomes from the health system, healthcare 
(including medicines) causes significant patient harm, ranging from short-term illness to 
permanent disability or death (Institute of Medicine, 2000; Institute of Medicine Report, 
2001). Modern medicine‘s products and procedures cannot always be used harmlessly 
(Schimmel, 1964). Patients are harmed by treatments and in the process of being treated 
via three main ways: lethal/dangerous treatments, errors, and unintended consequences 
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(Institute of Medicine of the National Academies, 2007b; Sandars, 2007; Sharpe & 
Faden, 1998; Vincent, 2006). Healthcare interventions (including drugs) can produce 
unwanted adverse effects (Edwards & Aronson, 2000). ―New innovations bring new 
risks, greater power brings greater possibility of harm and new technology offers new 
possibilities for unforeseen outcomes and lethal hazards‖ (Vincent, 2006, p. 2). The 
occurrence of these risks, unforeseen outcomes (adverse events), errors and hazards in the 
health system compromise patient safety (Institute of Medicine of the National 
Academies, 2007b). Patient safety is not synonymous with absence of errors or harm. 
Patient safety is attained when mistakes are reduced to the minimum humanly possible 
(Al-Assaf et al., 2003) and the instances in which an error harms a patient are minimized 
(Nolan, 2000).  
Notable patient safety improvements have been seen over the years partly spurred 
by litigation and the need to avoid the high cost of dealing with the consequences of 
negligently inflicted injuries (Jones, 2006). In the U.S. and United Kingdom (U.K.), 
patient safety issues received considerable attention from the landmark publications: 1) 
To Err is Human: Building a Safer Health System, 2) Building a Safer NHS for Patients: 
Improving Medication Safety and 3) A Spoonful of Sugar: Medicines Management in the 
NHS Hospitals (Audit Commission, 2001; Department of Health, 2001; Institute of 
Medicine, 2000). The publication of the U.S. Institute of Medicine‘s 1999 report To Err 
is Human is considered to be the single most important spur to the development of patient 
safety initiatives. In addition, the media has featured reports of dangerous doctors and 
killer medicines, thus further heightening public awareness of the dangers of modern 
medicine (Walshe & Boaden, 2006). Notwithstanding these efforts and initiatives, 
healthcare still lags far behind other high-risk industries in its attention to patient safety. 
There is little emphasis on patient safety and more could be done to reduce or prevent 
harm (Al-Assaf et al., 2003).  
 12 
Many problems that compromise the quality of health care systems and patient 
safety are associated with the use of medicines and are referred to as drug safety (Walshe, 
Bennett, & Ingram, 1995). Given that every medicine carries some degree of risk even 
when it is used correctly, drug safety is relative and involves weighing the benefits and 
risks of drugs. Safe drugs are those whose benefits outweigh their risks for the intended 
use and for the population the drug is intended to treat (Meadows, 2002). Only drugs that 
are deemed to be safe (benefits > risks) are approved for marketing. Thus, safe medicines 
are not necessarily harmless. 
Regulatory agencies and pharmaceutical manufacturers are constantly grappling 
with safety concerns about approved drugs that are increasingly attracting media 
attention. The harm or risk associated with medicines is a cause for concern and has 
become a major public health issue worldwide (Institute of Medicine, 2000; Vincent, 
2006). The risks associated with drugs manifest mainly in the form of medication errors 
and adverse drug events (ADEs) including adverse drug reactions (ADRs)2.  
 
2.3 RELATIONSHIP BETWEEN MEDICATION ERRORS, ADES AND ADRS 
Medication errors, ADEs and ADRs are hazards or irregularities related to the 
medication use process (Manasse, 1989), and are collectively referred to as incidents or 
medication misadventures (American Journal of Health-System Pharmacy, 1998; 
Morimoto, Gandhi, Seger, Hsieh, & Bates, 2004). Researchers may prefer to use the 
terms incidents and medication misadventures to refer to medication errors, for example, 
because they are less judgmental.  Incidents and misadventures are ‗catch all‘ terms and 
are often used before a classification decision is made (Morimoto et al., 2004). Another 
collective term used in the literature to refer to all harm emanating from the practice of 
                                                 
2 There are many other drug-related problems such as drug use without indication, failure to receive drugs 
(for pharmacological, psychological, sociological or economic reasons), and improper drug selection 
(patient is taking the wrong drug) (Gharaibeh, Greenberg, & Waldman, 1998). 
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medicine is iatrogenic disease. Medication errors and ADRs are the major causes of 
iatrogenic disease.  
There are interrelationships and similarities between medication errors, ADEs, 
and ADRs (see Table 2.1 and Figure 2.1). The diagram is only illustrative and the sizes of 
the parts of the diagram are imprecise. Medication errors may harm or kill patients via 
ADEs and ADRs (categories E to I; Table 2.1). Examples of these medication errors 
include failure to appropriately monitor or manage an ADR and injury resulting from 
administering chloroquine to a person known to be allergic to chloroquine. Unintended 
errors may also cause ADRs. Such incidents are both medication errors and ADRs (see 
category III; Figure 2.1) and are generally preventable. In one study, medical errors were 
responsible for 58 percent of the adverse events (AEs) (Leape et al., 1991). 
 
Table 2.1: Classification of Medication Errors and ADEs  
Category  Description 
No error 
A Circumstances or events that have the capacity to cause error. 
Error, no harm 
B An error occurred but the error did not reach the patient. 
C An error occurred that reached the patient, but did not cause patient harm. 
D An error occurred that reached the patient and required monitoring to 
confirm that it resulted in no harm to the patient and/or required intervention 
to preclude harm. 
Error, harm 
E An error occurred that may have contributed to or resulted in temporary harm 
to the patient and required intervention. 
F An error occurred that may have contributed to or resulted in temporary harm 
to the patient and required initial or prolonged hospitalization. 
G An error occurred that may have contributed to or resulted in permanent 
patient harm. 
H An error occurred that required intervention necessary to sustain life. 
Error, death 
I An error occurred that may have contributed to or resulted in the patient‘s 
death. 
Source: National Coordinating Council for Medication Error Reporting and Prevention 
(NCCMERP) 
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In addition, although the terms medication errors, ADEs and ADRs are often used 
interchangeably in the literature (Gharaibeh, Greenberg, & Waldman, 1998), there are 
important differences between them. Some medication errors do not harm patients either 
because they are trivial or they are caught before they reach the patient (see categories B, 
C and D in Table 2.1) (American Journal of Health-System Pharmacy, 1998; Bates, 
Boyle, Vander Vliet, Schneider, & Leape, 1995a). Also, not all ADEs are (or are caused 
by) medication errors (see categories V and IV; Figure 2.1). ADEs may be due to factors 
other than medication errors such as nonadherence (White, Arakelian, & Rho, 1999). 
Some ADEs (see category V; Figure 2.1) represent unavoidable injuries that are not a 
mistake (e.g., expected side effects). Similarly some ADRs are not caused by medication 
errors (see category IV; see Figure 2.1). Only a small proportion of ADEs are associated 
with medication errors (see category II; Figure 2.1). 
 
Figure 2.1: Relationships Among Medication Errors, ADEs and ADRs 
 











Collectively, medication errors, ADEs and ADRs (incidents), constitute the 
potential risk or adverse effects associated with the use of medicines. These are discussed 
in turn below. Much research in the literature especially outside the U.S. has been on 
ADRs. However, because this thesis is on ADEs, subsequent sections focus on ADEs.  
 
2.3.1 Medical and Medication Errors 
Error is defined as, ―the failure of a planned action to be completed as intended or 
the use of a wrong plan to achieve an aim‖ (Institute of Medicine, 2000, p. 28). 
Healthcare-related errors are called medical errors—the most common category of which 
is medication error. There are many definitions of a medication error.  A medication error 
has been defined as,  ―A dose of medication that deviates from the physician‘s order as 
written in the patient‘s chart or from standard hospital policy and procedures‖ (American 
Journal of Hospital Pharmacy, 1982, p. 321). This definition excludes errors of 
prescribing and does not consider the clinical significance of the harm. This later aspect 
was incorporated in Dean and colleagues‘ (2000, p. 233) definition as follows: ―A 
clinically meaningful prescribing error occurs when, as a result of a prescribing decision 
or prescription writing process, there is an unintentional significant (1) reduction in the 
probability of treatment being timely and effective or (2) increase in the risk of harm 
when compared with generally accepted practice.‖  
The National Coordinating Council For Medication Error Reporting and 
Prevention (NCCMERP) defines a medication error as: ―Any preventable event that may 
cause or lead to inappropriate medication use or patient harm while the medication is in 
the control of the health care professional, patient or consumer. Such events may be 
related to professional practice, health care products, procedures, and systems, including 
prescribing; order communication; product labeling, packaging, and nomenclature; 
compounding; dispensing; distribution; administration; education; monitoring; and use‖ 
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(Santell, Hicks, McMeekin, & Cousins, 2003, p. 761). The critical aspects of many 
definitions of a medication error are captured in the following definition: ―A medication 
error is a failure in the treatment process that leads to, or has the potential to lead to, harm 
to the patient‖ (Ferner & Aronson, 2000, p. 1013). 
Most errors occur during dispensing and are referred to as dispensing errors, 
pharmacy errors or pharmacist errors. A dispensing error occurs when there are 
unauthorized deviations from the doctors‘ orders. There are many types of dispensing 
errors including: wrong administration technique, wrong drug preparation, administration 
of wrong dosage form, improper dose and unauthorized drug and wrong time errors 
among others (Flynn, Barker, & Carnahan, 2003; Manasse, 1989). 
In medical error research, a variety of terms are used to refer to medical and  
medication errors including: mistakes, noxious episodes, negligence, incompetence, 
misconduct, slips, violations, substandard care, complications, accidents, mishaps, 
potentially compensatable events, preventable adverse events, iatrogenic illness and 
critical incidents. These terms are sometimes used interchangeably in the literature.  
 
2.3.1.1 Categorization of Medication Errors 
Medication errors can be classified as either errors of omission or errors of 
commission. Errors can either be intentional or unintentional and can be said to be 
potential (they are detected and corrected before the patient uses the drug) or actual 
(incidents whereby the drug reaches the patient). Medication errors can either be latent 
(errors waiting to happen such as faulty interface design and system defects that set 
people to fail) or active errors. Active errors are space and time-specific and occur at the 
provider level (the frontline). An active error may result from latent errors (Thomas & 
Petersen, 2003). 
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The NCCMERP‘s medication error index categorizes errors according to severity 
of the outcome (e.g., whether the error reached the patient, if the patient was harmed and 
if so to what degree?) (The National Coordinating Council for Medication Error 
Reporting and Prevention, 2005). The index has nine categories which are classified into 
four classes ranging from no error to error, death (see Table 2.1). This classification is 
widely used by many organizations including the United States Pharmacopeia (USP).  
 
2.3.1.2 Causes and Consequences of Medication Errors 
There are many causes of medication errors including technological faults, human 
inadequacies and systemic frailties. Most errors and accidents occurring in hospitals are 
systems-related (e.g., faulty or complicated systems) (Leape, 1997; Olsen, 2002; Santell 
et al., 2003). The opportunity of error increases with the increasing complexity of the 
health system. In the community and ambulatory sites, errors may be proximally caused 
by lack of knowledge of the drug or patient, faulty drug identity checking, and inadequate 
monitoring among other issues.  The pharmacists‘ work environment (e.g., lighting, 
interruptions and distractions, and noise) and workload (prescription volume) can also 
impact dispensing error rates (Bond & Raehl, 2001; Flynn et al., 1999; Flynn et al., 
1996). 
Medication errors are associated with significant health (increased mortality and 
morbidity), psychological and economic consequences (Flynn & Barker, 2006; Flynn, 
Barker, & Carnahan, 2003; West, 2006). Some medication errors may result in patient 
harm and may also affect healthcare professionals (HCPs) (Morimoto et al., 2004). An 
estimated 1.5 percent to 4 percent of errors have potentially harmful effects (Allan, 
Barker, Malloy, & Heller, 1995; Guernsey et al., 1983; Kistner, Keith, Sergeant, & 
Hokanson, 1994). Among others, medication errors affect the relationship between HCPs 
and their patients. Medication errors may result in patient anger, suspicion and breach of 
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trust (Mulcahy & Rosenthal, 1999).  The impact of ADEs on patients and their HCPs is 
discussed in the subsequent sections.  
 
2.3.1.3 Extent of Medication Errors 
Many studies have been conducted to quantify the occurrence of medication 
errors. Kaushal and colleagues (2001) reviewed 10,778 medication orders of 1,120 
pediatric inpatients at two academic institutions and found 616 medication errors (5.72% 
of orders). Bates and colleagues (1995b) found that medication errors occurred at a rate 
of five per 100 medication orders (5%). The Institute of Medicine (IOM) estimated that a 
hospital patient is subject to at least one medication error per day (Institute of Medicine 
of the National Academies, 2007b). A similar estimate—one error per patient per day—
was also reported by Barker and colleagues (1984). The failure rate in medicine has been 
estimated to be a minimum of one percent. In other words, one in 100 activities taken by 
HCPs goes wrong (Smith, 1999).  
Barker and colleagues (2002) studied 36 different healthcare facilities and found 
that the administration error rate (excluding wrong time errors) ranged from 0 to 26 
percent, with a median value of 8.3 percent. Gopher and colleagues (1989) found that 1.7 
errors (1%) occurred per day per patient (who each had an average of 178 ―activities‖ per 
day). Two to 14 percent of hospital in-patients experienced medication errors (Classen, 
Pestotnik, Evans, & Burke, 1991; Lesar et al., 1990; Raju, Kecskes, Thornton, Perry, & 
Feldman, 1989). Palmer and colleagues (1983) found that operational errors (e.g., failure 
to treat promptly or to get a follow-up culture) occurred in 52 percent of patients in a 
study of children with positive urine cultures. 
The rates of errors reported by researchers depend on the definition of error used 
and the intensity of the error detection methods (Institute of Medicine of the National 
Academies, 2007b). The use of different methods makes it difficult to compare reported 
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error rates across studies. Although the true frequency of medication errors is unknown 
and cannot be determined, it is generally agreed that the rates of medication errors are 
high in the U.S. healthcare system (Institute of Medicine, 2000; Institute of Medicine 
Report, 2001; Leape, 1994).  
 There is an urgent need to minimize errors, most of which are preventable. The 
IOM proposed that medical errors can be prevented through ―building a safer health 
system‖ that among other things limits the ability of HCPs to make mistakes. Some 
strategies to reduce medication errors include: increased patient counseling, medication 
error reporting, improved working conditions, higher standards of care, education, 
training and registration of medical practitioners, improved motivation of HCPs, better 
identification of bad doctors (incompetent and ill), improved access to information, 
increased use of information technology, error proofing, standardization of tasks and 
identification of psychological precursors to error (e.g., fatigue) (Vincent & Reason, 
1999).  
 
2.3.2 Adverse Events and Adverse Drug Events 
About 100,100 patients are estimated to die from medical errors annually in the 
U.S (American Hospital Association, 1999; Institute of Medicine, 2000). [Unless stated 
otherwise all the data (costs, statistics, and facts) cited in this section and subsequent 
sections pertain to the U.S.]. This is more than the number of people who die from 
highway accidents, AIDS, breast cancer or workplace accidents (Institute of Medicine, 
2000).  Recently, the IOM estimated that at least 1.5 million people are harmed by 
treatments annually (Institute of Medicine of the National Academies, 2007b). Medical 
treatment may cause adverse events (AEs). An AE is an injury caused by medical 
management rather than by the disease process (Harvard Medical Practice Study, 1990) 
or any unintended, undesirable and harmful response to medical care (McLamb & 
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Huntley, 1967). AEs exhibit three key characteristics: negativity (by nature undesirable 
or detrimental to the health care process or to the patient); patient involvement/impact (in 
some way involve patients); and causation (some relationship to some part of a healthcare 
process either through commission or omission) (Walshe, 2000). AEs may manifest as 
new findings (signs, symptoms, diagnoses, and laboratory values) or alterations in pre-
existing conditions.  
AEs may be drug-related (Leape et al., 1991; Sandars, 2007). The Harvard 
Medical Practice Study, a classic AE study, found that drug complications (19%) were 
the most common type of AEs. AEs that are associated with the use of drugs are known 
as adverse drug events (ADEs) (Brennan et al., 1991).  ADEs are injuries resulting from 
medicines (Bates et al., 1995b) and instances where patients are unintentionally harmed 
as a result of drug use. According to the FDA, an ADE is any adverse event that is 
associated with the use of a drug whether or not that event is considered drug-related. 
Common ADEs include failure of expected pharmacologic action, drug abuse, drug 
withdrawal, and overdoses (accidental or intentional) (Trontell, 2001). ADEs are the most 
common threat to patient safety in secondary care (Sandars, 2007).  
ADEs may arise from overdoses of drugs, underuse of drugs (e.g., untreated 
indication, failure to receive drugs, sub-therapeutic dosage), improper drug selection and 
when the patient is taking a drug for no medically valid indication (Gharaibeh, 
Greenberg, & Waldman, 1998). Some examples of ADEs include symptoms (e.g., 
headache, nausea), syndromes of disease, physical findings [e.g., lump, elevated blood 
pressure (BP)], abnormal lab values and toxicities (Bates et al., 1995a; Morimoto et al., 
2004). ADEs can occur inside and outside of hospitals. ADEs injure or kill over 770,000 
people annually in the U.S. (Classen et al., 1997; Cullen et al., 1995; Cullen et al., 1997), 
with an estimated cost of up to $5.6 million per hospital per annum. This cost does not 
include costs of resultant admission, estimated to be between $1.56 and $5.6 billion 
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annually, and malpractice or litigation (Bates et al., 1995b; Bates et al., 1997; Thomas et 
al., 1999).  
Although ADEs are epidemic, their actual prevalence is largely unknown given 
the methodological challenges of arriving at these figures (Dean, 2003). In the U.S., it has 
been estimated that there are 6.5 ADEs per 100 admissions (Bates et al., 1995b).  Other 
studies reported different figures varying from 0.7 percent to 25 percent of hospitalized 
patients (Bates, 1998; Leape et al., 1991; Rozich, Haraden, & Resar, 2003).  
An Australian review of drug-related hospital admissions studies published 
between 1988 and 1996 reported that 2.4 percent to 3.6 percent of all hospital admissions 
were drug-related. Among the elderly, a higher percentage (15-22%) of emergency 
admissions were reported to be drug-related (Roughead, Gilbert, Primrose, & Sansom, 
1998). Kanjanarat and colleagues (2003) found that the median ADE rate was 1.8 percent 
of hospitalized patients. In a review of 15 studies, Winterstein and colleagues (2002) 
found that an average of 4.3 percent of all hospital admissions were drug-related. The 
authors concluded that drug-related morbidity is a significant problem.  
ADEs have a huge economic cost to patients, prescribers, health care 
organizations and society at large. ADEs result in extended hospital stays, malpractice 
suits (litigation costs), injury to the patient and many other associated costs. In one study, 
ADEs increased the patients‘ average hospital stay by eight to 12 days and hospitalization 
cost by $16,000 to $24,000 (Winterstein et al., 2002). The total economic impact of AEs, 
including lost income and disability, has been estimated to be $38 to $50 billion a year in 
the U.S. (Sandars, 2007). A significant part of these costs are directly attributed to serious 
ADEs. In addition to the enormous economic costs, serious ADEs also have a significant 
psychological and social effect on HCPs, patients and their families. The occurrence of 
these events, especially preventable ones, also result in loss of public trust in the 
healthcare system.  
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2.3.3 Adverse Drug Reactions  
An important type of an ADE or drug-related hazard is the adverse drug reaction 
(ADR). ADRs are as old as medicine itself and have been widely researched (Routledge, 
1998). The World Health Organization (WHO) defines an ADR as, ―a response to a drug 
that is noxious and unintended and occurs at doses normally used in man for the 
prophylaxis, diagnosis or therapy of disease, or for the modification of physiological 
function‖ (World Health Organization, 2002a, p. 40). This definition however is 
incomplete as it excludes the effects of intentional or accidental overdose. Another 
definition of an ADR by Edwards and Aronson (2000) only consider responses that cause 
significant harm: ―An appreciably harmful or unpleasant reaction, resulting from an 
intervention related to the use of a medicinal product, which predicts hazard from future 
administration and warrants prevention or specific treatment, or alteration of the dosage 
regimen, or withdrawal of the product‖ (Edwards & Aronson, 2000, p. 1255). Beard and 
Lee (2006) define an ADR as, ―an unwanted or harmful reaction experienced after the 
administration of a drug or combination of drugs under normal conditions of use and 
suspected to be related to the drug‖ (p. 1). All drugs have the potential to produce 
unintended harmful or even beneficial reactions in some patients. The literature and 
medical practice however mainly focuses on the harmful and serious reactions (Martin, 
1978). 
 
2.3.3.1 Categories of ADRs 
Traditionally, ADRs have been classified into two main categories: type A 
reactions and type B reactions (Beard & Lee, 2006; Wiffen, Gill, Edwards, & Moore, 
2002). Type A reactions are an exaggeration of a drug‘s known therapeutic effects and 
are caused by known toxicity or pharmacological actions of the drug. An example is 
when taking antihypertensive medicines results in hypotension (too low blood pressure), 
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resulting in the patient feeling dizzy or light-headed. Another example is when insulin or 
an oral antidiabetic drug results in hypoglycemia (too low blood glucose). Type A ADRs 
mostly result from administration of high drug doses, unusual patient sensitivity and 
drug-drug interactions. Type A ADRs are common, predictable and potentially 
preventable (Wiffen et al., 2002). Type A ADRs typically are more of a nuisance and 
sometimes can be dangerous or serious. There are three main type A ADRs: a) extension 
effect (exaggerated effect), b) side effect, and c) drug interaction effect (Martin, 1978).  
Type B reactions, also known as idiosyncratic or allergic reactions, are less 
common. Most type B reactions are serious, not predictable and are mostly not 
preventable (Wiffen et al., 2002). Kidney damage, jaundice, skin rashes, anemia, and a 
decrease in the white blood cell count are some examples of such ADRs.  These result 
from drug intolerance, hypersensitivity (allergic reactions), or idiosyncratic reactions. 
Some patients for unknown reasons develop exaggerated negative effects with 
conventional doses. The mechanisms of action of these reactions are not known or 
understood and therefore are difficult to predict. Genetic differences or some underlying 
abnormality of the individual may account for the occurrence of these ADRs (Martin, 
1978). Some of the differences between type A and type B ADRs and their treatments are 
provided in Table 2.2.  
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Table 2.2: Comparison of Type A and Type B ADRs 
 Type A Type B 
Synonyms Augmented, predictable, toxic, dose-
related 
Bizarre, unpredictable, allergic, 
dose-independent 
Mechanism Predictable, understood Usually poorly understood 
Site 1. Same site of primary drug action. 
2. Another site for primary and 
secondary actions. 
Unrelated to the site of action 
Incidence High (70%) Low (30%) 
Morbidity Mild Severe 
Mortality Low High 
Treatment Adjust the dose Stop treatment 
Source: Gharaibeh, Greenberg, and Waldman (1998, p. 327) 
 
ADRs are also classified according to severity (i.e., from minor to severe) (Table 
2.3). Although many ADRs are mild, some are severe and even life threatening 
(Pirmohamed & Park, 2003). 
  
Table 2.3: Classification of ADRs by Severity 
Category  Definition 
Severe Potentially life threatening, causes permanent damage, or requires 
intensive medical care. 
Moderate Requires a change in drug therapy or specific treatment to prevent a 
further adverse outcome, symptoms resolved in >24 hours, prolonged 
length of stay by >24 hours, caused a hospital admission to a non-
intensive medical care unit. 
Minor Requires no therapy or antidote, symptoms resolve in <24 hours, does not 
contribute to prolonging length of stay. 
Source: McDonnell and Jacobs (2002, p. 1332). 
 
2.3.3.2 Extent and Consequences of ADRs 
Of the estimated 100,000 deaths due to medical errors in the U.S., the IOM 
estimated that 7,000 deaths occur due to ADRs (Institute of Medicine, 2000). These 
fatalities are the fourth leading cause of death, ahead of deaths caused by diabetes and 
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pneumonia (Lazarou, Pomeranz, & Corey, 1998; White, Arakelian, & Rho, 1999). In a 
meta analysis of prospective studies, Lazarou and colleagues (1998) found that an 
estimated 6.7 percent of hospital patients had serious ADRs and 0.32 percent had fatal 
ADRs. Hospitalized patients have higher incidence of ADRs than outpatients. The 
incidence of ADRs in hospitalized patients varies widely (1.5% to 35%) by study and the 
rigor with which the events were sought (Bates et al., 1995b).  In addition, an estimated 
350,000 ADRs occur in nursing homes annually (Gurwitz et al., 2000). A U.K. study 
found that 4.3 per 1,000 patients on two or more medications were prescribed interacting 
drugs (Yen-Fu et al., 2005). In Finland, a study found that 2.1 percent of patients taking 
at least two drugs were using potentially harmful combinations, while in Sweden, a study 
reported that 12 percent of prescriptions for two or more drugs contained potential drug 
interactions (Linnarsson, 1993). The results of a prospective case-control study in 
hospitalized patients showed that ADRs caused 3.5 percent mortality, complicated 2.3 
percent of the cases, and increased hospital stays by 174 percent (Classen et al., 1997). 
Significant healthcare costs are associated with ADRs. ADRs account for a 
significant part of the estimated $177.4 billion annual cost of drug-related morbidity and 
mortality in the ambulatory setting (Ernst & Grizzle, 2001). ADRs also cause patient 
suffering, negatively affect the physician-patient relationship and reduce the therapeutic 
effect of drugs (Yen-Fu et al., 2005). 
 
2.3.3.3 Factors Predisposing Patients to ADRs 
Many factors explain the occurrence of ADRs. First, the widespread use of 
medications by the population increases the risk of ADRs (Hutchinson, Flegel, Kramer, 
Leduc, & Kong, 1986). An estimated 3.6 billion prescriptions were filled in 2008—about 
12 prescriptions for every person (The Henry J. Kaiser Family Foundation, 2008). Many 
people also use over-the-counter (OTC) medications and traditional medicines alongside 
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prescription medicines. Patients taking four or more medications are at an exponentially 
higher risk of experiencing ADRs (Jacubeit, Drisch, & Weber, 1990). A study of over 
9,000 Italian patients (>60 years old) showed that the ADR rate increased from 1.2 
percent with one medicine to about 50 percent with 10 medicines (Carbonin, Pahor, 
Bernabei, & Sgadari, 1991). In another study, the ADR rate was 5 percent with one or 
two medicines, rising to 20 percent or more above five medicines (Grymonpre, Mitenko, 
Sitar, Aoki, & Montgomery, 1988).  
Second, age is often suspected to be an independent risk factor for ADRs (Hoigne 
et al., 1984). The elderly and the very young are at greater risk of experiencing severe 
ADRs (McInnes & Brodie, 1988). The variable drug absorption and metabolism in both 
these groups increase their risk of ADRs (Osterberg & Blaschke, 2005). Children have an 
elevated risk of ADRs because many drugs prescribed for children are not licensed for 
use in children (unlicensed use) and are commonly prescribed outside the terms
 
of the 
product license (off-label use) (Conroy et al., 2000). Enzyme systems that are responsible 
for the metabolism of drugs are immature in neonates, resulting in reduced clearance of 
many drugs (Ajayi, Sun, & Perry, 2000).  With respect to the elderly, most have poor 
compliance, have altered pharmacokinetics and pharmacodynamics, and their illnesses 
tend to be treated with drugs with a poor therapeutic ratio (Wiffen et al., 2002). Also, the 
presence of many diseases in the elderly which are treated by more medicines is a risk 
factor for ADRs. However, one study found that age was not an independent risk factor 
after controlling for the number of drugs prescribed to a particular patient (Jacubeit, 
Drisch, & Weber, 1990).  
Third, being female was reported to be associated with a higher incidence of 
ADRs than being male (Drici & Clement, 2001; Fattinger et al., 2000; Grymonpre et al., 
1988; Pouyanne, Haramburu, Imbs, & Bagaud, 2000; Rademaker, 2001; Tran, Knowles, 
Liu, & Shear, 1998). ―Female patients have a 1.5- to 1.7-fold greater risk of developing 
an ADR compared with male patients‖ (Rademaker, 2001, p. 349). The higher percentage 
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of women experiencing ADRs than men can be related to fat distribution, body size 
differences and gender-related polymorphisms in pharmacokinetics and 
pharmacodynamics as well as differences in the use of medications by gender 
(Gharaibeh, Greenberg, & Waldman, 1998; Gray, Mahoney, & Blough, 1999; 
Rademaker, 2001). The mechanisms explaining the different incidences of ADRs 
between male and female patients remain unclear. However, similar ADR rates between 
men and women have also been reported (Hallas et al., 1992; Schneitman-McIntire, 
Farnen, Gordon, Chan, & Toy, 1996).  
Fourth, certain classes of medicine are associated with higher ADR rates than 
others. For example, warfarin and digoxin carry a higher risk for causing ADRs than 
other drugs because of their narrow therapeutic indices (Osterberg & Blaschke, 2005). In 
addition, the use of aspirin, antibiotics, opioids, diuretics, hypoglycemic agents and 
NSAIDS are associated with higher ADR rates (Wiffen et al., 2002).   
Fifth, poor patient adherence may increase the rate of ADRs. Nonadherence rates 
for patients with chronic conditions have been found to be between 50 percent and 60 
percent on average (Ashcroft, Morecroft, Parker, & Noyce, 2006). For some conditions 
like HIV and breast cancer, nonadherence is associated with dangerous adverse effects. 
Adherence is influenced by several factors such as affordability of medication, access to 
care (insurance coverage), knowledge, beliefs regarding treatment, and patient 
information (labeling and education) (Bardel, Wallander, & Svardsudd, 2007; Escobar et 
al., 2003; Kane, Brixner, Rubin, & Sewitch, 2008; Wu, Moser, Lennie, & Burkhart, 
2008).  
Finally, other factors such as disease state, genetic factors, past history of 
allergies, quality of prescribing, inadequate monitoring and poor administration are also 
associated with ADR rates (Gharaibeh, Greenberg, & Waldman, 1998). The rates of 
ADRs are affected by many other factors that affect drug response such as lactation, 
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pregnancy, tobacco or marijuana smoking, alcohol intake, stress, and dietary factors 
(Merck Manual, 2003). 
 
2.3.3.4 Diagnosing ADRs 
It is critical for HCPs to be able to determine the presence of ADRs, their causes 
and their mechanisms of action. This helps them to ―initiate corrective action for a 
particular patient, to prevent future incidence for patients in general, and to avoid 
medicolegal complications‖ (Gharaibeh, Greenberg, & Waldman, 1998, p. 335). 
Knowing the harmful reactions helps in achieving optimal pharmacotherapy—balancing 
the drug‘s effectiveness against its possible undesirable reactions. However, diagnosing 
ADRs is extremely difficult for HCPs including physicians, resulting in most of the 
ADRs reported in the literature being only suspected—not proved (Martin, 1978). 
Diagnosing ADRs is complicated by the fact that ADRs resemble many diseases or 
syndromes, and are vague, confusing and rarely specific. In addition, ADRs can affect 
any tissue or organ and a host of ADRs are mild (Beard & Lee, 2006; Gharaibeh, 
Greenberg, & Waldman, 1998). Making a causal association between the drug and the 
observed clinical outcomes is complex. Causal association may be assessed using several 
criteria available including Irey‘s criteria (see Table 2.4). 
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To be responsible for an ADR, the drug must have been administered 
before the reaction is observed. 
Latency 
period 
This refers to the expected interval from the time of drug administration 
to the appearance of the ADR. 
Singularity of 
the drug 
If the patient is taking only one drug and develops a suspected ADR, it 
increases the likelihood of a causal relationship. 
Exclusion Sometimes, cessation of one or more drug treatments suggests the 
identity of the offending drug causing the ADR. 
Dechallenge Many ADRs are reversible upon discontinuing the suspected drug. 
Rechallenge Although there is some risk associated with this maneuver, 
readministration of a suspected drug might be accompanied by the 
reappearance of the ADR in question. 
Pattern Many drugs elicit ADRs with a characteristic clinicopathological pattern, 
which suggests an association with a particular drug. 
Drug 
quantitation 
Determination of the levels of drug in blood and body fluids may yield 
insights into the causal relationship of drug administration and ADRs. 
Drug 
qualitation 
Qualitative identification of the drug in tissues may be of diagnostic 
significance in establishing the etiology of an ADR. 
Source: Gharaibeh and colleagues (1998, p. 330) and Irey (1982). 
Irey suggested five degrees of causation including: a) causative or definitive—
there is an objective laboratory finding which documents causal association, b) probable 
or consistent with—no objective laboratory finding to document the causal association, c) 
possible—the relationship can neither be denied nor confirmed, d) coincidental—a 
nondrug cause is more likely responsible for the reaction, and e) negative—it is 
confirmed that the drug was not in the patient‘s system at the time of the illness after 
suspecting an ADR (Irey, 1982).  
The difficulty of separating disease-related symptoms from drug-related ones 
(Jacubeit, Drisch, & Weber, 1990) means that HCPs may mistake ADRs for disease 
progression or dismiss them as being a side effect. On the other hand, clinicians may 
wrongly ascribe an adverse reaction to a drug (Osterberg & Blaschke, 2005). Accurate 
diagnosis of ADRs is complicated by polypharmacy, variability of clinical responses of 
patients to most diseases, incomplete information, absence of objective diagnostic criteria 
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and in cases where there is a long time between drug administration and the effect. There 
is low agreement (less than 50%) between expert physicians in determining the 
probability of a causal relationship of ADRs (Naranjo, Shear, & Lanctot, 1992). Medical 
practitioners lack adequate knowledge and information on drugs and ADRs (Ajayi, Sun, 
& Perry, 2000).  
 
2.3.3.5 Minimizing and Preventing ADRs 
As noted above, some ADRs are preventable and avoidable (McDonnell & 
Jacobs, 2002; Siddins, 2002) and there are different categories of avoidability 
(McDonnell & Jacobs, 2002) (Table 2.5). The definitely avoidable and possibly 
avoidable ADR rates can be reduced through better understanding of possible ADR 
outcomes, better monitoring of prescribing, better drugs, use of computer systems and 
improved communication and education (Bates et al., 1998; McDonnell & Jacobs, 2002; 
Raschke et al., 1998; Wiffen et al., 2002).  
 




The ADR was due to a drug treatment procedure inconsistent with 
current knowledge of good medical practice. 
Possibly avoidable The ADR could have been avoided by an effort exceeding the 
obligatory demands of current knowledge of good medical practice. 
Unavoidable The ADR could not have been avoided by any reasonable means. 
Source: Hallas and colleagues (1990). 
 
 ADRs may be inevitable and justified (Yen-Fu et al., 2005); sometimes 
prescribers may prescribe dangerous drug combinations by design, after a careful 
consideration of the patient‘s condition and the available treatment options. An 
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interaction may be tolerated in the case of drugs or combination of drugs that treat life-
threatening illnesses (Meadows, 2002).   
 
2.4 INTEGRATION OF DRUG THERAPY RISK INFORMATION IN DECISION MAKING  
The occurrence of ADEs is a risk—the probability that something negative will 
happen—associated with drug therapy (Institute of Medicine, 2007). Given that patients 
with different characteristics (e.g., genetics, age, weight, hepatic and renal function) 
respond differently to standard regimens and doses (Smith, 1978), a good drug for some 
patients may be a bad drug for others who are at risk of serious adverse events (Edwards, 
2001). In making optimal decisions, drug regulatory authorities, pharmaceutical 
companies, HCPs and patients consider and weigh the risks and benefits of drug 
therapy—a process called benefit-risk assessment3. For example, patients consider the 
potential negative effects of medicines in deciding to start or to continue taking 
medicines. Physicians also consider the risks of drugs in making treatment decisions 
aimed at minimizing the likelihood of the occurrence of serious ADEs (e.g., ADRs) in 
their patients. In addition, in approving drugs, regulatory authorities compare the risk 
associated with a drug with its benefits and approve for marketing only drugs that have 
higher benefits than the risks.4 Approved drugs fall in the bottom right hand triangle in 
Figure 2.2.  
                                                 
3Benefit-risk assessment is the balancing or weighing of a drug‘s therapeutic effectiveness against its 
potential risks or adverse effects. Currently there are no tested, standardized, validated, quantitative or 
semi-quantitative methods to conduct benefit-risk assessment (Institute of Medicine, 2007). Benefit-risk 
assessment is adhoc, qualitative, informal and relies on human judgments and is compromised by 
limitations (biases, fallibility, inconsistencies and subjectivity) of human judgment (Institute of Medicine of 
the National Academies, 2007a). As a result, there is a wide variability in how decisions are made (Tilson, 
Gibson, & Suh, 2006). The main outcome of a benefit-risk assessment is a benefit-risk ratio that is also 
called benefit-risk difference, benefit versus risk, safety profile, risk-benefit decision, therapeutic margin 
and therapeutic index.    
 
4 Licensing decisions are made based on group data and use a societal perspective (for the population at 
large) (Hurley, 1985).  Currently, there are two methods for weighing a drug‘s benefits and risks: a) 
comparative approach —which involves comparing a drug‘s benefits and risks with those of similar drugs. 
If a new drug has similar risks and benefits to another drug already being marketed, it is allowed to be 
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Figure 2.2: Relationship Between Benefits and Risks 
  
There are several challenges that affect the integration of risk information in 
decision making by patients, regulatory authorities and physicians. First, risks associated 
with drugs are difficult to quantify. Second, the risks and benefits of drugs are measured 
in different units and there is currently no quantitative approach to readily compare them 
(Institute of Medicine, 2007). Third, it is difficult to adequately reflect patient preferences 
in assessing drug risks at a societal level. Risk perception and acceptability vary widely 
across individuals and some individuals accept certain risks more readily than others for 
various reasons (Edwards, 1997; Hurley, 1985). Fourth, although a substantial amount of 
risk information pertaining to drugs is obtained during clinical trials, getting complete 
information on benefits and risks takes time, effort and resources. Often decisions cannot 
wait until complete information is available, resulting in most regulatory decisions being 
                                                                                                                                                 
marketed (Rawlins, 1985a); and b) judgmental approach—the most commonly used method in practice 
where decisions are made on the basis of views of experts and professionals. The FDA does not currently 
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made on the basis of incomplete data. Uncertainty cannot be eliminated in drug therapy 
decision-making.  
 
2.4.1 Risk Identification in the Premarketing Stage  
Before new drugs are approved, they undergo extensive testing and rigorous 
evaluation of their safety and efficacy during clinical trials. The common serious ADEs 
(incidence > 0.1%) are detected during clinical trials (Amery, 1999). However, clinical 
trials have a simple design (the effects of cormobid conditions or multiple drug use are 
not assessed), are of a limited duration, use a narrow dosage range and do not include 
extremities of ages (Edwards, 1997). Clinical trials are held under conditions that do not 
represent all the situations likely to be encountered in ―real life.‖ In addition, clinical 
studies include a small (about 1,500 patient exposures) (Jefferys, Leakey, Lewis, Payne, 
& Rawlins, 1998; Meadows, 2002) and homogenous (susceptible patients are excluded) 
patient population (Edwards, 1997). The small sample sizes increase the chance of 
missing rare side effects. For example, there is a 95.1 percent chance of missing a rare 
side effect (e.g., 1 in 20,000 exposures) for a clinical trial involving 500 people (Amery, 
1999) (Table 2.6). This chance decreases with increasing patient exposures (Table 2.6).   
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Table 2.6: Chance of Not Observing a Very Rare Side Effect (0.01%) 











Source: Amery (1999, p. 61). 
 
Given the above limitations, all the potential side effects of drugs are not 
identified before drugs are marketed even with a flawless drug development process 
(World Health Organization, 2002b). Events and reactions that have a long latency and 
those that occur discretely after discontinuation of the drug may not appear during the 
course of the trial given the limited time frame (Brewer & Colditz, 1999; Simon, 2002). 
In addition, animal toxicology is often not a good predictor of effects in humans, and 
even detected events will be incompletely described, since they are too few. As a result, 
serious adverse effects of a majority (51%) of approved drugs are not detected prior to 
approval (U.S. General Accounting Office, 1990). The safety profile of new medicines is 
not fully understood at the time of approval and any drug safety conclusions that are 
made are only provisional (Rawlins, 1995). Once a drug is marketed, more patients will 
be exposed to it, and the drug may be used for different and unanticipated indications. In 
addition, the drug may be used for a longer period and in certain subgroups within 
populations, such as the elderly and children, resulting in the emergence of new and rare 
events (Institute of Medicine, 2007; Lee & Thomas, 2003). These problems may be 
identified through pharmacovigilance and postmarketing surveillance. 
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2.5 OVERVIEW OF PHARMACOVIGILANCE AND POSTMARKETING SURVEILLANCE 
Pharmacovigilance emerged in response to the drug safety challenges experienced 
in the 1960s, mainly the thalidomide disaster. The thalidomide disaster revealed the 
shortcomings and limitations of using clinical trials data in defining the safety profile of 
drugs (Rawlins, 1995; Simon, 2002). The word pharmacovigilance was coined by the 
French as, ―the study of the undesirable effects of drugs‖ (Rascol, Pathak, Bagheri, & 
Montastruc, 2004, p. 611). Pharmacovigilance is ―the science and activities relating to the 
detection, assessment, understanding and prevention of adverse effects or any other 
possible drug-related problem‖ (World Health Organization, 2002a, p. 42). 
Pharmacovigilance promotes drug safety and involves detecting, confirming, 
investigating, monitoring and developing strategies to reduce ADEs (Edwards, 1997).  
Although pharmacovigilance occurs both before (pre-marketing) and after a drug 
is marketed (postmarketing stage) (Begard & Tubert-Bitter, 1993), it is dominant in the 
postmarketing stage. As a result, many definitions in the literature characterize 
pharmacovigilance as a postmarketing activity. For example, the U.K.‘s Committee on 
Safety of Medicines (CSM) defines pharmacovigilance as the process of identifying, and 
then responding to safety issues about marketed drugs (Committee on Safety of 
Medicines and Medicines Control Agency, 1993). Pharmacovigilance has also been 
defined as ―The study of the safety of marketed drugs under the practical conditions of 
clinical usage in large communities‖ (Mann & Andrews, 2002, p. 3).  
The objectives of pharmacovigilance are to: a) identify and quantify all previously 
unidentified drug safety hazards; b) elucidate the factors predisposing patients to the 
hazards; c) obtain evidence of safety of approved drugs; and d) refute false positive ADE 
signals (Rawlins, 1995). The following are five activities that are essential to 
pharmacovigilance:  
 Suspected ADR signal generation and formation of hypothesis; 
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 Analysis of all issues around the signal, particularly confirmation (or refutation) of 
hypotheses, estimation of the size of the risk and whether susceptible patients exists; 
 Consideration of possible changed benefit-to-risk issues in therapy; 
 Communication of information to health professionals and patients in a useful way 
and possible regulatory action; and  
 Consequence evaluation (Edwards & Aronson, 2000) 
Pharmacovigilance is often equated with postmarketing surveillance (PMS) in the 
literature (van Grootheest, 2003). PMS is the main task of pharmacovigilance. PMS is the 
continuous monitoring of the safety of all marketed drugs. It is aimed at identifying and 
quantifying any emerging drug hazards, mostly serious ADEs. The most common method 
of PMS and pharmacovigilance is spontaneous reporting (SR) of individual clinical 
observations by HCPs and patients. Other methods include: case reports, cohort studies, 
case-control studies, controlled clinical trials, cross-sectional analyses, demographic 
methods, drug use surveys, automated databases linking drugs and disease and registries 
(Gharaibeh, Greenberg, & Waldman, 1998; Simon, 2002).  
 
2.6 SPONTANEOUS REPORTING OF ADES 
SR is the cornerstone of PMS and pharmacovigilance in many countries (Rawlins, 
1988a, 1988b, 1995). SR is ―the system whereby case reports of adverse drug events are 
voluntarily submitted from health professionals and pharmaceutical manufacturers to the 
national regulatory authority‖ (World Health Organization, 2002a, p. 43). These case 
reports are called spontaneous reports. In making reports, HCPs imply a causal 
association between a drug and the clinical event. The reports are spontaneous, implying 
that they are voluntary (van der Heijden, van Puijenbroek, van Buuren, & van der 
Hofstede, 2002). 
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Many countries operate elaborate spontaneous reporting systems (SRSs) which 
facilitate the reporting of ADEs. In 2001, 55 countries had operational SRSs (Edwards, 
2001). Reports are sent mostly to a government agency, but also to drug manufacturers or 
a designated third party (Cobert, 2007). SRSs are the principal monitoring technique after 
a drug is marketed in many countries (Gharaibeh, Greenberg, & Waldman, 1998).  The 
importance of SR in identifying previously unknown ADEs has been documented 
previously (Rossi et al., 1983). The objective of SRSs is to generate signals—indicators 
of potential drug safety hazards or problems associated with drug use—and hypotheses 
(Gharaibeh, Greenberg, & Waldman, 1998; Meyboom et al., 1997a; Strom & Tugwell, 
1990).  
There are many advantages of SR:  
 SR is cost-effective: SRSs are relatively inexpensive to operate but are effective. 
They are the most cost-effective way of monitoring drug safety (Layton, Key, & 
Shakir, 2003). They detect new and unsuspected ADEs better than other Phase IV 
postmarketing studies (Rossi et al., 1983).  
 SR is comprehensive: SRSs cover the entire ADE data for the population in a 
defined geographic region across all the therapeutic agents (Pirmohamed, 
Breckenridge, Kitteringham, & Park, 1998; Waller, Coulson, & Wood, 1996). SRSs 
detect all types of ADEs.  
 SR is rigorous and monitors drugs over a long period of time: SRSs monitor the 
safety of drugs throughout their marketed life (Waller, Coulson, & Wood, 1996). 
 SR is directly related to clinical practice: SR data are based on the experiences of 
HCPs with the use of a drug in patients. SR involve a clinical judgment and reflect 
HCPs‘ clinical concerns about drugs they prescribe (Edwards, 1999). 
Drug regulatory agencies in many countries predefine which ADEs ought to be 
reported. As a result, there are inter-country differences on what is to be reported. For 
example, in the U.K., all suspected reactions attributable to a new (e.g., first two years of 
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marketing) drug should be reported whereas only serious and unusual suspected reactions 
should be reported for established drugs (Inman, 1985). In general, all evidence that casts 
suspicion on the safety of a drug should be collected. The motto of the Committee on 
Safety of Drugs is ‗when in doubt—report‘ (Committee on Safety of Medicines, 1968).  
Although different from country to country, the general content of ADE reports 
covers four main areas:  
 Patient information: patient identifier, age at time of event or date of birth, gender 
and weight; 
 Adverse event or product problem: description of event or problem, date of event, 
date of this report, relevant tests/laboratory data (if available), other relevant patient 
information/history and outcomes attributed to adverse event; 
 Suspected medication(s): name [international nonproprietary number (INN) and 
brand name], dose, frequency and route used, therapy date, diagnosis for use, batch 
number, expiration date, event abated after use stopped or dose reduced, event 
reappeared after reintroduction of the treatment, concomitant medical products and 
therapy dates; and 
 Reporter: name, address, telephone number, specialty and occupation (World Health 
Organization, 2002b, p. 16). 
 
2.6.1 Analysis and Evaluation of SR Data 
When regulatory centers receive SRs, they acknowledge (e.g., send reporters a 
‗thank you‘ note) and validate them. The reported ADEs are then analyzed and evaluated 
to detect or generate signals—scrutinize spontaneous reports for hazards (Evans, Waller, 
& Davis, 2001). Signal detection involves analyzing individual case reports as well as 
aggregated data. The process of generating ‗signals‘ of positive unrecognized hazards 
from spontaneous ADE reporting data has been likened to looking for a needle in a 
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haystack (Evans, Waller, & Davis, 2001). Both qualitative methods (where experts or 
trained assessors assess each incoming report) and quantitative methods (e.g., statistical 
analyses) are used to detect signals. Quantitative methods are able to detect complex 
associations and relationships such as drug-drug interactions and drug-induced 
syndromes (Hauben & van Puijenbroek, 2005; van der Heijden et al., 2002).  
The simplest quantitative index that can be calculated is the reporting rate—the 
ratio of the number of reports for a particular drug over the number of patients exposed to 
the drug. This can be used as an estimate of ADE incidence. However, the reporting rate 
is not a good indicator of incidence given the biases in the numerator and the difficulty in 
getting accurate patient exposure data (the denominator). To avoid the limitations and 
biases encountered with the use of reporting rates, disproportionality measures such as 
proportional reporting ratio (PRR) and reporting odds ratio (ROR) are preferred. These 
measures ascertain whether the number of observed cases differs from the number of 
expected cases (Egberts, Meyboom, & van Puijenbroek, 2002). Disproportionality 
analyses are commonly used in pharmacovigilance. Drug and ADE combinations that are 
disproportionately present among the reported suspected ADEs represent potential 
signals (Egberts, Meyboom, & van Puijenbroek, 2002).  
The identified signals need to be followed up through collecting further 
information on the following: chronology, dechallenge, rechallenge, clinical 
symptomatology, other possible explanations, possible predisposition and complementary 
investigations (Dongoumau, Evreux, & Jouglard, 1978). Spontaneous reports data often 
need to be complemented by data collected through other methods such as 
epidemiological studies (Hauben & van Puijenbroek, 2005) thus further delaying the 
validation of ADEs. 
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2.6.2 Action Decision 
The next step after assessing and evaluating the SR data is to make a decision 
aimed at improving patient and drug safety. Regulators and pharmaceutical 
manufacturers are sometimes compelled to act on the basis of spontaneous reports they 
receive. The actions they can take include: a) changing product information; b) 
modifying the product or its use; and c) withdrawing the product from the market as 
discussed in turn below.  
First, the most common action taken by pharmaceutical manufacturers and drug 
regulatory agencies in response to new ADE information gathered through SRSs is 
updating the product information (i.e., reviewing or adding the newly acquired 
information to the label) (Moore, Psaty, & Furberg, 1998; Simon, 2002). Possible 
changes include: a) adding new warnings, ADRs, contraindications, and interactions; b) 
changing the wording of ADRs; c) restricting the product‘s indications; and d) removing 
some information (Council for International Organization of Medical Sciences, 1998). 
The changes are made to the package insert, summary of product characteristics (SPC) 
and the drug label (Edwards, 2001) which are important sources of drug treatment 
information to physicians and patients. In the event of serious ADEs, ‗Dear Doctor‘ 
letters are written directly to individual HCPs with more urgent warnings (Edwards, 
2001).  
Second, to minimize risk, manufacturers and drug regulatory agencies may also 
decide to restrict product availability (Council for International Organization of Medical 
Sciences, 1998). Possible changes include changing the status of a drug from non-
prescription to prescription status, imposing institutional selectivity (restricting a product 
for distribution only to hospitals or other institutions), and improving professional 
selectivity (restriction of prescribing to specialists). Limits on reimbursement may also be 
considered (Council for International Organization of Medical Sciences, 1998).  
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Third, in rare and extreme circumstances, where a drug‘s risks are considered to 
exceed its benefits, regulatory authorities may reassess and change the approval decision 
(Meadows, 2002; Schafer, 1997). Some of the factors that prompt the decision to 
withdraw a drug from the market include: occurrence of rare and unpredictable problems, 
more than expected drug toxicity (when safer options are available), dangerous 
combinations, improper use and failure of other risk management options (Meadows, 
2002). Many drugs have been withdrawn from the market on the basis of spontaneous 
reports (Edwards, 1997; Jefferys et al., 1998; Moride, Haramburu, Requejo, & Bagaud, 
1997; Rawlins, 1995). Arnaiz and colleagues (2001) studied 22 drugs that had been 
withdrawn from the Spanish market in the 1990s and observed that most of the 
withdrawals (n = 18) were based on case series or reports. Between 1969 and 2002, more 
than 75 drugs/drug products (about 1% of marketed drugs) were removed from the 
market for safety reasons in the U.S. (Wysowski & Swartz, 2005).  
Finally, all decisions that are made should be communicated effectively to 
patients and HCPs. ―Dear Doctor‖ letters, journal publications, educational programs, 
patient leaflets and advertisements (Council for International Organization of Medical 
Sciences, 1998) can be used as the communication channels. This information promotes 
safe use of medicines by the population and is used by patients and HCPs in optimizing 
the selection of treatment (Davis, Furberg, Wright, Cutler, & Whelton, 2004).  
 
2.7 REPORTING ADES BY PATIENTS AND HCPS 
HCPs (e.g., nurses, doctors and pharmacists) are expected to report the ADEs that 
they come across (Edwards & Aronson, 2000; Gharaibeh, Greenberg, & Waldman, 
1998). In addition to HCPs, consumers in some countries (e.g., U.S. and Canada) can also 
report ADEs as discussed in turn below. 
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2.7.1 ADE Reporting by Patients 
Patient reporting is when users of drugs (or their caregivers) report suspected 
ADEs directly to a reporting center (van Grootheest, de Graaf, & de Jong-van den Berg, 
2003). Some countries such as Canada, New Zealand, Denmark, Sweden, the 
Netherlands, the U.K. and Australia allow the users of medicines (consumers or patients) 
to submit ADE reports. Patients in the U.S. can also directly report ADEs to the FDA 
through MedWatch, the FDA‘s Safety Information and Adverse Event Monitoring 
Program.  
Allowing patients to report ADEs has advantages. Studies have found that 
patients do not tell their physicians all the symptoms they suspect and that physicians, in 
turn, do not record all symptoms they are informed about (Savett, 2002). As a result, 
physicians are not aware of all the ADEs (about 50%) that patients suspect (Aspinall, 
Whittle, Aspinall, Maher, & Good, 2002; Gandhi et al., 2000). Allowing patients to 
directly report suspected ADEs may identify these problems and also highlight problems 
related to off-label use and problems associated with the use of over-the-counter (OTC) 
products. Patient reporting increases the number and heterogeneity of reports. In addition, 
it makes SRSs relevant to patients to whom they matter most. A recent review 
(Blenkinsopp, Wilkie, Wang, & Routledge, 2007) of published literature and 
international experience on patient reporting of suspected ADRs noted several potential 
benefits of patient reporting including: 
 Patients may report ADRs that are different from those reported by HCPs; 
 Patients may be more likely to identify a symptom as a suspected ADR than HCPs; 
 Patients may report new ADRs that do not feature in existing product information; 
 Patients may report suspected ADRs that they would not wish to discuss with their 
HCPs; and  
 Patients report their ADR experiences without filtering or ‗interpretation‘ by a HCP 
resulting in a better understanding of their experiences. 
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A three-year study conducted in the Netherlands compared patient ADR reports 
with reports submitted by HCPs (de Langen, van Hunsel, Passier, de Jong-van den Berg, 
& van Grootheest, 2008) and concluded that patient reporting is feasible and enhances 
pharmacovigilance (de Langen et al., 2008). Another study found that the quality of 
patient reports did not differ significantly from those of physicians (van Grootheest, de 
Graaf, & de Jong-van den Berg, 2003). However, patient reporting has several potential 
disadvantages such as: quality of reports, challenges in associating a drug and suspected 
event and not having sufficient information to carry out causality assessment. Patient 
reporting might provide noise and thus deter signal detection.  
 
2.7.2 ADE Reporting by HCPs 
The effectiveness of SRSs and pharmacovigilance requires the goodwill and 
cooperation of HCPs including pharmacists through reporting ADEs (Cobert, 2007). 
Reporting ADEs by HCPs is a professional responsibility and all healthcare providers 
(e.g., physicians, pharmacists, nurses, and dentists) should report ADEs as part of their 
professional activities (World Health Organization, 2002b). However, the actual 
professionals who report are governed by national legislation and vary from country to 
country.  
Pharmacists and physicians account for most of the ADE reports received by 
pharmacovigilance centers worldwide. Pharmacists‘ reports reflect their special 
professional backgrounds and experiences (Edwards, 1999). ADE reporting behavior 
may differ between pharmacists and physicians (Lawton & Parker, 2002). A study 
conducted in the Netherlands found that, ―Compared to pharmacists, physicians reported 
statistically significantly more ADEs related to the cardiovascular system, malfunctions 
of the liver and psychiatric disorders, whereas pharmacists reported a significant greater 
number of presumed ADEs of ‗external‘ organ systems such as disorders of the skin and 
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eyes‖ (van Grootheest, van Puijenbroek, & de Jong-van den Berg, 2002). In the U.S. and 
the U.K., no difference was found in the quality of reports submitted by pharmacists and 
physicians (Ahmad, Freiman, Graham, & Nelson, 1996). Although both pharmacists and 
physicians are critical for effective SRSs and play an integral role in pharmacovigilance 
(Lee & Thomas, 2003; Olsson, 1999) in most countries, this study focuses on 
pharmacists. Pharmacists are willing to report and are capable of reporting ADEs 
(Emerson, Martin, Tomlin, & Mann, 2001; Green, Mottram, Rowe, & Pirmohamed, 
2001; Sweis & Wong, 2000). The pharmacists‘ special training, expert knowledge of 
pharmacokinetics, pharmacodynamics, and knowledge of chemical relations coupled with 
their widespread use of computers and their interaction with patients put them in a unique 
and special position to detect and report ADEs (Inman 1986). In addition, ADE reporting 
fits in well with pharmacists‘ responsibility of ensuring safe use of medicines.  
Pharmacists in different countries play different roles with respect to reporting 
ADEs. For example, pharmacists in Finland, Norway, Sweden, Denmark, Iceland and 
Estonia are not authorized to report ADEs (Olsson, 1999). However, pharmacists can 
report ADEs in most of the countries that participate in the WHO Programme for 
International Drug Monitoring (van Grootheest, Olsson, Couper, & de Jong-van den 
Berg, 2004). It is standard practice for pharmacists to report ADEs in many other 
countries (Griffin, 1986). In some countries, pharmacists contribute the greatest number 
of reports. For example, reports submitted by pharmacists accounted for 88 percent of all 
reports submitted by HCPs in Canada, 40 percent in the Netherlands and 18 percent in the 
U.S. (van Grootheest et al., 2004). In other countries, the pharmacists‘ contribution is 
small.  
Serious ADEs occur mostly in the hospital setting and hospital pharmacists who 
are involved in patient care play an important role in drug safety through reporting those 
ADEs (Leape et al., 1999a). In many countries, hospital pharmacists submit the bulk of 
reports submitted by pharmacists (van Grootheest et al., 2004). Much of the literature on 
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the contribution of pharmacists towards ADR reporting relate to hospital pharmacists 
(Ahmad et al., 1996; Leape et al., 1999a; Winstanley, Irvin, Smith, Orme, & 
Breckenridge, 1989). Hospital pharmacists were found to be more likely to report ADRs 
than community pharmacists (Herdeiro, Figueiras, Polonia, & Gestal-Otero, 2006). ADR 
reporting was found to be 20-fold higher among hospital than community pharmacists 
(OR 20.0, 95% CI: 3.3, 125; p < 0.001) (Herdeiro et al., 2006). One study reported that 
ADR reports submitted by hospital pharmacists were of better quality compared to those 
submitted by community pharmacists (Ahmad et al., 1996). Hospital pharmacists were 
also reported to be better informed about pharmacovigilance than community pharmacists 
(Cox, Marriott, Wilson, & Ferner, 2004). This may be explained by the fact that hospital 
pharmacists have access to additional pertinent information (e.g., lab test results) which is 
not available to community pharmacists (Emerson et al., 2001). Community pharmacists 
have a special position in reporting ADEs associated with over-the-counter (OTC) 
products and alternative therapy (Hammerlein, Griese, & Schulz, 2007; van Grootheest et 
al., 2004).  
 
2.8 FACTORS AFFECTING ADE REPORTING BY HCPS INCLUDING PHARMACISTS 
Inman (1978) published a classical piece on ADR reporting in which he provided 
the reasons for underreporting of ADRs by HCPs. He termed them the ‗seven deadly 
sins‘: a) fear of possible involvement in litigation; b) lack of economic incentive; c) 
ambition to collect and publish; d) complacency; e) difference about reporting mere 
suspicions; f) indifference; and g) ignorance of ADR reporting requirements (Inman, 
1978). Later, he added an eighth ‗sin‘ named insecurity (Inman, 1996). Inspired by this 
landmark publication, many research studies have shed more light on the factors that 
affect ADR reporting by HCPs in the literature. Most of the research on the factors 
influencing reporting or underreporting were conducted on medical practitioners (Aziz, 
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Siang, & Badarudin, 2007; Bäckström, Mjörndal, Dahlqvist, & Nordkvist-Olsson, 2000; 
Bateman, Sanders, & Rawlins, 1992; Belton, Lewis, Payne, Rawlins, & Wood, 1995; 
Belton & The European Pharmacovigilance Research Group, 1997; Eland et al., 1999; 
Figueiras, Tato, Fontainas, & Gestal-Otero, 1999; Hasford, Goettler, Munter, & Müller-
Oerlinghausen, 2002; Herdeiro, Figueiras, Polonia, & Gestal-Otero, 2005; Rogers et al., 
1988). Fewer studies investigated the factors affecting underreporting among pharmacists 
(Generali, Danish, & Rosenbaum, 1995; Green et al., 2001; Herdeiro et al., 2006; 
Houghton, Woods, Davis, Coulson, & Routledge, 1999; Sweis & Wong, 2000; van 
Grootheest, Mes, & de Jong-van den Berg, 2002). There are many reasons that have been 
provided as to why HCPs do or do not report ADEs. Some of the common reasons are 
discussed below:  
First, reluctance to send reports based on mere suspicion. Before submitting a 
report, HCPs should be able to detect the reaction or event and attribute it to a drug 
(Council for International Organization of Medical Sciences, 1990). Many pharmacists 
and doctors are more likely to report an ADE if they are confident of recognizing it 
(Sweis & Wong, 2000). As a result, uncertainty regarding the cause and effect of an ADE 
deters reporting (Aziz, Siang, & Badarudin, 2007; Cosentino et al., 1997; Eland et al., 
1999; Rogers et al., 1988). In one study, about two-thirds of physicians did not report 
suspected ADEs due to uncertainty concerning definite causality (Hasford et al., 2002). 
Most HCPs only report ADEs they believe are directly caused by the drug or if they have 
a strong suspicion of a causal relationship between a drug and the event (Biriell & 
Edwards, 1997; Inman, 1985). However, having conclusive evidence that a drug was 
responsible for an ADR is not required for submitting a report (Committee on Safety of 
Medicines, 1968; MADRAC, 2002). Nevertheless, many doctors are reluctant to report 
suspected (as opposed to proven) reactions or events (Belton & The European 
Pharmacovigilance Research Group, 1997).  
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Second, pharmacists and doctors may not report ADEs because they feel that self-
identification could result in personal repercussions including possible involvement in 
litigation or investigation (Ashcroft et al., 2006; Bateman, Sanders, & Rawlins, 1992; 
Inman, 1978). The medico-legal difficulties that may arise from the submission of reports 
negatively affect ADE reporting (Institute of Medicine Report, 2004; Kaufman, 
Stoukides, & Campbell, 1994; Vincent et al., 2006). However, this reason has not been 
consistently supported in the literature (Hasford et al., 2002).  
Third, lack of knowledge and misconceptions about the ADEs to be reported, 
purpose of ADE reporting and the safety of drugs hinder HCPs from reporting (Biriell & 
Edwards, 1997; Eland et al., 1999). Despite the fact that the Germany Drug Commission 
regularly publishes ADR reporting criteria in the German Medical Journal, which is 
mailed to all physicians, 86.7 percent of physicians stated that they did not know the 
criteria of ADRs to be reported (Hasford et al., 2002). Many HCPs do not have optimal 
knowledge about ADEs (Bateman, Sanders, & Rawlins, 1992). For example, only 26 
percent of Dutch medical practitioners knew which ADRs to report (Eland et al., 1999). 
Some HCPs do not report ADEs because they believe that the association between the 
ADE and a particular drug is already well known. Others do not make reports because 
they believe that the regulatory authorities will already be aware of the ADEs (Inman, 
1985). Other misconceptions held by HCPs are summarized below: 
 Only proven ADRs should be reported;  
 Serious ADRs are well-documented before a drug is marketed (Herdeiro et al., 2005; 
Khoza, Madungwe, Nyambayo, Mthethwa, & Chikuni, 2004);  
 Impossible to determine causality; and  
 One case reported by an individual doctor will not contribute to medical knowledge.  
Fourth, ‗lack of time‘ is associated with underreporting. To compile information 
for a good case report takes some time, which is scarce. Many HCPs consider themselves 
too busy to record their observations (Inman, 1985). Thirty eight percent of medical 
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practitioners in the Netherlands reported that they did not have enough time to report 
ADRs (Eland et al., 1999). Other studies reported similar findings (Bäckström et al., 
2000; Belton & The European Pharmacovigilance Research Group, 1997; Eland et al., 
1999; Hasford et al., 2002; Herdeiro et al., 2006). Some HCPs consider reporting ADRs 
as extra workload and as taking too much time (Bateman, Sanders, & Rawlins, 1992). 
The lack of time may be explained by the heavy workload that HCPs carry (Bateman, 
Sanders, & Rawlins, 1992; Figueiras et al., 1999; Inman, 1996). However, other studies 
did not find lack of time to be a significant predictor of ADR reporting among physicians 
(Aziz, Siang, & Badarudin, 2007; Li et al., 2004).   
Fifth, difficulty in accessing the means of reporting suspected ADEs (e.g., report 
forms and telephone numbers) and finding the right form deter ADE reporting 
(Bäckström et al., 2000). The availability of simple reporting forms greatly enhances 
ADE reporting by HCPs (Biriell & Edwards, 1997).  
Sixth, ADE reporting is negatively impacted by a lack of information on how to 
report ADEs (Belton & The European Pharmacovigilance Research Group, 1997; Li et 
al., 2004; Perlík et al., 2002). In one study in the Czech Republic, about one-third of the 
physicians said they did not know the correct way to report ADRs (Perlík et al., 2002). In 
the U.K., Sweden, and Denmark, 2.7 percent, 8.6 percent and 3.4 percent of physicians, 
respectively, were unsure how to report suspected ADRs (Belton & The European 
Pharmacovigilance Research Group, 1997).  
Seventh, type and nature (severity, novelty and seriousness) of the ADE or the 
drug (Hazell & Shakir, 2006) affect ADE reporting. Unexpected and serious ADEs are 
more likely to be reported than nonserious ones. About three-quarters of medical doctors 
in Sweden reported ―that the severity of the reaction was the main factor determining 
whether a suspected ADR was reported or not‖ (Bäckström et al., 2000, p. 731). Similar 
results were also reported elsewhere (Hasford et al., 2002). Clinicians report events for 
new treatments (e.g., first 2 years) more than they do for older drugs (Auriche & Loupi, 
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1993), a phenomenon called the Weber effect or the product life cycle effect (Heeley, 
Riley, Layton, Wilton, & Shakir, 2001; Martin, Kapoor, Wilton, & Mann, 1998). In the 
U.K., for example, serious events on new drugs were found to have a five-times greater 
chance of being reported than similar events on other (established) drugs (Heeley et al., 
2001). The number of reports for a particular drug tapers off with the passage of time. 
Also, ADEs that HCPs consider to be too trivial or to be too well known are less likely to 
be reported than other types of ADEs (Aziz, Siang, & Badarudin, 2007; Bäckström et al., 
2000; Cosentino et al., 1997; Eland et al., 1999; Hasford et al., 2002). 
Eighth, attention drawn to a particular drug, also called temporal bias or secular 
effects, affects ADE reporting (Biriell & Edwards, 1997). The reporting of ADEs for a 
particular drug or class of drugs can increase after increased media attention, use of 
medication by a celebrity and a warning from a health agency among others (Cobert, 
2007; Sachs & Bortnichak, 1986). 
Ninth, many personal characteristics of the reporter have been found to be 
associated with ADE reporting. The tendency to report ADEs was found to increase with 
seniority (Irujo et al., 2007; Sweis & Wong, 2000). Other factors associated with ADE 
reporting found in the literature include age, years of work experience (positive 
relationship), gender (female less), clinical specialty, and participation in educational 
activities related to the detection of drug related problems (Bateman, Sanders, & Rawlins, 
1992; Eland et al., 1999; Figueiras et al., 1999; Herdeiro et al., 2006; Irujo et al., 2007). 
In a study of medical practitioners in nine European Union (EU) member states (i.e., 
Denmark, France, Ireland, Italy, the Netherlands, Portugal, Spain, Sweden, and the U.K.), 
Belton and others (1997) found that a higher percentage of general practitioners than 
specialists indicated that they were ‗ever‘ reporters. In addition, the reporting 
environment (e.g., culture of organizations) also affects reporting (Goldman, 1998; 
Inman, 1985). 
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Tenth, is the sense of responsibility. ―Physicians are motivated by a sense of their 
responsibility to inform their colleagues of the adverse experiences they have 
encountered‖ (Inman, 1985, p. 51). ADE reporting is considered to be a professional 
responsibility by many HCPs. Many physicians believe that it is their duty to report 
ADEs (Figueiras et al., 1999). 
Eleventh, the nature of the relationship between the agency receiving reports and 
the reporter affects the willingness of HCPs to report ADEs. If this relationship is 
positive or at least the reporter perceives it as being positive, the more likely reporting 
will take place (Biriell & Edwards, 1997). A positive relationship is built and supported 
through active personal and general feedback and encouragement from the agency to 
reporters. The content of the feedback to the HCPs also influences reporting rates 
(Wallerstedt, Brunlöf, Johansson, Tukukino, & Ny, 2007).  
Finally, the attitude of HCPs towards reporting affects ADE reporting. Many 
studies investigated the ‗attitude‘ of reporters and potential reporters (Biriell & Edwards, 
1997; Eland et al., 1999; Martin et al., 1998; Moride et al., 1997). It has been reported 
that pharmacists‘ and doctors‘ attitudes toward their national ADE reporting schemes 
significantly determine their reporting rates (Bateman, Sanders, & Rawlins, 1992; 
Herdeiro et al., 2006; Koch-Weser, Sidel, Sweet, Kanarek, & Eaton, 1969; Rogers et al., 
1988). HCPs including pharmacists have favorable beliefs concerning ADE reporting 
(Lawton & Parker, 2002; McArdle, Burns, & Ireland, 2003; Uribe et al., 2002). 
Community pharmacists in the Netherlands were found to be highly motivated to report 
ADRs (van Grootheest, Mes, & de Jong-van den Berg, 2002).  
 
2.9 LIMITATIONS OF SPONTANEOUS REPORTS DATA FOR IMPROVING SAFETY 
The use of ADE spontaneous reports data in pharmacovigilance has a number of 
limitations (Goldman, 1998): underreporting, false causality attribution, reporting biases, 
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inaccurate and unreliable quantification of population risks, inability to identify some 
dangers and the poor quality of reports.  
 
2.9.1 Underreporting of ADEs 
Many ADEs are not reported to the SRS and many HCPs are unaware and 
unmindful of pharmacovigilance activities (Gogtay, Dalvi, & Kshirsagar, 2003; 
Kshirsagar, Karande, & Potkar, 1993). Underreporting is an oft-cited weakness of all 
SRSs.  Underreporting of ADEs by HCPs is a widespread problem (Alvarez-Requejo et 
al., 1998; Cullen et al., 1995; Lawton & Parker, 2002). There are numerous estimates of 
the magnitude of underreporting of ADEs. In one study, general practitioners (GPs) 
reported only one out of every 1,144 ADRs they came across to the pharmacovigilance 
centre (Alvarez-Requejo et al., 1998).  A systematic review of 37 ADR studies from 12 
countries, found a median underreporting rate of 94 percent (range: 6 - 100%; 
interquartile range: 82 - 98%) (Hazell & Shakir, 2006). Other studies estimated the rate of 
underreporting to be equal to or greater than 90 percent (Fletcher, 1991; Rawlins, 1988a). 
Underreporting is estimated to occur at a rate of 50 percent to 96 percent annually in the 
U.S. (Barach & Smith, 2000). A study in the Netherlands reported that only one (1) in 70 
ADRs was reported (van der Heijden et al., 2002).  A study to investigate the rate of 
underreporting of serious ADRs of selected diagnoses in Sweden found that of 107 
patients who had received drugs that could have been a probable or possible cause to the 
diagnoses, only 15 were reported, giving an overall underreporting rate of 86 percent 
(Bäckström, Mjörndal, & Dahlqvist, 2004).  
Although underreporting varies by the severity and seriousness of the event 
(Bäckström, Mjörndal, & Dahlqvist, 2004), high rates of underreporting have also been 
reported for serious ADEs and those with fatal outcomes (Bäckström, Mjörndal, & 
Dahlqvist, 2004; Hazell & Shakir, 2006; Moride et al., 1997). A systematic review 
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reported a median underreporting rate for serious ADRs across the studies of 85 percent 
(Hazell & Shakir, 2006). In the U.K., it was estimated that only 10 to 15 percent of even 
severe reactions were reported (Rawlins, 1988a). A 100 percent reporting is not 
achievable even for serious and fatal ADEs (Bäckström, Mjörndal, & Dahlqvist, 2004). 
Owing to the high rates of underreporting, SRSs may fail to detect all the risks  
associated with the use of drugs (Begard & Tubert-Bitter, 1993). Underreporting delays 
the identification of signals and complicates the analysis of data (van der Heijden et al., 
2002). Concerted efforts are required to minimize the rate of underreporting by HCPs 
(Bäckström, Mjörndal, & Dahlqvist, 2004). 
 
2.9.2 False Causality Attribution 
A common and major limitation associated with the use of ADE reporting data is 
false causality attribution (Edwards, 1997, 1999; Meyboom et al., 1997a; Meyboom, 
Hekster, Egberts, Gribnau, & Edwards, 1997b; Rawlins, 1995). In making ADE reports, 
HCPs make an association between a drug and the event/reaction. These subjective 
associations are at times unreliable. Making a correct association between a drug and the 
event is complicated by many factors. First, many ADEs mimic disorders that can occur 
without having any exposure to drugs (Inman, 1985; Stephens, 1985).  
Second, some symptoms or injuries that are similar to ADEs are caused by the 
condition being treated or its complications (Mulcahy & Rosenthal, 1999), making them 
difficult to differentiate from ADEs. The difficulty of separating disease-related 
symptoms from drug-related ones (Jacubeit, Drisch, & Weber, 1990) results in two 
problems. The first is the problem of over ascertainment, which occurs when prescribers 
wrongly attribute an adverse event to a drug (Osterberg & Blaschke, 2005).  For example 
in one study, thirty-eight percent of the 94 submitted ADE reports were attributed to 
other causes when additional data about these reports were later obtained (Stephens, 
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1985). The second problem is under ascertainment, which occurs when prescribers fail to 
recognize that the ADE is caused by the drug (when it actually is).  Prescribers may 
mistake ADEs for disease progression or dismiss an ADE as being a side effect.  
Third, for most suspected ADEs, it is difficult to rule out other explanations for 
the patient‘s negative experiences. This is so because even without exposure to a drug, 
there is always an underlying rate in the population (Goldman, 1998), and even healthy 
individuals taking no medication have many symptoms that are similar to those 
attributable to ADEs (Lee & Thomas, 2003).  
Thus, the above challenges complicate the signal generation process resulting in 
two types of errors being experienced: calling a true signal noise (a false negative) and 
calling noise a signal (a false positive) (Evans, 2007). These errors cannot be completely 
eliminated given the current state of knowledge and unless true experimentation is done.  
 
2.9.3 Reporting Biases 
As noted earlier, ADR reporting is selective and reported cases may differ from 
those not reported in terms of severity, the length of time the product has been on the 
market, the groups of users, novelty of the effect of the drug and publicity surrounding 
the drug or ADE (Gharaibeh, Greenberg, & Waldman, 1998; Inman, 1985; Sachs & 
Bortnichak, 1986). As a consequence, the reported ADEs may not be representative of 
the universe of ADEs. Selective reporting makes it inappropriate to compare ADE 
reporting rates across studies and across drugs. Such a comparison will find spurious 
differences in toxicity (Moride et al., 1997).  
 
2.9.4 Inaccurate and Unreliable Quantification of Population Risks  
It is difficult to accurately quantify the risks associated with a drug in a population 
using SRS data. An accurate quantification of population risk (incidence) requires an 
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accurate value for risk (the numerator) and an accurate value for drug utilization (the 
denominator). The true drug utilization is unknown and sales data is often used as an 
estimate. However, sales do not accurately reflect actual usage levels. Reporting biases 
and underreporting also make the numerator inaccurate (Hazell & Shakir, 2006). 
Therefore, it is inappropriate to calculate ADE rates using spontaneous ADE reporting 
data and to make safety comparisons among drugs (Griffin & Weber, 1985).  
 
2.9.5 Inability to Identify Some Dangers 
Data from spontaneous reports are incapable of identifying some potential 
dangers associated with the use of approved drugs. Compared to automated (computer 
database) and manual (chart review) active surveillance, SRSs identify significantly 
fewer events. SRS data have a low signal, and detect only about 10 percent of ADEs 
(Classen et al., 1991). Monitoring systems based on spontaneous reports do not readily 
identify the following dangers: 
 A drug that causes an event that might be expected as part of the natural history of the 
disease being treated (e.g., cardiac arrest caused by flecainide and encainide) (Moore, 
Psaty, & Furberg, 1998); 
 ADEs that manifest themselves as a disease with high prevalence or high background 
rate in the population (e.g., cancer or heart disease) (Institute of Medicine of the 
National Academies, 2007a; Moore, Psaty, & Furberg, 1998); 
 Negative effects that occur years or even decades after exposure to the drug (e.g., 
cancer) (Moore, Psaty, & Furberg, 1998); and 




2.9.6 Poor Quality of Reports 
SRS data make a positive contribution to patient safety if HCPs provide good 
quality reports. Some reports of valid concerns do not have enough detail to allow for a 
remote expert assessment and thus are of limited value (Edwards, 1999). The poor quality 
of the data may be due to the poorly controlled, inexact and voluntary nature of the data 
(Gharaibeh, Greenberg, & Waldman, 1998) and recall bias. In addition, the amount of 
information that can be provided through spontaneous reports is limited (Stephens, 1985). 
Critical information for evaluating an ADE such as chronology, dechallenge, rechallenge, 
clinical symptomatology, other possible explanations, possible predisposition and 
complementary investigations (Stephens, 1985) is often missing in reports. These quality 
limitations compromise the use of the data.  
In summary, while the information provided by spontaneous reports makes 
valuable contribution, it needs to be augmented by information from other sources. 
However, despite the above limitations, the ability to draw valid conclusions from SRS 
data is high (Inman, 1985). SRSs are the most informative systems currently in use 
(Wade & Beeley, 1976).  
 
2.10 STRATEGIES FOR INCREASING ADE REPORTING RATES 
The effectiveness of SRSs could be greatly enhanced if more HCPs reported 
serious ADEs (Wade & Beeley, 1976). Many strategies have been implemented to 
increase the rate of ADE reporting by HCPs. These include legally mandating ADE 
reporting, making reporting more convenient, improving education and training, having 
an independent organization to receive the ADE reports and providing encouragement 




a) Legally Mandating Reporting 
Some countries, such as Sweden, mandate the reporting of ADEs by HCPs. In 
Sweden, all prescribing officers are obliged to report all cases of serious ADEs to the 
regulatory authority. The Swedish law requires that all unknown side effects and ―drug-
suspected deaths, reactions leading to life threatening reactions, side effects leading to 
hospital admissions, new and unexpected reactions and ADRs that seem to increase in 
frequency and seriousness should be reported‖ (Bäckström et al., 2000, p. 729). In 
France, reporting of ADRs has been compulsory since 1984. Physicians are required by 
law to report serious and unexpected ADRs to their regional pharmacovigilance centers 
(Sommet et al., 2008).  
 
b) Making ADE Reporting More Convenient 
Streamlining the reporting process and procedures increases ADE reporting rates 
(Brewer & Colditz, 1999). Specific measures that can be taken include increasing 
availability of forms, giving more options for HCPs to use to submit reports (phone, fax, 
mail or internet websites), providing a toll-free phone, using postage-paid forms, and 
developing and using information technology (IT).  
 
c) Improving Education and Information 
Improving the HCPs‘ understanding of the purpose of pharmacovigilance through 
education and training increases ADE reporting rates (Brewer & Colditz, 1999). 
Education and training aimed at providing potential reporters with information on what 
constitutes a good report, and the benefits of reporting in overall patient care boost 
reporting rates (Cosentino et al., 1997; Davis, Thomson, Oxman, & Haynes, 1992; Lomas 
et al., 1991; Scott et al., 1990). In 1986, the Rhode Island Department of Health 
implemented a physician education project targeted at increasing the physicians‘ 
reporting rates. The Rhode Island Department of Health provided professional education 
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to physicians on the reporting system through direct mailings, presentations to physician 
groups and advertisements and articles in local periodicals (Scott et al., 1990). One year 
prior to the project, in 1985, only 11 reports were received from over 2,000 physicians in 
the state. As a result of the project, the number of reports increased from an average of 
11.6 per year (1981-1985) to 209 direct reports in 1988, a 17-fold increase. The project 
demonstrated that reporting of suspected ADRs by HCPs can be stimulated through 
promotional and educational interventions (Scott et al., 1990).  
 
d) Establishing an Independent Organization to Receive ADE Reports 
In most countries, reports are submitted to the regulatory authority (e.g., the FDA 
in the U.S.). Some HCPs may be unwilling or be hesitant to report ADEs to a regulatory 
authority or government agency. Establishing an independent organization that 
coordinates this process increases the confidence and support of the HCPs in the system 
and eliminates some of the challenges associated with reporting ADEs (van Grootheest, 
2003). An example of such an arrangement is the founding of the Netherlands 
Pharmacovigilance Centre, Lareb which is run by doctors and pharmacists. All large 
medical and pharmacists‘ bodies are fully represented on Lareb‘s Administrative Board.  
 
e) Providing Encouragement and Motivation 
HCPs need to be motivated to report suspected serious ADEs. Encouraging HCPs 
to always be vigilant for the occurrence of serious ADEs, and making all HCPs aware 
that ADE reports are welcomed increase ADE reporting rates. A special request can be 
sent to practitioners to encourage them to report serious ADEs. A U.K. study found that 
reporting among pharmacists increased when reporting was promoted in the hospital 
(Sweis & Wong, 2000).  
Providing incentives to HCPs for reporting is another way to motivate them to 
report serious ADEs. Monetary (fees) or non-monetary (e.g., credit points for continuing 
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education (CE) and provision of feedback) rewards can motivate HCPs to report ADEs 
(Bäckström & Mjörndal, 2006; Bracchi et al., 2005; Feely, Moriarty, & O'Connor, 1990). 
In one study, researchers offered three pounds to junior doctors for each completed report 
submitted and reporting rates increased by almost 50-fold (Feely, Moriarty, & O'Connor, 
1990). Many of the reactions reported in response to the fee would normally go 
unreported. The study helped introduce newly qualified doctors to the reporting system 
(Feely, Moriarty, & O'Connor, 1990). However, reporting rates declined after the fee was 
stopped.  
Reporters and potential reporters are also motivated by receiving assurances that 
they will not experience any personal negative consequences or retribution (e.g., 
managerial scrutiny, threats to promotion and employment) for reporting ADEs. ADE 
reporting rates are boosted by addressing the HCPs‘ fear of public scrutiny and lawsuits 
emanating from personal disclosure. To get support from HCPs, the system must protect 
clinicians and other HCPs from unwarranted public scrutiny. 
Pharmacists in the Netherlands were asked to provide the factors that motivated 
them to report suspected ADRs through an open-ended question (van Grootheest, Mes, & 
de Jong-van den Berg, 2002). The pharmacists provided the following 10 main 
suggestions listed in Table 2.7. 
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Table 2.7: Suggestions to Encourage Reporting ADRs (n = 147) 




Information about the national centre 17 
Simplification of reporting procedure 14 
Promoting reporting as part of professional duty 13 
Encouraging patients to report ADRs to the pharmacist 7 
Financial compensation 7 
More attention to ADR reporting in university curriculum 6 
Database of national centre available on the internet 6 
Compulsory reporting 2 
Source: Van Groothest, 2002. 
 
2.11 PHARMACOVIGILANCE AT THE INTERNATIONAL LEVEL 
The WHO plays an important role in pharmacovigilance at the international level. 
Under the auspices of the WHO, 10 countries started a historic cooperative effort in 1968 
which culminated in the setting up of the WHO International Drug Monitoring 
Programme. The WHO technical report, “International Drug Monitoring: The Role of 
National Centres” (1972) spurred the development of pharmacovigilance (World Health 
Organization, 1972). The establishment of the WHO Collaborating Centre for Drug 
Monitoring (The Uppsala Monitoring Centre, UMC) to maintain the international ADR 
database further spurred the development of pharmacovigilance. 
Over the years, there has been a phenomenal increase in the number of countries 
affiliated with the UMC. More than 72 countries regularly send extracts from their 
spontaneous databases of local reports to the UMC which is based in Sweden. The UMC 
database has over 4 million cases. The U.S. is the single largest contributor of reports to 
the UMC database accounting for about half of the reports. The UMC collates and 
analyzes these reports and disseminates the information on drug safety to member 
countries (Edwards & Aronson, 2000; Edwards, 2001). This larger database has increased 
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power of vigilance that allows more new ADE signals to be identified that may not be 
apparent to a national centre (Edwards, 2001). The worldwide database contains 
information from diverse countries and cultures, most of which are not represented in 
clinical studies (Amery, 1999). 
The UMC acts as a communication centre or a drug information clearing house 
for regulatory authorities and the pharmaceutical industry (Edwards & Biriell, 2007). All 
of UMC‘s clients can communicate with the UMC through the UMC‘s internet homepage 
(http://www.who-umc.org). The UMC‘s responsibilities and functions are: 
 Providing support to national centers through developing information technology 
(IT), organizing training courses on pharmacovigilance and giving technical advice; 
 Leading in developing guidelines for finding signals (Edwards, Lindquist, Wiholm, & 
Napke, 1990); 
 Harmonizing the definition of pharmacovigilance terms (Edwards, 1997); 
 Providing advice and recommendations on the safe use of medicines to HCPs; and 
 Participating in refining the concept of benefit-risk analysis (Edwards & Biriell, 
2007). 
Another organization that played a prominent role in the development of 
pharmacovigilance at the international level is the Council for International Organization 
of Medical Sciences (CIOMS). The CIOMS was jointly established by the United 
Nations Educational and Scientific Organization (UNESCO) and WHO in 1949 as a non-
profit international organization (Council for International Organization of Medical 
Sciences, 2008). The membership of CIOMS comprises mainly representatives of drug 
manufacturers and regulatory authorities. CIOMS‘ work champions the standardization 
of ADR reporting at the international level. CIOMS‘ efforts have helped improve 
understanding and communication on drug safety issues (Council for International 
Organization of Medical Sciences, 1998). CIOMS has also invested heavily in providing 
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guidance on developing standard approaches to weighing the benefits and risks of drugs 
(Council for International Organization of Medical Sciences, 1998). 
 
2.12 PHARMACOVIGILANCE IN THE U.S. 
The FDA plays an important role in pharmacovigilance or in monitoring the 
safety of all drugs marketed in the U.S. These PMS activities are premised on the FDA‘s 
adverse event reporting system. The Spontaneous Reporting System (SRS) originated in 
1969. All reports are collected and stored in the Adverse Event Reporting System 
(AERS) database. The reporting system has undergone major transformations over the 
years. In 1993, the system was renamed MedWatch. MedWatch facilitates the reporting 
of AEs by physicians, pharmacists, dentists, nurses, consumers and pharmaceutical 
companies in the U.S. and disseminates clinically useful safety information to patients 
and HCPs. The system went online in 1997. As of 2001, the AERS database had over 2 
million reports of adverse events for drug and therapeutic biologics (Trontell, 2001). 
AERS provides state-of-the-art analytic capabilities and is compliant with International 
Conference on Harmonization (ICH) agreements. There is a separate system for vaccine 
safety data called the Vaccine Adverse Event Reporting System (VAERS) and another 
one for medication error reporting called MEDMARX5.  
The U.S. Code of Federal Regulations (CFR) requires all drug companies to 
report to the FDA all ADEs for all drugs they market. Pharmaceutical companies collect 
these reports from HCPs. Pharmaceutical companies are required to report all serious and 
unexpected ADEs to the FDA within 15 calendar days of receiving them from HCPs or 
                                                 
5 MEDMARX is a national medication error reporting program that was developed and implemented in 
1998 by the United States Pharmacopea (USP). MEDMARX is ―an anonymous, confidential, de-identified, 
internet-accessible medication error reporting program‖ (Santell et al., 2003).  MEDMARX facilitates the 
reporting, tracking, and sharing of medication error data in the U.S. Since its inception, MEDMARX has 
uncovered previously unknown information and trends and identified problem areas in many hospitals 
(Santell et al., 2003). 
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patients. A serious adverse event is defined as any event that is fatal, life threatening, is 
permanently/significantly disabling, requires or prolongs hospitalization, causes a 
congenital anomaly and requires intervention to prevent permanent impairment or 
damage. Other events (i.e., serious and expected, nonserious and unexpected, and 
nonserious and expected) are to be periodically reported (Trontell, 2001).  
The FDA has issued several guidance documents defining and clarifying what is 
to be reported by HCPs and drug companies. Some of the documents include: CDER’s 
Guideline for Postmarketing Reporting of Adverse Drug Experiences (March 1992), and 
CDER’s Guideline for Adverse Experience Reporting for Licensed Biological Products 
(October 1993). Hard copies and electronic versions of these documents are available 
from the FDA. According to the FDA, a safety report from drug companies should have 
four elements: a) an identifiable patient, b) an identifiable reporter, c) a suspect drug or 
biological product, and d) an adverse event or fatal outcome (FDA/Center for Drug 
Evaluation and Research, 1997). The FDA recommends that only complete reports 
should be submitted to the FDA.  
The FDA receives approximately 250,000 reports of adverse events annually. 
Most (80%) of the HCPs‘ reports are submitted to the FDA through pharmaceutical 
companies and approximately 20 percent of the reports go directly to the FDA through 
MedWatch. Compared to other HCPs in the U.S., pharmacists submit the greatest number 
of reports to the FDA. In 2001, pharmacists submitted 41 percent of the reports made by 
individuals. The rest of the reports were made by physicians (11%), nurses (11%), other 
health care professionals (11%), unknown (18%), and consumers (8%) (Cobert, 2007; 
Office of Drug Safety, 2001). In 2004, the FDA received 422,889 reports of suspected 
drug-related adverse events broken down as follows: MedWatch reports directly from 
individuals (21,493), manufacturer 15-day (expedited) reports (162,107), serious 
manufacturer periodic reports (89,960), and nonserious manufacturer periodic reports 
(149,329). The number of ADE reports has been increasing over the years (Figure 2.3). 
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Figure 2.3: Adverse Events Reported to the FDA (1995 – 2004) 
 
 
 Source: CDER Report to the Nation: 2004 
  
In reporting AEs through the MedWatch Program, HCPs use a standard form. 
These forms are widely available (e.g., available in the Physicians‘ Desk Reference and 
can be downloaded from the internet). The form is two pages long and asks HCPs to 
provide information on the event, the patient, the product and about themselves (see 
Appendix A). Reports can be submitted to the FDA by mail (postage free), fax (1-800-
FDA-0178), internet (www.fda.gov/medwatch), or phone (1-800-FDA-1088).  
Like all other SRSs, the AERS has strengths and limitations. The strengths of the 
system include: comprehensive coverage of all drug products, simplicity, low cost 
relative to active surveillance, and good ability to detect rare events (Trontell, 2001). The 
system also faces problems similar to those experienced by many other SRSs elsewhere 







































in detecting signals and in calculating incidence rates (Trontell, 2001). The main 
challenges and limitations of the conduct of PMS in the U.S. are discussed below. First, 
there is no independent body (i.e., completely separate from the drug regulators and 
manufacturers) that monitors and investigates ADEs in the U.S. (Wood, Stein, & 
Woosley, 1998). The FDA is both the regulator and collector of patient safety 
information. The need for, and importance of, independent safety monitoring is 
recognized in the U.S. (Institute of Medicine Report, 2001).  
Second, PMS activities in the U.S. are under-funded (Young, 2006). The FDA 
does not have adequate resources to optimally identify and quantify all drug-induced 
problems. Until recently, the FDA charged pharmaceutical companies a fee for reviewing 
drug applications, but did not collect any fees for PMS. In addition, the FDA was 
prohibited by the Food and Drug Administration Modernization Act of 1997 from 
spending the fees they collected on PMS or other drug safety programs (Wood, Stein, & 
Woosley, 1998). This is expected to improve with the passage of the Food and Drug 
Administration Amendments Act (FDAAA) of 2007 which now allows the FDA to use 
the funds for PMS. 
Third, low priority is given to PMS in the U.S. The IOM reported that the FDA 
focused mainly on evaluating new drugs and devoted less resources and staff to drug 
safety monitoring for approved drugs (Institute of Medicine Report, 2004; Moore, Psaty, 
& Furberg, 1998). As a result, the FDA is not able to review the submitted reports of 
adverse events in a timely manner (Schultz, 2007) and does not aggressively promote the 
reporting of ADEs.  
Fourth, the FDA has minimal powers to regulate approved drugs. Until recently, 
the FDA could not order companies to conduct postmarketing studies and to make 
labeling changes. This is expected to improve with the passing of the FDAAA of 2007 
which gave the FDA significant regulatory powers.  
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Fifth, drug safety in the U.S. is also compromised by lack of information 
technology (IT) capacity and the shortage of trained experts in drug safety and drug 
epidemiology at the FDA (Schultz, 2007). The FDA has a limited technological capacity 
(Cassell, 2008). The Office of Surveillance and Epidemiology (OSE) faces a shortage of 
trained and skilled personnel. Some scientific positions at the FDA have turnover rates 
more than double those of other government agencies (Schmit, 2007). These capacity 
challenges impede the monitoring of products that use new science (Cassell, 2008). The 
size of the FDA workforce does not match its wideranging responsibilities which also 
involve regulating the safety of food, cosmetics, feeds, dietary supplements, blood 
products, veterinary products and medical devices.  
The above notwithstanding, information gathered through the AERS is critical 
and indispensable. According to the IOM: ―while AERS is not perfect, it is still all that 
we have right now in terms of providing a system for patients and physicians to alert the 
FDA. … there is no real substitute for the information collected through AERS‖ (Institute 
of Medicine, 2007, p. 54).  
 66 
2.13 SUMMARY OF LITERATURE REVIEW, GAPS AND AREAS OF FUTURE RESEARCH 
Healthcare, including drug therapy, provides many benefits to society. However, 
the common occurrence of serious ADEs, many of which are preventable, threaten 
patient safety. Though inherently negative, serious ADEs are a valuable source of safety 
information and can contribute towards clinical and scientific progress (Vincent, 2006). 
The occurrence of serious and other ADEs provides unique learning opportunities for 
health systems and HCPs (McIntyre & Popper, 1983). Pharmacovigilance and PMS are 
the vehicles through which such learning can occur and they play a critical role in drug 
safety and drug therapy decision-making. PMS monitors drug safety through collecting 
and analyzing spontaneous reports from HCPs, pharmaceutical companies and patients.  
SRSs are an important component of any comprehensive surveillance program of risks 
induced by drug use. Information collected through SRSs informs drug regulatory 
agencies‘ and pharmaceutical companies‘ actions. Possible actions and measures include 
modifying product information and warnings, modifying the product or its use and 
withdrawing the product from the market.  
Pharmacists play an important and indispensable role in PMS and other efforts 
aimed at improving patient safety and outcomes through reporting ADEs. Pharmacists, 
like other HCPs, are encouraged to report ADEs. There are many factors that affect the 
reporting of ADEs by pharmacists: reluctance to send reports based on mere suspicion, 
fear of personal repercussions, sense of professional responsibility, difficulty in accessing 
the means of reporting, lack of information, the type and nature of ADEs, attention drawn 
to a particular drug and ADE, beliefs and opinions, and ‗lack of time,‘ among others. In 
addition, pharmacists‘ attitude towards reporting is a major factor influencing ADE 
reporting. 
The objective of SRSs is to generate signals and hypotheses. SRSs are cost-
effective, comprehensive and directly related to clinical practice. However, the 
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effectiveness of SRSs is compromised by underreporting by HCPs including pharmacists. 
Underreporting of serious ADEs is a serious problem with an estimated less than one 
percent of serious ADEs being reported.  
Many strategies have been implemented to increase ADE reporting rates among 
HCPs including mandating reporting, encouraging and motivating HCPs to report, 
streamlining the reporting process, offering targeted training and education, and 
establishing independent organizations to coordinate and receive ADE reports. These 
strategies have had mixed results.  
There are several gaps in the literature on ADE reporting. None of the studies 
reviewed investigated attitudes of pharmacists toward ADE reporting using a theoretical 
framework. The empirical literature lacks a systematic theoretical framework and fails to 
define independent and dependent variables in a theoretically justified way (Hoff, 
Jameson, Hannan, & Flink, 2004). Little is known about the attitude of pharmacists 
towards ADE reporting. Moreover, many studies in the literature that purported to be 
studying the attitudes of HCPs more accurately studied their beliefs and opinions, one 
aspect of attitude, about ADE reporting (Generali, Danish, & Rosenbaum, 1995; Sweis & 
Wong, 2000). More research applying theoretical models in studying and understanding 
ADE reporting by healthcare professionals, especially pharmacists, is warranted.  
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CHAPTER THREE: THEORY 
3.1 RATIONALE OF THE STUDY 
The literature review shows that increasing the number of ADE reports submitted 
by HCPs (including pharmacists) is an indispensable part of the drug safety system and is 
associated with improved safe use of drugs through: a) facilitating the identification and 
elimination/withdrawal of unsafe products from the market; b) informing better and safer 
ways of using available drugs (e.g., imposition of restrictions); c) facilitating the 
education and training of health professionals on the safe use of medicines; and d) 
identifying other positive effects of drugs. The submitted ADE reports are used by the 
FDA and pharmaceutical companies in calculating the benefit-risk ratio or in defining the 
safety profile of a drug. This process helps in formulating strategies to minimize the 
health (e.g., patient harm and mortality) and economic impact associated with ADEs, by 
reducing the chances of having drug-related problems in the future.  
Pharmacists have the responsibility to promote the safe use of medications. Their 
actions with respect to identifying and reporting ADEs are one way they can do so 
effectively.  In addition, through reporting ADEs, pharmacists have the opportunity to 
promote public health and patient safety. However, research regarding pharmacists‘ 
participation in reporting ADEs is limited. Even less is known about their decision-
making with respect to ADE reporting. No known study has specifically assessed 
pharmacists‘ beliefs, attitudes, subjective norms and intentions to report ADEs using a 
grounded theoretical model. Thus, there is a need to conduct a theory-driven study to 
identify and understand the factors affecting the likelihood of ADE reporting by 
pharmacists. This study will contribute to the literature by providing insight into the 
factors that influence pharmacists‘ decision-making process regarding ADE reporting. 
Policy makers, public health officials and regulatory agencies require this critical 
information in order to improve medication use safety in the U.S. In addition, continuing 
education (CE) programs need this information in order to better design and target their 
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interventions to meet the needs of pharmacists, to increase their willingness to report and 
actual reporting of serious ADEs, and thus better serve the community. 
The pharmacists‘ decision to report serious ADEs may be affected by their 
attitudes towards ADEs. It may also be affected by their perceptions of the beliefs of 
significant others (e.g., physicians, other pharmacists, pharmacy managers, and patients). 
It is also speculated that some external factors (e.g., resources and opportunities) may 
influence pharmacists‘ intentions to report serious ADEs. 
This study seeks to identify and analyze the factors that influence pharmacists‘ 
intended reporting behaviors. Once the pharmacists‘ beliefs and attitudes are identified 
and analyzed, the next step is to develop appropriate interventions tailored to these beliefs 
and attitudes. The interventions meant to increase ADE reporting by pharmacists will 
likely succeed if they are appropriate. The long-term goal is to facilitate pharmacists‘ 
education and monitoring activities and to promote the safe and appropriate use of 
medications in the U.S.  
There are many social psychology theories that have been used to predict and 
understand behavior. Among these theories, Fishbein and Ajzen‘s (1991) theory of 
planned behavior has been extensively used. The theory of planned behavior (TPB) is an 
extension of the theory of reasoned action (TRA). The TPB is well developed and has 
been used successfully to predict many health-related behaviors (Godin & Kok, 1996; 
Millstein, 1996) and to predict the intentions of HCPs including physicians, nurses and 
pharmacists (Coleman, 2003; Feng & Wu, 2005; Millstein, 1996; Nwokeji, 2007). Given 
this, the TPB might be effective in predicting intentions and behaviors of pharmacists in 
reporting ADEs as well.  
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3.2 THEORY OF REASONED ACTION 
The TRA has its roots in social psychology, which seeks to explain the 
association between attitude and behavior. The TRA was developed by Fishbein and 
Ajzen to explain why people behave the way they do (Ajzen & Fishbein, 1980). 
According to the TRA, an individual‘s behavior is determined by intention. Behavioral 
intentions are in turn a function of attitudes toward engaging in the behavior and 
subjective norm. The TRA has three main components: a) attitude toward the behavior; 
b) subjective norm; and c) behavioral intention (Figure 3.1).  
 
Figure 3.1: The Theory of Reasoned Action 
 
Source: Ajzen, I. and M. Fishbein (1980). Understanding attitudes and predicting social 
behavior. Englewood Cliffs, New Jersey, Prentice Hall. 
 
Attitude toward the behavior or performing the behavior is the positive or 
negative evaluation by an individual. Other things being equal, if a person has a positive 








determined by expectations for the outcome of the behavior and evaluations of the 
expected outcomes of the behavior as shown below. 
A = ∑ eibi 
A = attitude towards the object of behavior 
ei = evaluation of attributes or consequences 
bi = belief about the object‘s attributes or about the behavior‘s consequences 
 
Subjective norm, also called social norms, is the social pressure to perform or not 
to perform a behavior. It reflects the social influences on the individual. Like attitude, 
subjective norm has two components: a) the individual‘s perception of the most salient 
group norms, and b) individual‘s motivation to comply with these norms. These 
components are important in the decision making process (Vanlandingham, Somboon, 
Grandjean, & Sittitrai, 1995). The likelihood of individuals intending to engage in a 
behavior is higher if the intention is considered important by persons or groups the 
individual wishes to please. Subjective norm is a function of the individual‘s normative 
beliefs about the behavior and the individual‘s motivation to comply with the referents‘ 
wishes as shown below. 
SN = ∑nimi 
SN = subjective norm 
ni = normative belief about the behavior 
mi = motivation to comply with the referent 
 
Behavioral intention defines a person‘s willingness or ambition to perform a 
given behavior. The person‘s degree of willingness can be seen from the degree of effort 
s(he) intends to invest towards performing the behavior. According to Ajzen, behavioral 
intention is affected by attitude and subjective norm (Ajzen, 1991).  
The TRA has been applied to predict intentions in many behaviors across many 
settings. Much research supports the predictive validity of this model (Ajzen & Fishbein, 
1980). The model has been successfully used in behaviors such as breast feeding, 
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drinking, smoking, exercise, substance use, HIV and sexually transmitted disease 
prevention, seat belt use and utilization of health care services (Albarracin, Johnson, 
Fishbein, & Muellerleile, 2001; Bandawe & Foster, 1996; Beadnell et al., 2008; Bogart, 
Cecil, & Pinkerton, 2000; Gastil, 2000; Morrison, Spencer, & Gillmore, 1998; Munoz-
Silva, Sanchez-Garcia, Nunes, & Martins, 2007). Meta-analyses conducted on the use of 
the TRA confirmed the theory‘s predictive ability (Albarracin et al., 2001; Sheppard, 
Hartwick, & Warshaw, 1988).   
In a meta-analysis to investigate the effectiveness of TRA in predicting intentions 
and behavior, Sheppard, Hartwick and Warsaw (1988) reviewed 87 separate studies 
involving 174 behaviors including abortion, taking birth control pills, resigning from a 
job, and voting in presidential elections among others. The results of the meta-analysis 
showed that, on average, attitude and subjective norm explained 43 percent of the 
variance in intention and intention accounted for 28 percent of the variance in behavior. 
These results indicate that the TRA constructs significantly influence intention and 
behavior and the TRA model performed extremely well (Sheppard, Hartwick, & 
Warshaw, 1988). In another study, Albarracin and colleagues (2001) conducted a meta-
analysis of TRA in predicting condom use behavior. The results of 42 studies reviewed 
showed that TRA highly predicted condom use intentions and behavior (Albarracin et al., 
2001).  
The TRA has been applied across many different settings, behaviors and 
circumstances. It has been successfully applied to study health behaviors, with most of 
the TRA applications primarily focusing on predicting patients‘ intentions and behaviors 
(Bandawe & Foster, 1996; Godin & Kok, 1996; Morrison, Spencer, & Gillmore, 1998). 
In addition to patients, the TRA model has been found to be relevant for studying 
healthcare providers‘ behaviors as well (Godin et al., 2008; Millstein, 1996). This section 
focuses on the studies that used the TRA model to predict the intentions of healthcare 
providers.  
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A total of six (6) studies that used the TRA as the conceptual model to study 
HCPs‘ behavior were found in the literature (Coleman, 2003; DiIorio, 1997; Fried, 
DeVore, & Dailey, 2001; Millstein, 1996; Sable, Schwartz, Kelly, Lisbon, & Hall, 2006; 
Werner & Mendelsson, 2001) (Table 3.1). One study by Kleier (2004) was excluded from 
the discussion because it did not use the model correctly (the study did not conduct 
elicitation interviews to develop the survey items) and did not report the needed statistics 
(beta weights and R
2
) (Kleier, 2004). The number of studies that did not use the model 
correctly is less than what has been reported by Sheppard, Hartwick and Warshaw 
(1988). Sheppard, Hartwick and Warshaw (1988) found that only 20 percent and 11 
percent of the studies predicting intentions and behavior, respectively, used the models 
correctly. In addition, one study could not be obtained and thus, was excluded from our 




Table 3.1: Studies Using the TRA to Predict HCPs‘ Intentions  
Study Author (s) 
& Year 













β = 0.22*** β = 0.28*** R
2 
= 0.15** 





β = 0.184*** β = 0.048 R
2 
= 0.042*** 
Fried et al., 2001 Self assessment 119 dental 
hygienists  
r = 0.667**** r = 0.278 R
2
 = 0.497**** 
Werner and 
Mendelsson, 2001 
Use of physical 




β = 0.66*** β = 0.12** R
2 
= 0.48**** 





β = 0.197*** NA R
2 
= 0.14 





B = 1.39*** B = 0.05* NA 
A-I = Attitude-Intention; SN-I= Subjective norm-Intention 
NA = not available 
*p < 0.05, **p < 0.01, ***p < 0.001, ****significant, p value not reported 
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Millstein (1996) conducted a study that applied the TRA and later the TPB in 
predicting physicians‘ behavior with respect to educating their adolescent patients 
concerning transmission of HIV and other sexually transmitted diseases (also referred to 
as delivery of preventive services). The study sample consisted of 765 physicians 
practicing in California who were predominantly male (64%). Using multiple regression 
analysis, the authors found that both attitude (β = 0.22, p < 0.001) and social norms (β = 
0.28, p < 0.001) independently and significantly predicted physicians‘ behavioral 
intentions (Millstein, 1996). Social norms or subjective norm was the strongest predictor 
of behavioral intentions. Overall, the two TRA predictors explained 15 percent of the 
variance in intention (p < 0.01).   
Fried, DeVore and Dailey (2001) applied the TRA to study the perceptions of 
Maryland dental hygienists regarding self-assessment (SA). A total of 119 respondents 
participated in the study. A majority of respondents received their initial dental hygiene 
licensure 19 or more years prior to the study (59.6%). Sixty six percent of the 
respondents had an associate degree in dental hygiene as their highest education (n = 79) 
and 83.2 percent were employed in general dental practice. Results indicated that 
respondents had high intention to self-assess (SA) (X = 2.7; scale: -3 to +3) as well as a 
favorable attitude (X = 2.6) and strong subjective norm (X = 1.0). Attitude was strongly 
correlated with intention (r = 0.667, p < 0.01), but subjective norm mildly correlated with 
intention to SA (r = 0.278; p > 0.05). Taken together, attitude and subjective norm 
strongly predicted intention to perform self-assessment (R = 0.705; R
2
 = 0.497). Socio-
demographic variables except hours of employment did not independently influence 
intention to perform self-assessment. The dental hygienists who worked less than 20 
hours per week were significantly less likely to intend to self-assess than those who 
worked for 20 or more hours per week (p = 0.0089). The study concluded that dental 
hygienists are influenced more by their own attitudes (i.e., their belief in the benefits of 
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SA) than by what patients, employers, or other dental hygienists value in terms of their 
intentions to self-assess (Fried, DeVore, & Dailey, 2001).  
Werner and Mendelsson (2001) tested the assumptions of the TRA model in 
predicting nursing staff members‘ intentions to use physical restraints with older people 
in Israel (Werner & Mendelsson, 2001). A total of 303 respondents participated in the 
study. Participants were predominantly female (95.2%), of Israeli nationality (51.0%) and 
with an average age of 42.4 (SD = 8.6) years. Results supported the TRA model—
findings indicated that attitude and subjective norm explained 48 percent of the variance 
in nurses‘ intentions (Werner & Mendelsson, 2001). Both TRA predictors were 
statistically significant: attitude (β = 0.66, p < 0.001) and subjective norm (β = 0.12, p = 
0.01). The authors found that perceived moral obligation (PMO) (β = 0.22, p < 0.001) 
predicted intentions to use physical restraints with older people over and above the 
contributions of attitude and subjective norm (Werner & Mendelsson, 2001). In separate 
univariate analyses, PMO accounted for more variance in intention (R
2
 = 0.25) than SN.  
In 2006, Sable and colleagues published results of their study that applied the 
TRA in predicting emergency contraception (EC) prescribing behavior among faculty 
physicians (Sable et al., 2006). A total of 96 faculty physicians from one Southwestern 
and three Midwestern universities participated in the study. The average age of 
respondents was 46.9 years (range: 29 - 79 years). A majority of the respondents were 
family practitioners (52%), board certified (97%) and male (62%). The results of 
regression analysis showed that attitude toward prescribing (B = 1.39, p < 0.001) and 
subjective norm (indirect measure; B = 0.05, p < 0.05) were significant predictors of 
intention. The direct measure of SN, did not independently predict EC prescribing 
intentions. Physicians in the study had very strong opinions about the positive or negative 
aspects of prescribing EC and they were less influenced by their professional referent 
groups‘ perspectives (Sable et al., 2006). The study concluded that physicians‘ own 
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attitudes had a greater impact than the influence of significant others on whether or not 
they actually prescribed EC (Sable et al., 2006). 
While the TRA has been applied among HCPs, only one reference to the theory 
was found in the pharmacy literature. In a national study, Coleman examined the 
influence of community pharmacists‘ communication with customers about antibiotics 
and antibiotic resistance (referred to as discussion) (Coleman, 2003). A majority of the 
375 pharmacists in the study were male (57%), and had earned a Bachelor of Pharmacy 
degree (85%). Pharmacists filled an average of 126 (SD = 75.6) prescriptions per day. 
Attitude was found to be the strongest predictor of discussion (β = 0.197, p < 0.001). 
Three demographic and organization variables were significant predictors of discussion: 
prescriptions written per day (β = -0.169, p = 0.001), hours worked per day (β = 0.116, p 
= 0.023) and working in a non-chain pharmacy (β = 0.139, p = 0.011). Knowledge and 
years in practice were not significant predictors of discussion intention (p > 0.05).  
 
3.2.1 Summary and Overview of the Studies 
The studies above confirm the TRA model‘s validity in predicting HCPs‘ 
behavioral intentions. The TRA predictors (subjective norm and attitude) accounted for a 
significant proportion of the variance in HCPs‘ intentions, ranging from 4 percent to 50 
percent. The TRA model explained more variance in studies of volitional behaviors (self-
assessment by dental hygienists and use of physical restraints by nursing staff members) 
than in those that were not or less so.  
Attitude was expected to significantly influence intentions for behaviors that 
primarily affect the individual performing the behavior. In all studies that were reviewed, 
attitude was a significant predictor of intention and subjective norm was not significant in 
two of the studies.  In all studies except one (Millstein, 1996), attitude was a stronger 
predictor of intentions than subjective norm. This observation re-inforces the fact that 
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attitude is an important dimension in predicting intentions. HCPs were mostly influenced 
by their attitude than by what significant others (e.g., patients, employers or other HCPs) 
value.  
Millstein (1996) found that the delivery of preventive services by primary care 
physicians was driven more by SN (β = 0.28, p < 0.001) than by attitude (β = 0.22, p < 
0.001). This was expected given that the behavior under investigation (delivery of 
preventive services) affects others. In such behaviors, behavioral intention is expected to 
be significantly shaped by social influences. Yet SN was not significant in two of the 
studies that investigated behaviors that affect others (DiIorio, 1997; Fried, DeVore, & 
Dailey, 2001). This unexpected finding may be explained by several factors. First, the 
DiLorio study only explained 4 percent of the variance in intention signifying a possible 
problem in the way the constructs or variables were operationalized (DiIorio, 1997). In 
addition, although the Fried and colleagues‘ study had a high R-squared value, it did not 
report regression weights (standardized or unstandardized) (Fried, DeVore, & Dailey, 
2001).  
The TRA performs best in predicting behaviors that are under the individual‘s 
complete volitional control. Some behaviors require the individual to have some skill or 
opportunities to implement them. For such behaviors that are not under volitional control, 
other theories such as the theory of planned behavior (TPB) are preferred and have 
improved predictability.  
 
3.3 THEORY OF PLANNED BEHAVIOR (TPB) 
The TPB adds the construct of perceived behavioral control (PBC) to the TRA 
predictors. The TPB is similar to the TRA except for this additional component (PBC). 
Behaviors that are difficult to implement (in which the individual may not expect to 
successfully complete the behavior) or that require resources, skills or opportunities to 
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implement the decision are better predicted by TPB than by the TRA. TPB performs 
better than the TRA in explaining behaviors that are not under complete volitional control 
(Millstein, 1996). PBC is a stronger predictor of intention and behavior when perceived 
control is low and PBC has minimal influence on behavior when perceived control is 
high (Madden, Ellen, & Ajzen, 1992). The TRA and TPB perform nearly similarly in 
predicting behaviors that are fully volitional. However, the addition of PBC improves the 
TRA model‘s predictability even for behaviors that are under volitional control 
(Netemeyer, Burton, & Johnston, 1991; Richard, Dedobbeleer, Champagne, & Potvin, 
1994). The contribution of perceived control towards predicting intentions varies across 
different behaviors (Levin, 1999).  
 
Figure 3.2: The Theory of Planned Behavior 
 
Source: Ajzen, I. (1991). "The theory of planned behavior" Organizational Behavior and 
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According to the TPB, there are three independent determinants of intentions: 
attitude toward the behavior, subjective norm (SN), and perceived behavioral control 
(PBC). PBC refers to the perception of one‘s ability to perform a given behavior. PBC 
has a direct effect on behavior and an indirect one via behavioral intention. The 
likelihood of performing a behavior not only depends on the internal motivational factors 
but also on the external factors including availability of resources, skills and 
opportunities. PBC incorporates the extent to which a person is actually able to carry out 
the behavior and the effect of facilitating and inhibiting factors. PBC is the perceived 
ease or difficulty in performing a behavior (Ajzen, 1991). Perceived control is related to 
the concept of self-efficacy as espoused by Bandura (Ajzen, 1991; Bandura, Cioffi, 
Taylor, & Brouillard, 1988).  
An individual who has a positive attitude towards the behavior, favorable 
subjective norm toward the behavior and perceives him/herself to have greater control in 
performing the behavior will have stronger intention to perform the behavior. On the 
other hand, a person with a negative attitude, unfavorable subjective norm towards the 
behavior and who perceives him/herself to have less control of the behavior is less likely 
to intend to perform the behavior. Other things remaining equal, a person with lower PBC 
(perceived resources and opportunities) will have less intent to perform the behavior 
(Madden, Ellen, & Ajzen, 1992).  
The PBC component (indirect measures) consists of control beliefs and perceived 
power. PBC is measured by multiplying each salient control belief by the perceived 
power of the particular control factor and summing up the resulting products across the 
salient beliefs as shown below. 
PBC = ∑cipi 
PBC = perceived behavioral control 
ci = the control belief (perceived presence of specific factors that increase or reduce the 
difficulty of performing the behavior in question). 
pi = the perceived power of a particular control factor to facilitate or inhibit performance 
of the behavior. 
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The TPB has been applied to study an array of behaviors such as voting, weight 
loss (dieting, taking a low fat diet), cheating, attending class, smoking cessation, safe 
sexual practices (e.g., condom use), choice of leisure, dishonest actions, physical activity 
(e.g., exercise), household recycling, testicular self-examination, fruit and vegetable 
consumption, use and misuse of alcohol, health screening (cancer), food choice, blood 
donation, gift giving and driving violations (Armitage & Conner, 2001; Parker, 
Manstead, Stradling, Reason, & Baxter, 1992). Meta-analyses have confirmed the 
efficacy of the TPB. A meta-analysis of the studies utilizing the TPB revealed that the 
TPB accounted for 39 percent and 27 percent of the variance in behavioral intention and 
behavior, respectively (Armitage & Conner, 2001). A comparison of the TPB and the 
TRA showed that the TPB explained significantly more variance in behavioral intention 
than the TRA (Madden, Ellen, & Ajzen, 1992). PBC independently accounted for six (6) 
percent of the variance in behavior (Armitage & Conner, 2001). 
The usefulness of the TPB in predicting health-related behaviors in the literature 
was confirmed through systematic reviews (Godin et al., 2008; Godin & Kok, 1996). The 
review by Godin and Kok (1996) included 56 studies that covered 58 health behaviors 
that were classified into seven (7) behavioral categories: oral hygiene, eating, automobile, 
clinical screening, addictive, exercising and HIV/AIDS. ―The overall average correlations 
between intention and attitude, subjective norm and perceived behavioral control were 
0.46, 0.34 and 0.46 respectively‖ (Godin & Kok, 1996, p. 92). PBC significantly added to 
the prediction of intention in 65 of 76 analyses reported in the studies. The TPB‘s 
constructs, on average, explained 41 percent of the variance in intention (range: 32.0% - 
46.8%). PBC and attitude were found to be the strongest predictors of intention and 
explained an average of 34 percent of the variance in intention (Godin & Kok, 1996). 
Godin and Kok (2008) concluded that PBC was an important construct in explaining 
health-related behaviors and that the usefulness of the TPB model varied across different 
health-related behaviors.   
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Many theory-guided health interventions have been successfully implemented 
using the TPB framework (Valois et al., 2001; Walker, Grimshaw, & Armstrong, 2001; 
Walker et al., 2004). Over 600 empirical studies have predicted behavior and behavioral 
change using the TPB in the past two decades (Francis et al., 2004). The TPB model is 
useful for guiding behavioral change strategies. Meta-analyses found that communication 
strategies premised on the TPB were effective in promoting health behaviors (e.g., 
exercise and condom use) and in reducing health risk behaviors (e.g., speeding, unsafe 
sex, binge drinking among others) (Armitage & Conner, 2001; Godin & Kok, 1996). 
Another study that applied the TPB to continuing education for mental health 
professionals found that ―significantly more participants in the theory-guided class than 
in the standard class (74% versus 42%) had applied the tool by the three-month follow 
up‖ (Casper, 2007, p. 1324).   
In line with the nature of this project, the rest of this review is restricted to studies 
of the TPB that involve HCPs (Tables 3.2, 3.3 and 3.5). Some of the studies reviewed had 
intentions while others had behavior as their final outcome variable. This review will 
concentrate on the constructs of the model that relate to intention formation. Studies that 
did not correctly specify the model (Emeis et al., 2007; Kleier, 2004) and were not based 
on primary research (Ceccato, Ferris, Manuel, & Grimshaw, 2007) were excluded. 
Although every effort was made to include all relevant studies, it is possible that some 
articles were inadvertently missed.   
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Table 3.2: Studies Using the TPB to Predict HCPs‘ Intentions (Excluding Pharmacists) 
Study Author 
(s), Year 







Millstein, 1996 Deliver preventive 
services 
765 primary care 
physicians 
β = 0.11*** β = 0.21*** β = 0.37*** R
2 
= 0.27 




β = 0.078 (NS) β = -0.020 (NS) β = 0.365** R
2 
= 0.16 
Levin, 1999 Use of gloves 527 nurses and 
lab workers 
Β = 0.14* NS Β = 0.29* R
2 
= 0.74 
O‘Boyle et al., 
2001 




β = 0.107* β = 0.192* β = 0.076* R
2 
= 0.56 
Walker et al., 
2001 




β = 0.33** β = 0.36* β = 0.14 R
2 
= 0.48 




β = 0.48*** β = 0.24*** NS NA 
Ko et al, 2004 Care for SARS patients 750 staff and 
head nurses 
β = 0.25*** NS β = 0.13*** R
2
 = 0.35 









Work with computers 411 registered 
nurses 
β = 0.30***  




Bercher, 2008 Home hazard 
inspections 









r = -0.03 (NS) r = 0.36** r = -0.09 (NS) NA 
A-I = Attitude-Intention; SN-I = Subjective norm-Intention; NA = not available, NS = not significant, r = correlation coefficient 
*p < 0.05, **p < 0.01, ***p < 0.001, ****significant, p value not reported, Lab = laboratory 
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In 1996, Millstein published the results of a study that used the TPB to predict the 
physicians‘ intention and behavior toward educating their adolescent patients about the 
transmission of HIV and other STDs (referred to as delivery of preventive services) 
(Millstein, 1996). Millstein (1996) first tested the TRA model and then added the PBC 
component to test the TPB. The results showed that A (β = 0.11, p < 0.001), SN (β = 
0.21, p < 0.001), and PBC (β = 0.37, p < 0.001) independently and significantly predicted 
intentions. Taken together, the TPB constructs accounted for 27 percent of the variance in 
behavioral intention and the overall model was significant (R = 0.52, p < 0.001). When 
PBC was entered separately in the regression model after running the TRA variables, the 
change in R
2
 was significant (0.12, p < 0.001). The study results show that physicians‘ 
perceptions about the extent of control they had over the delivery of preventive services 
to their adolescent patients was an important predictor of their behavioral intention 
(Millstein, 1996).  The PBC construct significantly improved the explanation of 
behavioral intention in the study. The authors concluded that the TPB, like the TRA, has 
relevance for studying HCPs‘ behaviors (Millstein, 1996). Intention and PBC accounted 
for 17 percent and 22 percent of the variance in behavior, respectively.  
Levin (1999) conducted a study to identify predictors of health care workers‘ 
intentions and self-reported use of gloves when there was potential for blood exposure. 
The authors tested the TRA, TPB and an extension of TPB, which included a perceived 
risk construct as a predictor of glove use and glove use intention. The authors 
hypothesized that the TPB extension model would explain more variance in nurses‘ and 
medical laboratory workers‘ use of gloves and would fit the data better than both the 
TRA and the TPB (Levin, 1999). Most respondents were female (91%), white (78%), 
married (68%) and worked in a hospital setting (74%). The mean age of respondents was 
38.7 years (SD = 9.8 years). The TPB model had a better fit than the other two models in 
explaining intention. The TPB constructs explained 74 percent of the variance in 
intention and the TPB extension model constructs explained 73 percent of the variance in 
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intention. Attitude (β = 0.14, p < 0.05), and PBC (β = 0.29, p < 0.05) independently and 
significantly predicted the nurses‘ intentions. Perceived control was the strongest 
predictor of health care workers‘ intention to wear gloves and SN was not a significant 
predictor of intention (Levin, 1999).  Behavioral intention accounted for 69 percent of the 
variance in behavior (β = 0.80, p < 0.05). 
O‘Boyle and colleagues (2001) conducted a study to test an explanatory model for 
adherence to hand hygiene guidelines based on the TPB. The authors collected 
longitudinal observational data from 120 registered nurses working in critical care and 
post critical care units of four teaching hospitals in the Midwest. Data collection also 
included observing nurses‘ hand hygiene performance while they provided patient care. 
Each nurse was observed twice and observations were conducted between two (2) weeks 
to four (4) months apart. The study did not provide the respondents‘ demographic or 
practice characteristics. The authors ran the TPB model using structural equation 
modeling. The study results supported the TPB model which explained 56 percent of the 
variance in nurses‘ intention to adhere to hand hygiene recommendations. Attitude (β = 
0.107, p < 0.05), SN (β = 0.192, p < 0.05) and PBC (β = 0.076, p < 0.05) independently 
and significantly predicted nurses‘ intention to adhere to hand hygiene recommendations. 
Nurses‘ intentions significantly predicted self-report hand hygiene (β = 0.385, p < 0.05), 
but not observed hand hygiene (β = 0.068, p > 0.05).  The study also found a low and 
positive association between self-reported and observed hand hygiene scores (r = 0.20).  
A cross-sectional study was conducted to test the utility of the TPB in predicting 
the U.K.‘s general practitioners‘ (GPs) intentions to prescribe antibiotics for adult 
patients presenting with an uncomplicated sore throat (Walker, Grimshaw, & Armstrong, 
2001). One hundred and twenty six GPs completed a postal questionnaire in 1998. The 
respondents were predominantly male (76%) and had been in practice for 10 or more 
years (88%). Taken together, the three TPB constructs accounted for 48 percent (adjusted 
R
2
 = 0.46) of the variance in intention. Using multiple regression analysis, A (β = 0.33, p 
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< 0.01), and the control belief scale—indirect perceived control measure (β = 0.36, p < 
0.01) were significant predictors of intention, but PBC was not (β = 0.14, p > 0.05). The 
addition of past behavior accounted for an additional 15 percent of the variance in 
intention. However, the addition of past behavior to the model made the A construct to be 
statistically insignificant (β = 0.14, p > 0.05), and made PBC to become statistically 
significant (β = 0.24, p < 0.05). The study concluded that attitude toward antibiotics and 
control beliefs were important predictors of intention to prescribe but their importance 
differed based on past behavior (Walker, Grimshaw, & Armstrong, 2001).  
Meyer (2002) used the TPB to predict nursing students‘ intention to ask for 
assignments to perform nursing behaviors. The study included 92 nursing students 
enrolled in an associate degree of science in nursing program at a university in 
Midwestern United States. The study hypothesized the following: a) nursing students‘ 
intentions to ask for assignments to perform nursing behaviors after using a self-report 
database will be predicted from the combination of attitudes towards the behavior and 
subjective norms; b) nursing students‘ intentions to ask for assignments to perform 
nursing behaviors after using a self-report database will be predicted from attitudes 
toward the behavior, subjective norms, perceived behavioral control, and underlying 
beliefs; and c) perceived behavioral control will have a significant effect on nursing 
students‘ intentions to ask for assignments to perform nursing behaviors after using a 
self-report database independent of attitudes and subjective norms. The results of the 
study supported hypothesis one but not hypotheses two and three. Attitude (β = 0.48, p < 
0.05) and SN (β = 0.24, p < 0.05) were significant predictors of intention and PBC (β = 
0.08, p = 0.377) was not a significant predictor of intention. PBC‘s influence on intention 
was completely mediated by SN and A. However, the control beliefs had a significant 
and negative effect on intention (β = -0.13, 0 < 0.05).   
Ko and colleagues (2004) tested the application of the TPB in predicting nurses‘ 
intention and volunteering to care for severe acute respiratory syndrome (SARS) patients 
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in Southern Taiwan. The authors collected data using a questionnaire from 750 staff and 
head nurses working in a 1,200 bed hospital. Most of the respondents were female 
(99.3%), single (63.2%) and less than 35 years of age (mean age = 30.3 years, SD = 6.4 
years). Most nurses had a positive attitude towards caring for SARS patients. PBC was 
measured using three scales: SARS-related knowledge, self-efficacy, and the availability 
of institutional resources. Four variables significantly predicted intentions, namely A (β = 
0.25, p < 0.001), self-efficacy (β = 0.39, p < 0.001), availability of resources (β = 0.13, p 
< 0.001), and hospital experience (β = -0.15, p < 0.001). These variables explained 35 
percent of the variance in intention to care for SARS patients. SARS-related knowledge 
did not significantly predict intentions (p > 0.05). SN did not significantly predict 
intentions in hierarchical regressions. Demographic variables (e.g., age, years of 
professional experience, and years of working in the study hospital) independently 
predicted intention over and above the TPB constructs. Nurses who were novice, 
younger, and with less professional experience had a more positive intention to care for 
SARS patients (Ko et al., 2004). Intention predicted 15 percent of the variance in 
behavior (volunteer to care) (β = 0.31, p < 0.05). 
Nwokeji examined Texas family physicians' willingness to prescribe controlled-
release opiate analgesics (CR opioids) to patients with moderate to severe chronic non-
malignant pain (CNMP) using the TPB (Nwokeji, 2007). A total of 267 family physicians 
participated in the study. The survey respondents were predominantly male (62.7%), 
worked primarily in an urban setting (35.8%) and were mostly white/European American 
(74.3%). Overall, the TPB model explained 49 percent of the variance in Texas family 
physicians' willingness to prescribe CR opioids for CNMP. All three TPB constructs 
were significant predictors of physicians‘ willingness to prescribe: A (β = 0.45), SN (β = 
0.21), and PBC (β = 0.22). Attitude was the most significant determinant of physicians' 
willingness to prescribe. A majority of the physicians (n = 179) were willing to prescribe 
CR opioids for CNMP (Nwokeji, 2007). 
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The intentions of hospital nurses to work with computers was investigated using 
an expanded TPB model (Shoham & Gonen, 2008). The dependent variable was the 
nurse‘s behavioral intention toward working with computers. Most (60%) of the nurses 
were less than 40 years old (range: 20-65 years), were staff nurses (72%), had 10 or less 
years of working experience (62%) and were female (100%). The authors examined the 
model by running path analysis using Lisrel software. The study results showed that age, 
participation in a computer course, access to a computer, job and department in which the 
nurse worked did not directly predict intention. The strongest predictor of behavioral 
intention was A (nursing: β = 0.30; and general: β = 0.20, p < 0.001). Nurses had a 
positive attitude toward use of computers (general attitude: mean = 71.55%, SD = 17.82; 
nursing attitudes: mean = 67.53, SD = 12.21). The final model which included additional 
predictor variables (threat, challenge, departmental climate, organizational climate, 
innovativeness and self-efficacy) explained 49 percent of the variance in behavioral 
intention. The study did not report the regression coefficients for SN and PBC.  
Bercher and colleagues conducted a study utilizing the TPB to determine the 
attitudes of U.S. paramedics toward performing home hazard inspections as an added 
everyday task (Bercher, 2008). A total of 202 paramedics from 37 states participated in 
the study. The average age of the paramedics was 38 years. Most respondents were male 
(74%), white (94%) and worked in small towns (34%) and for a fire department (42%). 
Using multiple regression, the study found that attitude toward the behavior (β = 0.66, p 
< 0.001), and PBC (β = 0.23, p < 0.001) were significant predictors of the intention to 
perform home injury prevention inspections. The model explained 57.5 percent of the 
variance in intention. SN was not a significant predictor of intention (p > 0.05). The study 
concluded that paramedics support home injury prevention inspections (Bercher, 2008).  
Hart and Morris conducted a TPB-based cross-sectional study to explore factors 
that facilitate or hinder professionals from screening patients for poststroke depression 
(Hart & Morris, 2008). A total of 75 U.K. HCPs comprising doctors (10.7%), 
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psychologists (9.3%), nurses (34.7%), physiotherapists (12.0%) and others (33.3%) 
completed a postal questionnaire. Most of the respondents were female (86.7%) and 
worked full time (69.3%). The respondents had favorable attitudes toward screening 
patients for poststroke depression (mean = 18.57, SD = 2.94; possible range: 3-21) and 
positive SN (mean = 8.20, SD = 3.25; possible range: 2-14). Direct measures of A (r = -
0.03, p > 0.01) and PBC (r = -0.09, p > 0.01) did not significantly predict intentions to 
screen. However, SN (r = 0.36, p < 0.01), past behavior (screening in the past month) (r = 
0.69, p < 0.01), and screening policy (r = 0.48, p < 0.01) were significant predictors of 
screening intention (Hart & Morris, 2008). The study found that the major barriers to 
screening were time pressure and concerns about screening tests.  
The literature search also yielded two studies pertaining to HCPs‘ reporting 
behavior (Feng & Wu, 2005; Randall & Gibson, 1991) (Table 3.3).  
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Table 3.3: Studies Using the TPB to Predict HCPs‘ Reporting Intentions  
Study Author (s), 
Year 









Report the healthcare 
professional 
116 nurses β = 0.67*** β = 0.22*** β = 0.05 (NS) R
2 
= 0.61 
Feng and Wu, 
2005 




β = 0.31** β = 0.15** β = 0.12** R
2 
= 0.91 
Feng and Wu, 
2005 




β = 0.26** β = 0.06** β = 0.07** R
2 
= 0.85 
A-I = Attitude-Intention 
SN-I = Subjective norm-Intention 
PBC-I = Perceived behavioral control-Intention 
NS= not significant 
*p < 0.05, **p < 0.01, ***p < 0.001. 
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Randall and Gibson (1991) conducted a study using the TPB to explain ethical 
decision making among 116 nurses. Nurses were provided with scenarios that depicted 
inadequate patient care and asked if they would report the health professionals 
responsible for the situation. Using regression analysis, the authors found that A (β = 
0.67, p < 0.001), and SN (β = 0.22, p < 0.001) were significant predictors of intention 
while PBC was not a significant predictor (β = 0.05, p = 0.41). Overall, the TPB 
constructs explained 61 percent of the variance in intention to report the healthcare 
professional. In addition, the study found that nurses were less likely to report a mistake 
(52%) than incompetence (72%) (p = 0.002).  
Feng and Wu (2005) conducted a study to identify the main predictors of nurses‘ 
intention to report suspected child abuse in Taiwan using an extended TPB model which 
added a knowledge construct (Feng & Wu, 2005). The authors ran separate models for 
severe and also for less severe cases. A total of 1,362 nurses working in 39 hospitals and 
involved in caring for children, participated in the study. A majority of respondents were 
female (98.7%), unmarried (62.7%), and childless (70.4%) and had a mean age of 30.5 
(SD = 6.01) years. All three TPB constructs significantly predicted intention to report 
severe as well as less severe cases. In addition to the TPB constructs, the authors found 
that knowledge independently predicted intention (β = 0.71, p < 0.01) and was the 
strongest predictor of intention in the model (Table 3.4). 
 
Table 3.4: Predictors of Intention to Report Child Abuse (n = 1,362) 
Predictors of Intention to Report Suspected 
Child Abuse 
Models 
Severe (β) Less severe (β) 
Knowledge 0.71 0.71 
Subjective norm 0.15 0.06 
Attitude 0.31 0.26 
Perceived behavioral control 0.12 0.07 
All predictors were significant (p < 0.01).  
Source: Feng and Wu (2005), p. 344.  
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SN and PBC were stronger predictors of intention to report child abuse in severe 
cases than in the less severe cases of child abuse. Nurses found it more socially 
acceptable to report severe child abuse cases than less severe cases. The extended TPB 
model explained 91 percent and 85 percent of the variance in intention to report severe 
and less severe cases, respectively.  The authors noted that most nurses did not perceive 
themselves to have strong control over reporting suspected child abuse; reporting child 
abuse was not mostly up to them (Feng & Wu, 2005).  
In all three cases that investigated reporting behavior, attitude was a stronger 
predictor of intentions than both SN and PBC. In addition, SN was significant in all three 
cases. Interestingly, the three models explained high variance in behavioral intentions 
(range: 61% - 91%).  
In addition to the above mentioned studies, the literature search yielded five 
studies that used the TPB in studying pharmacists‘ behavior (Table 3.5).   
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Table 3.5: Studies Using the TPB to Predict Pharmacists‘ Intentions  
Study Author 
(s), Year 
















Mashburn et al., 
2003 
Provide sterile syringes to 




β = 0.658** β = 0.200*** NS R
2 
= 0.74 
Walker et al., 
2004 






β = 0.28* NS NS R
2
 = 0.19 
Herbert et al. 
2006 
Provide Medicare medication 
therapy management services 
203 Iowa 
pharmacists 





Pradel et al., 
2007 
Pediatric asthma counseling 98 Maryland 
community 
pharmacists  
r = 0.37* r = 0.33*  r = 0.51* NA 
Saengcharoen et 
al., 2008 
Dispensing of antibiotics for 




β = 0.89* β = 0.07* β = 0.03 (NS) NA 




; NS = Not significant 




Mashburn and colleagues (2003) conducted a study to examine the factors 
predicting Texas community pharmacists' willingness to provide sterile syringes to 
known or suspected intravenous drug users (IDUs). The study used the TPB constructs 
(A, SN and PBC) and recent past behavior (RPB) to predict pharmacists‘ willingness to 
provide sterile syringes. A total of 176 Texas community pharmacists participated in the 
study. The average age of the respondents was 48.6 years (SD = 12.46, range: 26-78 
years). Most (59.5%) respondents were male, Caucasians (79.7%), and staff pharmacists 
(44.4%), and worked in chain pharmacies mainly in urban or suburban areas (78.9%). 
The study found that most respondents were not willing to provide sterile syringes to 
known or suspected IDUs. Study participants held negative attitudes toward the provision 
of sterile syringes and perceived themselves as having some control over the provision of 
sterile syringes. The study results supported the TPB model. The study results showed 
that A (β = 0.66, p = 0.001) and subjective norm (β = 0.20, p = 0.001) were significant 
predictors of willingness. PBC was not a significant predictor of willingness (β = 0.08, p 
= 0.133). 
Walker and colleagues (2004) applied the TPB to examine Scottish community 
pharmacists‘ attitudes, beliefs and intentions to supply non-prescription antifungals for 
the treatment of vulvovaginal candidiasis. A majority of respondents were female 
(64.5%), and employee pharmacists (58%) and worked full time (83%). The study results 
showed that pharmacists had a positive attitude (2, range: 0 - 3; measured on the scale -3 
to +3), negative subjective norm (-2, range: -3 to +3), and positive PBC (2, range: -3 to 
+3). Only A significantly predicted behavioral intention (β = 0.28, p < 0.05). The 
regression weights for SN and PBC were not reported in the study. The TPB constructs 
explained 19 percent of the variance in behavioral intention (Walker et al., 2004).  
Using the TPB, Herbert and colleagues (2006) published a study that predicted 
the behavioral intention of Iowa community pharmacists to provide Medicare medication 
therapy management services (MTMS). A majority of pharmacists were male (57.6%), 
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worked for independent pharmacies (50.2%), and had 21 or more years of experience 
(51.3%). Multivariate linear regression analysis showed that all the TPB constructs 
independently and significantly predicted the intent (p < 0.05). SN was the strongest 
predictor of intent (β = 0.41, p < 0.001), followed by PBC (β = 0.27, p < 0.001) and 
attitude (β = 0.19, p = 0.002). Pharmacists faced substantial barriers in implementing 
MTMS such as lack of support staff, computer support and time. The independent 
variables in the model accounted for 63.2 percent of the variation in intent (Herbert, 
Urmie, Newland, & Farris, 2006).  
A cross-sectional study was conducted to explore the factors that influence 
community pharmacists' pediatric asthma counseling in Maryland from September 2002 
through March 2003 (Pradel, Obeidat, & Tsoukleris, 2007). A mail survey was sent to 
399 community pharmacists and 98 responded for a 25 percent response rate. Most 
respondents reported that it was important to provide asthma counseling to children 
(54%) or caregivers (68%), although only a few reported counseling the children (27%) 
or the parent (47%). Lack of time, lack of parent's interest, and lack of placebo devices 
useful for demonstrating the inhalation technique were some of the barriers to counseling 
that were cited by pharmacists. Intention to counsel significantly predicted the provision 
of counseling to children or caregivers (p < 0.05). Attitude (r = 0.37, p < 0.05), subjective 
norm (r = 0.33, p < 0.05), and perceived difficulty (r = 0.51, p < 0.05) were significantly 
correlated with intention (Pradel, Obeidat, & Tsoukleris, 2007). The study did not 
provide the variance in intention and behavior that was explained by the model. 
Saengcharoen and colleagues (2008) studied the factors influencing dispensing of 
antibiotics for upper respiratory infections (URI) among Southern Thai community 
pharmacists.  In Thailand, practicing pharmacists can legally dispense antibiotics without 
a prescription. Most of the 656 respondents were female (59.6%), and young (age range: 
30-39 years, 54.8%), and had less than 10 years working experience (Saengcharoen et al., 
2008). Most pharmacists had an unfavorable attitude toward antibiotics use for URI 
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(mean = 2.61, SD = 2.00) and did not intend to dispense antibiotics (mean = 2.35, SD = 
1.85). Using structural equation modeling (SEM) to run the TPB model, the study found 
that attitude (β = 0.89, p < 0.05) and subjective norm (β = 0.07, p < 0.05) were significant 
predictors of intention. PBC (β = 0.03, p > 0.05) did not significantly predict intention to 
dispense antibiotics without a prescription. The authors suggested that the weak influence 
of subjective norm on intention to dispense antibiotics may be explained by the low 
professional interaction between pharmacists (Saengcharoen et al., 2008). The variance in 
intention and behavior that was explained by the model was not reported in the study. 
The final model had acceptable fit statistics [root mean square error of approximation 
(RMSEA) = 0.054, standardized root mean square residual (SRMR) = 0.056, Tucker-
Lewis Index (TLI) = 0.97 and comparative fit index (CFI) = 0.98].  
   
3.3.1 Other Predictors of Intention 
Other constructs have been added to the TPB model in research studies. The 
additional constructs that have been found to increase the predictive power of the TPB 
model include past behavior (Sheeran, Norman and Armitage, 2000)(Hart & Morris, 
2008), self-efficacy (Armitage & Conner, 1999; Ko et al., 2004), demographic factors, 
practice factors (Coleman, 2003; Fried, DeVore, & Dailey, 2001; Hart & Morris, 2008; 
Ko et al., 2004; Shoham & Gonen, 2008) and perceived moral obligation (Randall & 
Gibson, 1991; Werner & Mendelsson, 2001). The role of demographic and practice 
factors, past behavior and perceived moral obligation will be explored further owing to 
their potential relevance to this study.  
 
3.3.1.1 Past Reporting Behavior 
Past behavior (PB), the frequency with which a behavior has been performed in 
the past, is a good predictor of future action (Ajzen, 2002b). According to the TRA and 
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TPB, the effect of prior behavior on future behavior is fully mediated by intention and 
PBC. However, empirical research has found that the relationship between prior and 
future behavior is not fully mediated by the TRA and TPB constructs (Ajzen, 1991; 
Albarracin et al., 2001; Bagozzi, 1981). In previous studies, the addition of PB improved 
the prediction of behavioral intentions over and above the TRA and TPB constructs 
(Herbert et al., 2006; Leone, Perugini, & Ercolani, 1999; Mashburn et al., 2003; 
Millstein, 1996; Nwokeji, 2007; Quine & Rubin, 1997; Schaalma, Kok, & Peters, 1993; 
Walker, Grimshaw, & Armstrong, 2001). For example, in a study of Texas family 
physicians‘ willingness to prescribe long-acting opioid analgesics for patients with 
chronic nonmalignant pain, Nwokeji (2007) found that the addition of recent past 
behavior (RPB) to the TPB model significantly increased the explanatory power from 49 
percent to 58 percent (R
2
 change = 0.09). RPB was the strongest predictor of intention in 
the final model (β = 0.38, p < 0.001). Millstein (1996) found that PB was the single best 
predictor of future behavior of physicians (R
2
 = 0.42, p < 0.001). Mashburn also found 
that RPB contributed significantly to the prediction of Texas community pharmacists‘ 
willingness to provide sterile syringes to intravenous drug users (Mashburn et al., 2003). 
The PB construct is important in predicting intentions and behaviors and warrants 
consideration in studies of HCPs including pharmacists. 
Nwokeji (2007) found that the inclusion of RPB resulted in a reduction in the 
regression weights of A (β = 0.33), SN (β = 0.16), and PBC (β = 0.13) compared to A (β 
= 0.45), SN (β = 0.21), and PBC (β = 0.22) prior to adding RPB. In another study, the 
addition of past behavior to the model resulted in the attitude construct becoming 
statistically insignificant (β = 0.14, p > 0.05), and the PBC (β = 0.24, p < 0.05) becoming 
statistically significant (Walker, Grimshaw, & Armstrong, 2001). The addition of PB was 
associated with a lessened effect of intentions on behavior (Bagozzi, 1981). PB was also 
reported to be correlated with PBC and to influence individuals‘ beliefs about their 
control over a situation (Albarracin & Wyer, 2000; Sutton, McVey, & Glanz, 1999). 
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However, not all studies in the literature support this important role of past 
behavior in predicting intentions (Herbert et al., 2006). For example, Herbert and 
colleagues (2006) found that past participation in care-based services did not significantly 
predict pharmacists‘ intention to provide Medicare MTMS (β = 0.21, p = 0.061). These 
results may be explained by the way past participation was operationalized in the study. 
The article did not provide details on how past participation was operationalized in the 
study (Herbert et al., 2006).  
 
3.3.1.2 Demographic and Practice Factors 
According to the TRA and TPB, demographic factors (age, gender, education, 
working experience among others) are postulated to have no direct influence on intention 
and behavior (Sutton, McVey, & Glanz, 1999). These are said to influence attitude, 
subjective norm and PBC (Ajzen, 1991). In many studies on HCPs, demographic and 
practice factors did not independently and directly predict intentions (Herbert et al., 2006; 
Sable et al., 2006; Shoham & Gonen, 2008; Werner & Mendelsson, 2001). In Shoham 
and Gonen‘s (2008) study, age, job and department in which the nurse worked did not 
directly predict intention to work with computers. In another study, the pharmacists‘ 
gender, years of practice, practice setting and degree did not significantly predict 
intentions (p > 0.05) (Herbert et al., 2006). 
 However, in Coleman‘s (2003) study, three demographic and organizational 
variables were significant predictors of discussion: prescriptions written per day (β = -
0.169, p = 0.001), hours worked per day (β = 0.116, p = 0.023) and working in a non-
chain pharmacy (β = 0.139, p = 0.011). In another study, demographic variables (e.g., 
age, years of professional experience, years of working in the study hospital) 
independently predicted intention over and above the TPB constructs; nurses who were 
novice, younger, and with less professional experience had a more positive intention to 
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care for SARS patients (Ko et al., 2004). Also hours of employment significantly 
predicted self-assessment among Maryland Dental Hygienists (Fried, DeVore, & Dailey, 
2001). 
An important practice factor is knowledge about reporting ADEs. Feng and Wu 
(2005) found that knowledge was the strongest predictor of Taiwanese nurses‘ intentions 
to report child abuse. However, Sable and colleagues (2006) found that knowledge (score 
on a knowledge quiz) did not independently predict emergency contraception prescribing 
intentions. Coleman and Ko and colleagues also reported that knowledge did not 
significantly predict intentions (p > 0.05) (Coleman, 2003; Ko et al., 2004).  
Although there are conflicting results on the role and effect of demographic and 
practice factors on intention and behavior, gender, ethnicity, knowledge, years in practice 
(experience), hours worked per day and primary practice setting merit further 
consideration.  
 
3.3.1.3 Perceived Moral Obligation 
The addition of a perceived moral obligation (PMO) construct to the TPB 
significantly increased the prediction of intentions (Gorsuch & Ortberg, 1983; Randall & 
Gibson, 1991; Werner & Mendelsson, 2001).  The key features of moral situations are: a) 
importance—the choice and its consequences is viewed by the person as being significant 
and not trivial; b) immunity from deliberate change; and c) form of moral pressure—
appeals to respect the rules as important in themselves (Hart, 1961). The importance of 
PMO has been reported to vary by situation. The PMO construct is a strong predictor in 
morally relevant situations and is not a strong predictor of intentions in nonmoral 
situations and vice-versa (Gorsuch & Ortberg, 1983). For example, PMO was reported to 
be a stronger predictor of intentions than A and SN in moral situations (Gorsuch & 
Ortberg, 1983; Schwartz & Tessler, 1972).  
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Summary and Review of the Studies  
The above studies confirm the effectiveness of the TPB in predicting HCPs‘ 
intentions. The TPB model explained a wide range of HCPs‘ behaviors including 
delivering preventive services, using gloves, adhering to hand hygiene recommendations, 
reporting child abuse, and working with computers among others. The TPB‘s 
constructs—attitude, subjective norm, and perceived behavioral control—are good 
predictors of HCPs‘ behavioral intentions. The relative contributions of each of the 
constructs varied by behavior, study population and situation.  As observed by Godin and 
Kok (1996), overall, the TPB was found to be a good framework to explain and predict 
intentions of HCPs‘ behaviors. The variance in intention accounted for by the models 
ranged from 16 percent to 91 percent across the studies.  
A was the strongest predictor of behavioral intentions in most (n = 11) (Bercher, 
2008; Feng & Wu, 2005; Ko et al., 2004; Mashburn et al., 2003; Meyer, 2002; Nwokeji, 
2007; Randall & Gibson, 1991; Saengcharoen et al., 2008; Shoham & Gonen, 2008; 
Walker et al., 2004) of the TPB studies reviewed (n = 19). Note: Feng and Wu (2005) 
reported two studies. Most of these studies were on behaviors that are performed in 
private and which did not significantly involve or impact others. This is similar to Quine 
and Rubin (1997) who found that A is more important than normative beliefs in cases 
where the behavior is performed in private. 
SN was the strongest predictor in four studies (Hart & Morris, 2008; Herbert et 
al., 2006; O'Boyle, Henly, & Larson, 2001; Walker, Grimshaw, & Armstrong, 2001). In 
these studies, the behavior involved or impacted others. SN was statistically significant in 
all the studies (n = 13) that reported the regression weights or correlation coefficients (r).  
In the studies reviewed, PBC added significantly to the explanation and prediction 
of intention of most studies (n = 10). The addition of PBC improved prediction of 
intention, thus confirming that the PBC construct is an important construct for explaining 
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intention of HCPs. PBC was the strongest predictor in three studies (Levin, 1999; 
Millstein, 1996; Pradel, Obeidat, & Tsoukleris, 2007) (see Tables 3.2, 3.3, 3.5). 
Given the usefulness of the TPB in explaining HCPs‘ (including pharmacists‘) 
decision making processes, the TPB may be useful for predicting pharmacists‘ intentions 
to report serious ADEs. There is a need for more research to examine the healthcare 
providers‘ (pharmacists) decision-making processes to better predict ADE reporting 
intentions and behaviors. 
 
3.5 OBJECTIVES OF THE STUDY 
The aim of the study is to use the TPB to better understand the factors related to 
pharmacists‘ reporting of serious ADEs in Texas.  
The objectives of the study are to:  
1. Identify pharmacists‘ beliefs concerning reporting of serious ADEs;  
2. Explore the utility of the TPB model constructs (A, SN, PBC) in predicting 
pharmacists‘ intention to report serious ADEs;  
3. Determine the contribution of the PBC construct to the prediction of pharmacists‘ 
intention to report serious ADEs beyond A and SN constructs; 
4. Determine if the past reporting behavior (PRB) construct contributes toward the 
prediction of pharmacists‘ intention to report serious ADEs over and above the TPB 
constructs; 
5. Determine if PMO significantly increases the explanatory power of the regression 
model compared to only using the A + SN + PBC to explain pharmacists‘ intention to 
report serious ADEs; 
6. Determine if the pharmacists‘ A, SN or PBC toward reporting serious ADEs differs 
by practice characteristics and demographic factors; and  
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7. Recommend strategies for increasing the reporting rates of serious ADEs by Texas 
pharmacists. 
 
3.6 THEORETICAL FRAMEWORK 
A theoretical model will be employed to examine and predict pharmacists‘ 
intention to report serious ADEs. The TRA and TPB have been used extensively and 
successfully in the past to explain and predict healthcare professionals‘ intentions and 
behaviors. Many of the behaviors are not under the healthcare professional‘s complete 
volitional control. An accurate prediction of intentions requires an assessment of the 
extent to which the healthcare professional can exercise control over the behavior in 
question. This can be achieved by adding the PBC to the TRA. Thus, the TPB will be 
used to predict pharmacists‘ intention to report serious ADEs.  
 In addition to the three key TPB constructs (A, SN, and PBC), the study model 
includes three additional variables (1. PMO, 2. PRB and 3. demographic and practice 
factors) (Figure 3.3). Past behavior was found to help improve the ability to predict many 
health-related intentions and behaviors (Burak 1994, Leone, Perugin and Ercolani 1999, 
Sheeran, Norman and Armitage 2000). Similarly, PMO was also found to independently 
increase the variance in intention that is explained (Randall & Gibson, 1991; Werner & 
Mendelsson, 2001). Finally, a number of demographic and practice variables (gender, 
age, workload, knowledge and years of experience) have been found to independently 




Figure 3.3: The Conceptual Model of the Study 
 
 
This study model postulates that pharmacists should intend to report serious 
ADEs if they have positive attitudes toward ADE reporting, are motivated to comply with 
referent others perceived as supporting the behavior, have reported serious ADEs in the 
past, consider themselves to be morally obliged to report serious ADEs and are able 
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3.7 STUDY HYPOTHESES 
H1: Favorable attitude (A) is a positive and significant predictor of intention to report 
serious ADEs controlling for SN and PBC. 
H2: SN supporting ADE reporting is a positive and significant predictor of intention to 
report serious ADEs controlling for A and PBC. 
H3: Strong PBC is a positive and significant predictor of intention to report serious ADEs 
controlling for A and SN.  
H4: A + SN + PBC constructs explain a significant amount of variance in pharmacists‘ 
intention to report serious ADEs. 
H5: PBC significantly increases the explanatory power of the regression model compared 
to only using A + SN to explain pharmacists‘ intention. 
H6: PRB significantly increases the explanatory power of the regression model compared 
to only using the A + SN + PBC to explain pharmacists‘ intention to report serious 
ADEs. 
H7: PMO significantly increases the explanatory power of the regression model 
compared to only using the A + SN + PBC to explain pharmacists‘ intention to report 
serious ADEs. 
H08: There is no significant difference in A to report serious ADEs by gender. 
H09: There is no significant difference in SN regarding reporting serious ADEs by 
gender. 
H010: There is no significant difference in PBC over reporting serious ADEs by gender. 
H011: There is no significant relationship between A to report serious ADEs and 
pharmacists‘ years of experience. 
H012: There is no significant relationship between SN to report serious ADEs and 
pharmacists‘ years of experience. 
H013: There is no significant relationship between PBC to report serious ADEs and 
pharmacists‘ years of experience. 
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H014. There is no significant difference in A toward ADE reporting by pharmacists‘ 
primary setting (community-independent, community-multiple/chain, hospital-
independent, hospital-multiple/chain, other). 
H015: There is no significant difference in SN regarding ADE reporting by pharmacists‘ 
primary setting (community-independent, community-multiple/chain, hospital-
independent, hospital-multiple/chain, other). 
H016: There is no significant difference in PBC over ADE reporting by pharmacists‘ 
primary setting (community-independent, community-multiple/chain, hospital-
independent, hospital-multiple/chain, other). 
H017. There is no significant relationship between the pharmacists‘ number of hours 
worked and A toward ADE reporting. 
H018: There is no significant relationship between the pharmacists‘ number of hours 
worked and SN regarding ADE reporting.  
H019: There is no significant relationship between the pharmacists‘ number of hours 
worked and PBC over ADE reporting. 
H020: There is no significant difference in A toward reporting serious ADEs by the 
pharmacists‘ race/ethnicity. 
H021: There is no significant difference in SN regarding reporting serious ADEs by the 
pharmacists‘ race/ethnicity. 
H022: There is no significant difference in PBC over reporting serious ADEs by the 
pharmacists‘ race/ethnicity. 
H023. There is no significant relationship between the pharmacists‘ knowledge of ADE 
reporting and A toward ADE reporting. 
H024: There is no significant relationship between the pharmacists‘ knowledge of ADE 
reporting and SN regarding ADE reporting. 
H025: There is no significant relationship between the pharmacists‘ knowledge of ADE 
reporting and PBC over ADE reporting.  
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CHAPTER FOUR: RESEARCH METHODOLOGY 
 
4.1 STUDY DESIGN 
This study utilized a nonexperimental cross-sectional design and employed a self-
report mail data collection survey instrument. A mail survey was chosen over telephone 
and face-to-face interviews for various reasons. A mail survey is anonymous, convenient, 
requires the least amount of resources, is less sensitive to interviewer biases, and does not 
require immediate and rushed decision-making from the respondents (Nakash, Hutton, 
Jorstad-Stein, Gates, & Lamb, 2006; Salant & Dillman, 1994). In addition, a mail 
questionnaire is able to reach a widely dispersed sample (Diamantopoulos, 
Schlegelmilch, & Webb, 1991). These advantages make it a very attractive data 
collection technique in pharmacy research. 
The study data were analyzed primarily using multiple regression. The analyses 
statistically estimated the regression coefficients associated with the study variables in 
the model.  
 
4.2 SAMPLE FRAME  
This study‘s population of interest is all (active) Texas pharmacists. Texas 
pharmacists, like all other pharmacists, can report serious adverse drug events (ADEs) 
that they encounter to the FDA. The study used the current list of registered pharmacists 
in the state of Texas provided by the Texas State Board of Pharmacy (TSBP). The list 
comprises the name, license status (e.g., active), sex, race, and primary employment of all 






4.2.1 Inclusion and Exclusion Criteria 
Pharmacists who were currently active had a realistic chance of being familiar 
with ADE reporting. Only active Texas pharmacists were included in the study. It was 
assumed that pharmacists who had an opportunity to contact patients (e.g., involved in 
direct patient care) were familiar enough with ADEs to form an impression of ADE 
reporting. As a result, only pharmacists working in community (government, independent 
and multiple/chain) and hospital (government and non-government) pharmacies were 
included in the study.  Included pharmacists were not required to have reported ADEs in 
the past. Only pharmacists who were resident in the state of Texas were included. All 
non-active Texas pharmacists and those residing or practicing in other states were 
excluded from this study. 
 
4.2.2 IRB Procedures 
Two applications were sent to and approved by The University of Texas at 
Austin‘s Institutional Review Board (IRB) for this project. The first part of the study 
(focus groups) received expedited IRB approval and the second part comprising the mail 
survey received exempt approval.  
 
4.3 SAMPLE SIZE DETERMINATION 
Sample size determination is the a priori mathematical process of determining the 
number of subjects to be studied (Last, 1995). Determination of the sample size is a 
critical step of study design. To determine the sample size needed to meet the goals of the 
study, an a priori power estimation was conducted using G*Power version 3.0.10 
software (Erdfelder, Faul, & Buchner, 1996). The software calculated the a priori sample 
size (N) based on the provided significance level (α), power level (1-β), number of 
predictors and the estimated (to-be-detected) population effect size. The effect size for 
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this study was estimated by a computed average of all the effect sizes from the studies 
that used the TPB to investigate the intentions of healthcare professionals (HCPs). An 
average of 14 studies‘ effect sizes in predicting intention was calculated [(0.27 + 0.15 + 
0.74 + 0.56 + 0.35 + 0.49 + 0.49 + 0.58 + 0.61 + 0.91 +0.85 + 0.74 + 0.19 + 0.63)/14 = 
0.54] and was used as the estimate of the population effect size. With respect to the 
regression model, the effect size of 0.54 means that the independent variables in the 
model explained 54 percent of the variability in the dependent variable (mostly 
intention). The value of R-squared lies between zero (0) and one (1). The alpha level of 
significance for all statistical tests was set at α = 0.05, the statistical analyses‘ power was 
set at 0.80 and the number of predictors was set at five (5). The G*power software 
determined that the total sample size for the study should be 56.  
At least 10 subjects are required per predictor variable in multiple regression 
analysis (Elliott & Woodward, 2007). Given that the study had five predictor variables 
(attitude, subjective norm, perceived behavioral control, perceived moral obligation and 
past behavior), a minimum of 50 subjects was needed. This was achieved by the 
calculated sample size of 56.  
Low response rates are a challenge in mail surveys among HCPs (Nakash et al., 
2006; Sibbald, Addingtonhall, Brenneman, & Freeling, 1994). Low response rates, 
especially in the cases where respondents and non responders differ with respect to the 
outcome under study, reduce the validity of the study, the representativeness of the 
sample (introduce bias) and the effective sample sizes (Armstrong, White, & Saracci, 
1995; Nakash et al., 2006; Schulz & Grimes, 2002). The major factors influencing 
response to mail surveys among HCPs include increased paper work, type of population 
surveyed, investigating agency, questionnaire length, lack of interest in the study area and 
lack of time (Armstrong & Ashworth, 2000; Ashworth, 2001; Goyder, 1982; Heberlein & 
Baumgartner, 1978; Sibbald et al., 1994). Different response rates were obtained from 
studies involving HCPs. For example, a mean response rate of 61 percent was reported by 
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a review of published studies among doctors (Sibbald et al., 1994) and prescription event 
monitoring studies found average response rates of 50 to 70 percent (Mann, 2000).  
Many pharmacists do not respond to mail surveys. Studies of pharmacists using 
the mail survey found response rates ranging from 46 to 89 percent (Katz, Draugalis, & 
Lai, 1995; Wright-De Aguero, Weinstein, Jones, & Miles, 1998). Several studies have 
used mail surveys among Texas pharmacists and obtained varied response rates (Brown, 
1998; Brown, Barner, & Shah, 2005; Brown, Cantu, Corbell, & Roberts, 2007; Griggs & 
Brown, 2007; Mashburn et al., 2003; O'Donnell, Brown, & Dastani, 2006; Olson & 
Lawson, 1996) (see Table 4.1). These studies‘ response rates provide an indication of this 
study‘s expected response rate. Considering that response rates obtained by two of these 
studies seem to be outliers (Griggs & Brown, 2007; Olson & Lawson, 1996), this study 
used a median of these seven studies‘ response rates of 36 percent. 
 
Table 4.1: Response Rates Achieved in Studies Involving Pharmacists in Texas 
Author and Year Topic Response 
Rates (%) 
Olson and Lawson, 
1996 
Relationship between hospital pharmacists‘ job 
satisfaction and involvement in clinical activities. 
58.4 
Brown, 1998 Use of alternative therapies and their impact on 
compliance: perceptions of community 




Wilson, Barner and 
Marxwell, 2003 
Using the theory of planned behavior to predict 
Texas community pharmacists' willingness to 
provide sterile syringes to known or suspected 
intravenous drug users. 
35.1 
Brown, Barner and 
Shah, 2005.  
Community pharmacists‘ actions when patients 
use complementary and alternative therapies with 
medications. 
27.0 
O'Donnell, Brown and 
Dastani, 2006 
Barriers to counseling patients with obesity: A 
study of Texas community pharmacists.  
35.2 
Brown, Cantu, Corbell 
and Roberts, 2007 
Attitudes and interests of pharmacists regarding 
independent pharmacy ownership.  
36.0 
Griggs and Brown, 
2007 
Texas community pharmacists' willingness to 




The sample size was adjusted to take into consideration the low response rates. 
The adjusted sample size was calculated as the ratio of the number of responses needed 
and the expected response rate.  
Adjusted sample size = number of responses needed / expected response rate 
 
The adjusted sample size was calculated to be 56/0.36, N = 156. Thus, at least 200 
questionnaires were to be distributed to achieve 56 responses. This adjusted sample size 
is meant to accommodate for anticipated missing data and unreturned questionnaires. 
Given that we had resources for a larger sample and to counter for an unexpected low 
response rate, we increased the sample size to 1,500.  
 
4.4 SAMPLING 
The TSBP list had a total of 25,177 names. The flow chart below shows the 
numbers of pharmacists who were excluded from the study and the reasons for their 
exclusion (Figure 4.1). The Statistical Package for the Social Sciences software was used 
to select the sample from the TSBP list. From 12,904 active Texas pharmacists practicing 
in community and hospital settings, 1,500 pharmacists (potential participants) were 
selected through simple random sampling6. A majority of the 1,500 pharmacists were 
female (n = 772, 51.5%), and worked in the community setting (n = 1,043, 69.5%). A 
total of 1,500 survey packets were mailed out. 
 
  
                                                 
6 Prior to sampling, the TSBP list was sorted alphabetically using first names of the members. This was 
done in order to eliminate systematic ordering by year of licensure. The original TSBP list was sorted 
according to the license number of the members.  
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 Applicant (n = 30), delinquent (n = 286), inactive (n = 1343), probation (n = 125), 
restricted (n = 9), retired (n = 8), revoked (n = 21), surrendered (n = 3), and suspended (n 
= 13).  
b
 Comprised of those serving in armed services, HMO, home health, mail service, 
manufacturer or wholesaler, nuclear, other, sterile pharmaceutical (n = 3,637) and 
unknown (n = 2,280).  
 
4.5 INDEPENDENT AND DEPENDENT VARIABLES  
The dependent variable for the study is the pharmacists‘ intention to report serious 
ADEs. For this study, intention to report serious ADEs was defined as the degree of 
likelihood to report serious ADEs to the FDA through the MedWatch program. The 
independent variables are attitude (A), perceived behavioral control (PBC), subjective 
Members on the TSBP list (N = 25,177) 
 Female = 12,646 
 Male = 12,531 
Excluded according to the inclusion criteria (n 
= 6,356) 
 Not Activea (n = 1,838) 
 Non-Texas residents (n = 4,518) 
Active Texas pharmacists (n = 
18,821) 
Excluded according to the inclusion criteria—
Not in community or hospital setting
b
 (n = 
5,917) 
 
Final list of active Texas pharmacists practicing 
in community and hospital setting (n = 12,904). 
 Female = 6,416 
 Male = 6,488 
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norm (SN), past reporting behavior (PRB), perceived moral obligation (PMO) and 
demographic and practice factors (Table 4.2). PRB and PMO were included in the model 
as direct predictors of intention. These are defined below. 
 
Table 4.2: Definitions of the Independent Variables 
Independent Variable Definition 
Attitude toward reporting 
serious ADEs 
The degree of positive or negative value placed on 
reporting serious ADEs by pharmacists. 
Perceived behavioral control 
over reporting serious ADEs 
The perceived ease or difficulty of reporting serious 
ADEs and confidence in the ability to implement the 
reporting plans. 
Subjective norm Pharmacists‘ perception of social pressure to report 
serious ADEs. 
Perceived moral obligation An individual‘s self assessment of the level of moral 
obligation to report serious ADEs. 
Past reporting behavior The frequency with which ADE reporting (the 
behavior) has been performed in the past. 
Demographic and practice 
factors 
The personal factors and practice characteristics of the 
pharmacists. 
 
4.6 STUDY INSTRUMENT DEVELOPMENT 
The study instrument was developed in two stages. The first stage involved 
conducting qualitative studies with a convenience sample of Texas pharmacists. A total 
of 13 pharmacists participated in two (2) different focus group discussions to share their 
views and experiences with ADE reporting.  In the second stage, the instrument to 
measure pharmacists‘ attitudes, subjective norm, perceived behavioral control, past 
reporting behavior, perceived moral obligation and intention to report serious ADEs was 
developed, pilot tested and administered to a sample of pharmacists. The survey 
instrument has 94 items (see Appendix B). 
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4.6.1 Focus Groups Discussions 
In line with Ajzen and Fishbein (1980), preliminary/elicitation studies or focus 
groups were conducted to identify behavioral, perceived control and normative beliefs. 
Two focus groups were held in Austin. During the elicitation studies, the researcher 
conducted audiotaped interviews with a convenience sample of practicing Texas 
pharmacists. The first focus group was attended by Texas pharmacists attending graduate 
school at The University of Texas at Austin. The Capital Area Pharmacists‘ Association 
(CAPA) leadership helped to recruit members to participate in the second focus group. 
Each focus group had the minimum of 6-8 volunteers recommended in the literature 
(Patton 1990, Fowler 1993). The second focus group participants were given a $25.00 
gift card for participating. All potential focus group participants were informed of the 
time, date and location of the focus group through a letter (see Appendix C). They were 
also sent e-mail reminders the night before the meetings. All focus group participants 
signed an informed consent form (see Appendix D).  
The focus group was conducted to: a) determine the advantages and 
disadvantages of reporting serious ADEs by pharmacists; b) identify the individuals and 
groups who would approve or would not approve pharmacists reporting serious ADEs; 
and c) determine the factors that would make it easier or more difficult for pharmacists to 
report serious ADEs to the FDA. The purpose, length and rules of the focus group were 
explained to all focus group volunteers. The following open-ended questions, adapted 
from Montano and Kasprzyk (2002), were used in the focus groups (see Appendix E).  
1. What do you think are some of the advantages associated with pharmacists reporting 
serious ADEs to the FDA? 
2. What do you think are some of the disadvantages associated with pharmacists 
reporting serious ADEs to the FDA? 
3. Are there any individuals or groups who would approve pharmacists reporting serious 
ADEs to the FDA? 
 114 
4. Are there any individuals or groups who would not approve pharmacists reporting 
serious ADEs to the FDA? 
5. What do you think would make it easier to report serious ADEs to the FDA? 
6. What do you think would make it more difficult to report serious ADEs to the FDA? 
During the focus groups, the moderator guided the discussion using the outline of 
open-ended questions contained in the focus group interview guide (Appendix E). The 
moderator probed for details and asked follow-up questions to elicit more discussion.  
Each focus group lasted approximately one hour.  A content analysis was performed on 
the basis of the written transcriptions of the focus groups.  The data were coded in order 
to facilitate the search for patterns and themes within the data.     
The important behavioral outcomes and referents were identified. As 
recommended by Ajzen and Fishbein (1980), the beliefs gathered from the elicitation 
study were formatted to create an instrument that was later used in the mail survey. 
 
4.6.2 Measurement of Study Variables 
Elaborate measurement techniques for the components of the TPB and guidelines 
for measurement and questionnaire construction exist (Ajzen, 2002). All study variables 
were constructed based on the TPB guidelines (Ajzen & Fishbein, 1980). In addition to 
demographic and practice characteristics, the study examined attitude (A), subjective 
norm (SN), perceived behavioral control (PBC), past reporting behavior (PRB), 
perceived moral obligation (PMO) and behavioral intention (BI) variables (Figure 4.2). 
These variables are discussed below.  
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Figure 4.2: The Conceptual Model 
 
4.6.2.1 Predictor Variables 
The study‘s predictor variables comprise the three TPB constructs (A, SN and 
PBC), PRB and PMO. The three TPB constructs were measured through both direct and 
indirect measures. Although the indirect and direct measures of the same construct are 
measured in different ways, there should be a positive and strong correlation between 
them (Ajzen, 2002; Montano & Kasprzyk, 2002). Direct and indirect measures are 
expected to be correlated since they both serve as indicators of the same underlying latent 
construct (Ajzen, 2002). The direct measures of the TPB constructs are stronger 
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measures help researchers to understand the main drivers of behavior or ―why people 
hold certain attitudes, subjective norms, and perceptions of behavioral control‖ (Ajzen, 
2002, p. 8) that can be targeted by interventions. The study used seven-point Likert-type 
scales to measure the strength of behavioral beliefs and evaluations of the importance of 
behavioral beliefs. The corresponding evaluations of the behavioral, normative and 
control measures were measured as suggested by Ajzen and Fishbein (1980).  
The A, SN, and PBC items in this study were developed based on the findings 
from the focus group and on TPB recommendations (Ajzen, 2002).  
 
1) Attitude 
Direct Measure of Attitude 
The direct measure of pharmacists‘ attitude toward reporting serious ADEs was 
measured through a single multi-part item.  The item measured the pharmacists‘ overall 
evaluation of the behavior. The strength of attitude was assessed using a bipolar semantic 
differential scales anchored by worthless (-3) and valuable (+3), unpleasant (-3) and 
pleasant (+3), bad (-3) and good (+3), unenjoyable (-3) and enjoyable (+3), and harmful 
(-3) and beneficial (+3). The total score from these five items represents the pharmacist‘s 
overall positive or negative feeling toward reporting serious ADEs.  
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Q. For me to report serious ADEs to the FDA each time I come across them is 
 worthless: _3_:_-2_:_-1_:_0_:_1_:_2_:_3_: valuable 
           unpleasant: _3_:_-2_:_-1_:_0_:_1_:_2_:_3_: pleasant 
          bad: _3_:_-2_:_-1_:_0_:_1_:_2_:_3_: good 
         unenjoyable: _3_:_-2_:_-1_:_0_:_1_:_2_:_3_: enjoyable 
    harmful: _3_:_-2_:_-1_:_0_:_1_:_2_:_3_: beneficial 
 
Indirect Measure of Attitude 
The indirect measures of attitude were measured as a function of: a) behavioral 
beliefs (b), and b) outcome evaluations (e) (Ajzen & Fishbein, 1980). The eight (8) 
modal salient beliefs identified from the focus groups constitute the items. Each 
behavioral belief item was rated using a bipolar semantic differential scale anchored by 
extremely unlikely (+1) and extremely likely (+7). For example, a salient belief of 
increased risk of malpractice looked as shown below. 
 
Q.  My reporting of serious ADEs to the FDA whenever I encounter them will 
increase my risk of malpractice.  
extremely unlikely: _3_:_-2_:_-1_:_0_:_1_:_2_:_3_: extremely likely 
A similar but separate scale was used to measure the outcome evaluation (the 
consequences) (e). Each of the evaluative outcomes and attributes associated with the 
respective behavioral belief was measured and rated using a semantic differential scale 
anchored by extremely bad (+1) and extremely good (+7). For example, for the salient 
belief, the corresponding outcome evaluation looked as shown below.  
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Q.  Increased risk of malpractice is…  
extremely bad: _1_:_2_:_3_:_4_:_5_:_6_:_7_: extremely good  
For each respondent, the behavioral belief (b) and outcome evaluation (e) scores 
were multiplied. The attitude score was determined by summing these cross-products for 
all referents for each respondent. Higher absolute scores indicate that the respondents 
have more favorable attitude towards reporting serious ADEs to the FDA. 
A = ∑ biei 
a = attitude towards the object of behavior 
bi = belief about the object‘s attributes or about the behavior‘s consequences  
ei = evaluation of attributes or consequences 
 
2) Subjective Norm 
Similar to A, SN was measured through both direct and indirect measures.  
 
Direct Measures of Subjective Norm  
The direct subjective norm was assessed by a three-item scale. The pharmacists 
rated their agreement with three statements using a 7-point bipolar scale ranging from -3 
to +3. The total possible scores ranged from -9 to +9.  
Q.  Most people who are important to me think that 
I should: _3_:_2_:_1_:_0_:_-1_:_-2_:_-3_: I should not 
report serious ADEs that I encounter to the FDA. 
 
Q.  The people in my life whose opinions I value would 
approve: _3_:_2_:_1_:_0_:_-1_:_-2_:_-3_:  disapprove 
my reporting of serious ADEs that I encounter to the FDA. 
 
Q.  The pharmacists whose opinions I value 
report: _3_:_2_:_1_:_0_:_-1_:_-2_:_-3_:  do not report 




Indirect Measures of Subjective Norm 
The indirect subjective norm was assessed using two sub-scales: normative beliefs 
(n) and motivation to comply with each referent (m). The pharmacists‘ salient referents 
were obtained from the focus groups data. Pharmacists were asked to indicate the 
likelihood that the specified referents, who are important to them, would approve or 
disapprove of their reporting behavior. The strength of the normative beliefs was 
measured using a 7-point semantic differential scale ranging from extremely unlikely 
(+1) to extremely likely (+7). For example, the normative belief question pertaining to 
physicians was asked as follows.  
 
Q.  ―How likely is it that physicians would think that you should report serious ADEs 
to the FDA?‖  
extremely unlikely: _1_:_2_:_3_:_4_:_5_:_6_:_7_: extremely likely 
The pharmacists‘ level of motivation to comply with each referent was assessed 
using a 7-point semantic differential scale ranging from extremely unlikely (+1) to 
extremely likely (+7). The following question was asked. 
 
Q.   ―Generally speaking, how likely are you to do what the physicians want you to 
do when it comes to ADE reporting?‖  
 extremely unlikely: _1_:_2_:_3_:_4_:_5_:_6_:_7_: extremely likely 
For each respondent, the normative belief and motivation to comply scores were 
multiplied. The subjective norm (indirect measures) was determined by summing these 
cross-products for all referents for each respondent. Higher scores indicate that the 
referents have greater influence on the pharmacists.  
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SN = ∑nimi 
SN = subjective norm 
ni = normative belief about reporting ADEs 
mi = motivation to comply with the referent 
 
3) Perceived Behavioral Control 
Direct Measure of Perceived Behavioral Control (PBC)  
PBC refers to the pharmacist‘s perception of the ease or difficulty of undertaking 
the behavior (reporting serious ADEs) (Ajzen, 1991). Pharmacists were asked to rate 
their perceived control over reporting serious ADEs to the FDA. The study used two 
items to directly measure the PBC over reporting serious ADEs. The PBC items were 
measured using a 7-point bipolar semantic differential scale anchored by -3 (e.g., strongly 
disagree) and +3 (e.g., strongly agree).  The scores from the two items were then 
summed. The total possible score ranged from -6 to +6. Higher scores indicate 
pharmacists have greater confidence in their capability to report serious ADEs to the 
FDA. The following questions were used.  
 
Q.  How much control do you believe you have over reporting serious ADEs that you 
encounter to the FDA? 
no control: _-3_:_-2_:_-1_:_0_:_1_:_2_:_3_:  complete control 
 
Q.  It is mostly up to me whether or not I report serious ADEs to the FDA.  
strongly disagree: _-3_:_-2_:_-1_:_0_:_1_:_2_:_3_:  strongly agree 
 
Indirect Measures of Perceived Behavioral Control 
Two subscales were used to measure the pharmacists‘ indirect PBC over ADE 
reporting: control beliefs (c), and perceived power (p). The pharmacists‘ salient control 
beliefs reflect the main factors likely to inhibit or facilitate their reporting of serious 
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ADEs to the FDA. Pharmacists were asked to rate how much a specific factor would 
make it easy or difficult for them to report serious ADEs to the FDA. All the control 
items were measured using a 7-point bipolar semantic differential scale anchored by 
extremely difficult (+1) and extremely easy (+7). For example, the following question on 
the lack of time factor was asked of respondents to measure their control beliefs. 
 
Q.   ―Will the lack of time make it easy or difficult for you to report serious ADEs 
that you encounter to the FDA?‖   
extremely difficult: _1_:_2_:_3_:_4_:_5_:_6_:_7_: extremely easy 
The pharmacists‘ perceived power indicates how much control they (pharmacists) 
believe they have over reporting serious ADEs that they encounter to the FDA. Perceived 
power was measured using a 7-point bipolar scale anchored on no control (+1) and 
complete control (+7). For example, the following question on the lack of time factor was 
asked. 
 
Q.  ―How much control do you feel you have over the lack of time when it comes to 
reporting serious ADEs to the FDA?‖ 
no control:_1_:_2_:_3_:_4_:_5_:_6_:_7_: complete control 
For each respondent, the control belief (c) and perceived power (p) scores were 
multiplied. The PBC score for each respondent was determined by summing these cross-
products across the number of factors as shown below. Higher absolute PBC scores 
indicate that the pharmacists perceive themselves to have more control over reporting 
serious ADEs.  
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PBC = ∑cipi 
PBC = perceived behavioral control 
ci = the control belief toward the factor  
pi = the perceived power of a particular control factor to facilitate or inhibit ADE 
reporting. 
 
4) Past Reporting Behavior 
Given the importance of past behavior in explaining significant variance in 
behavioral intention, the past reporting behavior (PRB) construct was included in this 
study. The PRB measure was developed based on similar measures used in previous 
studies (Mashburn et al., 2003; Millstein, 1996; Nwokeji, 2007). PRB was measured 
using two dichotomous questions where respondents were required to make a choice 
between two response alternatives: 1 = no, and 2 = yes. A total score was obtained by 
summing the scores from these two items. Higher scores indicate higher PRB. Below are 
the two questions that were used to measure PRB.  
 
Q.  Have you ever reported any ADEs to the FDA through MedWatch?  
Q.  Have you reported any ADEs to the FDA through MedWatch in the previous 12 
months?  
 
5) Perceived Moral Obligation 
The study also included PMO as an additional determinant of intentions given that 
moral values may influence pharmacists‘ behavioral intention to report serious ADEs. 
The ability of PMO to predict pharmacists‘ reporting intention was assessed using a 
single item adapted from Randall and Gibson (1991) and Gorsuch and Ortberg (1983). 
The item was measured using a bipolar Likert response scale anchored by 1 = strongly 
disagree and 7 = strongly agree. The single item is shown below.  
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Q.  I believe I have a moral obligation to report serious ADEs that I will encounter to 
the FDA.  
 
6) Demographic and Practice Characteristics 
Given the importance of demographic factors and practice characteristics in 
influencing pharmacists‘ beliefs, evaluation of behavioral outcomes, motivation to 
comply with others, perceived power of difficulty of ADE reporting, PRB, and PMO, the 
following eleven demographic and practice variables were collected and examined.  
 
 Gender (male/female); 
 Age (year of birth); 
 Ethnic/racial background (African American/non-Hispanic black, American Indian or 
Alaska Native, Asian American/Pacific Islander, Caucasian/non-Hispanic white, 
Mexican American/Hispanic, or other; 
 Practice experience (in years); 
 Current job title at primary place of employment (pharmacy owner/partner, pharmacy 
manager/supervisor, clinical pharmacist, staff pharmacist, relief pharmacist, or other); 
 Practice setting at primary place of employment (community—independent, 
community—multiple/chain [3 or more pharmacies under common ownership], 
hospital—independent, hospital—multiple/chain [3 or more pharmacies under 
common ownership], or other); 
 Practice location (urban, suburban or rural); 
 Average number of hours worked per week;  
 Average number of hours per week spent dispensing medication;  
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 Pharmacist workload (average number of prescriptions or medication orders 
dispensed per day); and 
 Knowledge of ADE reporting (the study used nine questions as shown below).  
 
Pharmacists Knowledge of ADE Reporting 
Nine (9) dichotomous questions were used to measure the pharmacists‘ 
knowledge and awareness of ADE reporting and drug safety issues. The questions below 
cover the goals, procedures and expectations from MedWatch. Respondents were 
required to make a choice between two response alternatives: 0 = false and 1 = true. The 
correct answer for the first eight questions is shaded. For question nine (9), no response is 
shaded because there was no correct or wrong answer for this question. An individual‘s 
total score was obtained by summing his/her scores on the first eight items. This score 
was then converted to a percentage. Higher scores indicate higher knowledge of ADE 
reporting.  
 
1. All ADEs, irrespective of severity, should be reported to the FDA (True/False). 
2. Pharmacists should report serious ADEs even if they are uncertain that the product 
caused the event (True/False). 
3. Pharmacists should report serious ADEs even if they do not have all the details (e.g., 
complete patient history and demographic data) (True/False). 
4. All serious ADEs are known before a drug is marketed (True/False). 
5. The FDA does not disclose the ADE reporter‘s identity in response to a request from 
the public (True/False). 
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6. Pharmacists can report ADEs to the FDA anonymously (True/False). 
7. Adverse experiences with cosmetics and special nutritional products (e.g., dietary 
supplements, infant formulas) may be reported to the FDA (True/False).  
8. One case reported by a pharmacist does not contribute much to knowledge on drug 
risks (True/False). 
9. I have adequate knowledge on ADE reporting (e.g., what to report and how to report) 
(True/False). 
4.6.2.2 Outcome Variable 
Intention to Report Serious ADEs 
The pharmacists‘ intention to report serious ADEs to the FDA was measured 
using three items. The items asked pharmacists to indicate the extent to which they will 
try, plan or intend to report serious ADEs that they will encounter to the FDA. The 
strength of the intention was measured on a 7-point bipolar Likert-type scale anchored by 
1 (e.g., extremely unlikely) and 7 (e.g., extremely likely). The total possible scores 
ranged from 3 to 21. Higher total scores represent a higher intention to report serious 
ADEs. 
 
Q.  I intend to report serious ADEs that I will encounter to the FDA. 
extremely unlikely: _1_:_2_:_3_:_4_:_5_:_6_:_7_: extremely likely 
 
Q. I will try to report serious ADEs that I will encounter to the FDA. 
definitely true: _1_:_2_:_3_:_4_:_5_:_6_:_7_:  definitely false 
 
Q. I plan to report serious ADEs that I will encounter to the FDA. 
strongly disagree: _1_:_2_:_3_:_4_:_5_:_6_:_7_:  strongly agree 
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The behavioral intention was calculated as the weighted sum of A, SN, PBC, 
PMO and PRB using multiple regression analysis. Each of the regression coefficients in 
the equation was calculated using multiple regression analysis.  
 
BI = B0 + B1 (A) + B2 (SN) + B3 (PBC) + B4 (PRB) + B5 (PMO) + Ei 
BI = Behavioral intention 
A = Attitude 
SN = Subjective norm 
PBC = Perceived behavioral control 
PRB = Past reporting behavior 
PMO = Perceived moral obligation 
B1-5 = Unstandardized regression weights 
B0 = Constant 
Ei = Error term 
 
4.7 PILOT TESTING 
The developed instrument was pilot tested on a convenience sample of Texas 
pharmacists. As suggested by Polit and Beck (2004), the questionnaire was pre-tested to 
achieve the following: a) identify parts of the instrument package that are difficult for 
subjects to read or understand; b) identify any questions that participants may find 
objectionable; and c) determine if the measures yield data with sufficient variability. In 
addition, the pilot test was also used to assess the face and content validity of the 
instrument. Twelve pharmacists consisting of nine (9) community and three hospital 
pharmacists were asked to complete a questionnaire and then to give feedback and 
comments on the clarity and relevance of items. Pilot test participants were asked to 
recommend item word modifications as needed and to make a judgment on the extent to 
which the scales represented the domain concept. All participants were asked to record 
and report the time it took them to complete the survey. Respondents took an average of 
10 minutes to complete the survey instrument.  
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The responses from the pilot test were coded and analyzed. The reliability of the 
instrument was measured by Cronbach‘s alpha—a measure of internal consistency—
using the pilot test responses. Cronbach‘s alphas were calculated for all scales with 3 or 
more items. The calculated internal consistency or Cronbach‘s alpha are given in Table 
4.3. Cronbach‘s alpha values less than 0.60 are deemed not acceptable (Robinson, 
Shaver, & Wrightsman, 1991). All the calculated Cronbach alphas were greater or equal 
to 0.70. Overall, the instrument appeared to have acceptable reliability.  
 
Table 4.3: Reliability of Direct Measures Based on Pilot Test Results 
Scales Number of Items Cronbach’s Alpha 
Attitude (direct measure) 5 0.70 
Subjective norm (direct measure) 3 0.79 
Perceived behavioral control (direct measure)
a
 2 - 
Intention 3 0.84 
Past behavior
 a




reliability estimates were calculated for scales with less than 3 items 
 
Appropriate modifications were made to the survey instrument based on the 
participants‘ feedback during pilot testing. Based on the feedback from the pilot test, the 
following changes were made to the survey instrument: 
 The questions were re-ordered. The section on attitude was placed ahead of the 
intention section. The order of the two past reporting behavior items was swapped.  
 Some questions including the attitude item pertaining to ‗taking too much time‘ were 
re-phrased. 
 The counterbalancing of the positive and negative endpoints in the direct attitude 
scale which had been designed to counteract possible response sets was eliminated. 
After these refinements, the survey instrument was ready for distribution.  
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4.8 MAIL SURVEY DATA COLLECTION PROCEDURES 
For the mail survey, data collection included distributing the study materials and 
sending out follow-up materials and letters to the potential respondents as described 
below. First, the study materials consisting of a cover letter and the questionnaire were 
mailed to the potential respondents. The cover letter highlighted the objectives of the 
study, assured the respondents of confidentiality and anonymity of individual responses 
and requested the respondents‘ participation in the study. Through the cover letter, 
respondents were offered an aggregate summary of responses as an incentive for 
participation in the study. Participants were given two weeks to complete and return the 
questionnaire. A copy of the cover letter is in Appendix F.  
Second, a second mailing of the questionnaires together with a follow-up cover 
letter were distributed to the sample 21 days after the initial mailing. The mailings were 
sent to the entire sample given the anonymous responses. A copy of the follow-up cover 
letter can be found in Appendix F.  
 
4.9 DATA CLEANING 
Data were cleaned and prepared for analysis. The process addressed three 
fundamental aspects vis-à-vis outliers, violation of assumptions (nonnormality), and 
missing values as described below. First, outliers were identified and analyzed. For all 
non-dichotomous variables/items, z-scores were calculated and those items with z-values 
greater than +3.29 or less than -3.29 were identified and examined (p < 0.001). Those 
considered valid were retained and those that were considered invalid were considered 
outliers and were substituted with the median value.  
Second, given that multiple regression assumes that all the variables are 
multivariate normally distributed, the data were assessed for nonnormality. Skew and 
kurtosis statistics were calculated and used to test for nonnormality. Skew greater than |2| 
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and kurtosis greater than |7| were considered serious violations of the assumption 
(Curran, West, & Finch, 1996). Scatterplots and histograms of studentized residuals 
between all independent variables with the dependent variable were made to test the 
violation of assumptions of linearity and normality.  
Third, the study assessed the missing values and the pattern of these values. Pair-
wise and list-wise deletion was used if data were missing. The study also compared data 
on key variables (Intention, A, SN, PBC, PRB, PMO) between those with at least one 
missing response and those without.  
 
4.10 DATA ANALYSIS 
The data from the questionnaires were coded and inputted into the Statistical 
Package for Social Sciences (SPSS)® for Windows version 14.0 for analysis (SPSS inc, 
Chicago Illinois, 2005). The acceptable level of significance for all analyses was p < 
0.05. Several analyses were conducted in this study including descriptive statistics, 
correlation analyses, t-tests, analysis of variance (ANOVA) and multiple regression.  
 
Descriptive Statistics 
 Means, frequency distributions and standard deviations were calculated for all 
demographic and study variables (interval data) (BI, A, SN, PBC, PMO, PRB and 
demographic and practice characteristics). Frequencies and percentages of all categorical 
data (e.g., gender, race, practice setting) were obtained.  
 
Correlation Analyses 
Pearson correlation coefficients were calculated to show the correlation between 
the main variables in the conceptual model (BI, A, SN, PBC, PRB and PMO). 
 130 
Correlations between direct and indirect measures of each of the TPB‘s independent 
constructs (A, SN and PBC) were also computed and compared.  
 
T-Test Analyses 
Independent t-tests were applied to compare A, SN, and PBC among male and 
female pharmacists, and among intenders and non-intenders. To compare intenders and 
non-intenders, the following procedures were taken. All responses of one (1) to three (3) 
on any of the three intention items were re-corded with a minus one (-1) for that item. All 
responses between a five and a seven on any of these three items were re-coded with 
positive one (+1) for that item. Those who marked a four on any of the three intention 
items were re-coded with a zero for that item. For each respondent, the dummy codes (-
1s, 0s and +1s) were added together across the three intention items. This composite 
score was then used to categorize respondents into intenders (e.g., positive total score), 
non-intenders (e.g., negative total score) and neither intenders nor non-intenders (had a 
total score of zero). 
 
Analysis of Variance (ANOVA) 
ANOVA was conducted to assess the mean differences in A, SN, PBC and 
intention across the study‘s polytomous categorical variables (e.g., ethnicity, and 
pharmacists‘ primary setting).  
 
Multiple Regression Analyses 
Multiple (linear) regression analysis and hierarchical regression were used to 
regress behavioral intention on the TPB constructs (A, SN and PBC), PMO, and PRB. 
Multiple regression analysis was used to determine the predictors of Texas pharmacists‘ 
intention to report serious ADEs. Separate equations were run for direct and indirect 
measures of the TPB predictors. It is important to note that multiple regression does not 
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infer causality. Attributing causality is an issue of study design and not statistical 
analysis.  
The study used generalized linear models to compare responses for each item and 
for all domains. If significant differences were detected, the least squares mean post hoc 
test was used to determine significant pair-wise differences.  
The use of regression analysis is theoretically justified if the data satisfies four 
assumptions. Linear regression analysis assumes the following:  
 Linearity: there is a linear relationship between the dependent and independent 
variables. Scatterplots or partial regression plots for the dependent and independent 
variables were assessed for systematic patterning among the residuals to evaluate the 
linearity of the data. The existence of a pattern in the plot may suggest that the 
relationship between the plotted variables is non-linear. 
 No multicollinearity: there is no serial correlation or the independent variables are not 
highly correlated with each other. The values of correlation coefficients of the 
variables, tolerance, and variance inflation factors were used to test this criterion. 
Multicollinearity is a significant problem in cases where correlation coefficients 
exceed 0.75 (Graphpad Instat, 1990). Tolerance is the proportion of variance in the 
independent variable in question that is not explained by its association with other 
predictor variables. ―A tolerance value close to 1.00 means that you are safe in 
including that variable, whereas a value close to 0 shows that you run the risk of 
multicollinearity, possibly no solution, by including this variable‖ (Hays, 1994, pp. 
722, 723). Tolerance values range from zero to one. Variance Inflation Factors (VIF) 
are inverses of tolerance. VIF ranges from 1 to infinity. Higher values of VIF indicate 
there is a multicollinearity problem. As a rule of thumb, VIF greater than 10 raises 
concern about multicollinearity (Myers, 1990). 
 132 
 Normality of the distribution of errors: the residuals7 or errors are normally 
distributed around each predicted value of the dependent variable. The distribution of 
residual values was evaluated by inspecting histograms and normal probability plots. 
Histograms that differ markedly from a normal distribution raise concern. 
 Homoscedasticity (constant variance) of errors: the variances and standard deviations 
of the errors are constant for all the independent variables. This assumption was 
assessed by examining the scatterplots of residuals versus predicted values.  
 
Reliability 
Measures with low reliabilities ―lead to an underestimate of the relations among 
the theory‘s constructs and of its predictive validity‖ (Ajzen, 2002, p. 4). The reliability 
of all the multiple-item scales in the instrument was measured by Cronbach‘s alpha, a 
measure of internal consistency. These scales include intention to report ADEs, A (direct 
measures only), and SN (direct measures only). Cronbach‘s alpha values less than 0.60 
are deemed not acceptable (Robinson, Shaver, & Wrightsman, 1991).  
 
4.11 OBJECTIVES, HYPOTHESIS TESTS AND CORRESPONDING STATISTICAL ANALYSES 
Table 4.4 provides the objectives, hypotheses and statistical tests used in this 
study. 
 
                                                 
7 Residuals are the difference between the predicted value of the dependent variable and the obtained value 
of the dependent variable.  
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Table 4.4: Study Objectives, Hypotheses and Statistical Tests 
Objectives Hypotheses Statistical Model Statistical Test 
Objective 1 Identify pharmacists‘ beliefs concerning reporting 




Objective 2  To explore the utility of the TPB model 
constructs (A, SN, PBC) in predicting 
pharmacists‘ intention to report serious ADEs. 
  
 H1: Favorable attitude (A) is a positive and 
significant predictor of intention to report serious 
ADEs controlling for SN and PBC. 
BI = B0 + B1(Ad) + B2(SNd) + B3(PBCd) 






 H2: SN supporting ADE reporting is a positive 
and significant predictor of intention to report 
serious ADEs controlling for A and PBC. 
BI = B0 + B1(Ad) + B2(SNd) + B3(PBCd) 






 H3: Strong perceived behavioral control (PBC) is 
a positive and significant predictor of intention to 
report serious ADEs controlling for A and SN. 
BI = B0 + B1(Ad) + B2(SNd) + B3(PBCd) 






 H4: A + SN + PBC constructs explain a 
significant amount of variance in pharmacists‘ 
intention to report serious ADEs. 
BI = B0 + B1(Ad) + B2(SNd) + B3(PBCd) 






A = attitude, SN = subjective norm, PBC = perceived behavioral control; i = indirect measure, d = direct measure, ADE = adverse 
drug event, SD = standard deviation, B0-3 = unstandardized regression coefficients. 
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Table 4.4: Study Objectives, Hypotheses and Statistical Tests 
Objectives Hypotheses Statistical Model Statistical 
Test 
Objective 3 To determine the contribution of the PBC construct 
to the prediction of pharmacists‘ intention to report 
serious ADEs beyond A and SN constructs. 
  
 H5: PBC significantly increases the explanatory 
power of the regression model compared to only 
using A + SN to explain pharmacists‘ intention. 
BI = B0 + B1(Ad) + B2(SNd) + B3(PBCd)  






Objective 4 To determine if the past reporting behavior (PRB) 
construct contributes toward the prediction of 
pharmacists‘ intention to report serious ADEs over 
and above the TPB constructs. 
  
 H6: PRB significantly increases the explanatory 
power of the regression model compared to only 
using the A + SN + PBC to explain pharmacists‘ 
intention to report serious ADEs. 
BI = B0 + B1(Ad) + B2(SNd) + B3(PBCd) + 
B4 (PRB) 







Objective 5 To determine if PMO significantly increases the 
explanatory power of the regression model compared 
to only using the A + SN + PBC to explain 
pharmacists‘ intention to report serious ADEs. 
  
 H7: PMO significantly increases the explanatory 
power of the regression model compared to only 
using the A + SN + PBC to explain pharmacists‘ 
intention to report serious ADEs.  
BI = B0 + B1(Ad) + B2(SNd) + B3(PBCd) + 
B4 (PMO) 







A = attitude, SN = subjective norm, PBC = perceived behavioral control; i = indirect measure, d = direct measure, PRB = past 
reporting behavior, PMO = perceived moral obligation, ADE = adverse drug event, and B0-3 = unstandardized regression coefficients. 
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Table 4.4: Study Objectives, Hypotheses and Statistical Tests  
Objectives Hypotheses Statistical Model Statistical Test 
Objective 6 To determine if the pharmacists‘ A, SN or PBC toward 
reporting serious ADEs is related to practice characteristics 
and demographic factors. 
  
Gender H08: There is no significant difference in A to report 
serious ADEs by gender. 
Ad = B0 + B1 (gender)  
Ai = B0 + B1 (gender) 
T-test 
 H09: There is no significant difference in SN regarding 
reporting serious ADEs by gender. 
SNd = B0 + B1 (gender)  
SNi = B0 + B1 (gender) 
T-test 
 H010: There is no significant difference in PBC over 
reporting serious ADEs by gender. 
PBCd = B0 + B1 (gender)  




H011: There is no relationship between A to report serious 
ADEs and pharmacists‘ years of experience. 
Ad = B0 + B1 (years experience)  
Ai = B0 + B1 (years experience) 
Correlation 
 H012: There is no significant relationship between SN to 
report serious ADEs and pharmacists‘ years of experience. 
SNd = B0 + B1 (years experience)  
SNi = B0 + B1 (years experience) 
Correlation 
 H013: There is no significant relationship between PBC to 
report serious ADEs and pharmacists‘ years of experience. 
PBCd = B0 + B1 (years experience)  




H014. There is no significant difference in A toward ADE 
reporting by pharmacists‘ primary practice setting. 
Ad = B0 + B1 (practice setting)  
Ai = B0 + B1 (practice setting) 
ANOVA 
 H015: There is no significant difference in SN regarding 
ADE reporting by pharmacists‘ primary practice setting. 
SNd = B0 + B1 (practice setting)  
SNi = B0 + B1 (practice setting) 
ANOVA 
 H016: There is no significant difference in PBC over ADE 
reporting by pharmacists‘ primary practice setting. 
PBCd = B0 + B1 (practice setting)  
PBCi = B0 + B1 (practice setting) 
ANOVA 
A = attitude, SN = subjective norm, PBC = perceived behavioral control; I = indirect measure, d = direct measure, ADE = adverse 
drug event, B0-1 = unstandardized regression coefficients, ANOVA = analysis of variance. 
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Table 4.4: Study Objectives, Hypotheses and Statistical Tests 
Objectives Hypotheses Statistical Model Statistical 
Test 
Hours worked  H017. There is no significant relationship between the 
pharmacists‘ number of hours worked and A toward 
ADE reporting. 
Ad = B0 + B1 (hours worked)  
Ai = B0 + B1 (hours worked) 
Correlation 
 H018: There is no significant relationship between the 
pharmacists‘ number of hours worked and SN 
regarding ADE reporting. 
SNd = B0 + B1 (hours worked)  
SNi = B0 + B1 (hours worked) 
Correlation 
 H019: There is no significant relationship between the 
pharmacists‘ number of hours worked and PBC over 
ADE reporting. 
PBCd = B0 + B1 (hours worked)  
PBCi = B0 + B1 (hours worked) 
Correlation 
Race/ethnicity  H020: There is no significant difference in A toward 
ADE reporting by pharmacists‘ race/ethnicity. 
Ad = B0 + B1 (race/ethnicity)  
Ai = B0 + B1 (race/ethnicity) 
ANOVA 
 H021: There is no significant difference in SN 
regarding ADE reporting by pharmacists‘ 
race/ethnicity. 
SNd = B0 + B1 (race/ethnicity)  
SNi = B0 + B1 (race/ethnicity) 
ANOVA 
 H022: There is no significant difference in PBC over 
ADE reporting by pharmacists‘ race/ethnicity. 
PBCd = B0 + B1 (race/ethnicity)  
PBCi = B0 + B1 (race/ethnicity) 
ANOVA 
Knowledge H023. There is no significant relationship between the 
pharmacists‘ knowledge of ADE reporting and A 
toward ADE reporting. 
Ad = B0 + B1 (knowledge)  
Ai = B0 + B1 (knowledge) 
Correlation 
 H024: There is no significant relationship between the 
pharmacists‘ knowledge of ADE reporting and SN 
regarding ADE reporting. 
SNd = B0 + B1 (knowledge)  
SNi = B0 + B1 (knowledge) 
Correlation 
 H025: There is no significant relationship between the 
pharmacists‘ knowledge of ADE reporting and PBC 
over ADE reporting. 
PBCd = B0 + B1 (knowledge)  
PBCi = B0 + B1 (knowledge) 
Correlation 
A = attitude, SN = subjective norm, PBC = perceived behavioral control; I = indirect measure, d = direct measure, ADE = adverse 




There are several limitations associated with this study.  
1. The study did not validate the respondents‘ responses with the actual ADE reports. 
This task is impossible given the anonymity of the study‘s respondents and of the 
ADE reports and ADE reporting in general.  
2. Good quality serious ADE reports are necessary for a proper evaluation of drug safety 
signals. Poor quality reports or those with missing information may be of little value 
in efforts to improve patient safety and the quality of patient care. This 
notwithstanding, this study does not consider the quality of the reports submitted by 
the pharmacists. 
3. The problem of social desirability response bias which is ―the tendency of some 
individuals to misrepresent their responses consistently by giving answers that are 
congruent with prevailing social values‖ (Polit and Beck, p.359) cannot be 
completely ruled out in the study. Also given the sensitivity of the topic, it may be 
that some respondents gave socially desirable answers.  
4. The use of a structured questionnaire/data collection instrument does not allow 
respondents sufficient opportunity to qualify their responses. The use of an 
unstructured or loosely structured data collection tool/method may give the study 
even more depth. However, respondents got an opportunity to make open-ended 
comments on the survey instrument. Further studies employing qualitative methods 
may be needed to further explore pharmacists‘ intention to report serious ADEs. 
5. Other important variables influencing pharmacists‘ ADE reporting might not be 
included in the TPB (e.g., cues to action in the Health Belief Model). Also, belief-




6. Causality influences cannot be explicitly made in this study. This is so because the 
study used a nonexperimental research design with a cross-sectional data collection 
and did not control for all appropriate confounding variables. However, this 
nonexperimental model, with hypothesized causal relationships guided by the theory 
and prior research, seems plausible/suitable.  
7. This cross-sectional study assessed the effects of the independent variables in 
explaining intention at the time of data collection. This may provide a poor prediction 
and understanding of pharmacists‘ reporting behavior. Ideally, a prospective study 
design with the predictors and intention measured at one time and behavior measured 
at a later time point, is recommended. 
 
4.13 SUMMARY 
This chapter focuses on the research methods that were used for this study. It 
outlines the research design and the procedures that were used to develop the instrument 
and the steps that were taken in pilot testing and checking the reliability of the 
questionnaire. The chapter also describes the procedures for data collection (sampling, 







CHAPTER FIVE: RESULTS 
This chapter describes the main findings of the study. The first section details the 
findings from the two focus groups followed by the results of the mail survey. Internal 
consistency of the scale items and descriptive statistics of study constructs are presented. 
The multivariate analyses of data are described and a summary of hypothesss tests is 
detailed.  
 
5.1 FOCUS GROUP RESULTS 
A total of 13 Texas pharmacists participated in two focus groups. The first focus 
group was conducted at The University of Texas College of Pharmacy and was attended 
by six (6) practicing pharmacists. The second focus group was conducted during the 
monthly meeting of the Capital Area Pharmacists Association (CAPA) in Austin with 
seven (7) CAPA members. The focus groups lasted approximately an hour each. The 
pharmacists who participated in the first focus group were provided lunch. CAPA 
members who volunteered to participate in the second study were offered a $25 gift card 
as an incentive for participating. The focus groups identified the pharmacists‘ behavioral, 
normative and control beliefs that underpin their intention to report serious ADEs. 
Emerging themes were identified through content analyzing the focus group participants‘ 
responses to the study questions. The key words and phrases of all the three belief-based 
categories were tallied and their frequencies were ranked (Tables 5.1, 5.2, and 5.3).  
 
5.1.1 Behavioral Beliefs 
A total of 11 behavioral beliefs were identified from the responses of focus group 
participants (Table 5.1). Nine of the 13 pharmacists believed that reporting serious ADEs 
to the FDA was time consuming. Six pharmacists believed that reporting serious ADEs to 
the FDA educates others about drug risks. In addition, results of the focus groups showed 
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that pharmacists believed that reporting provided them little benefit/reward, compromises 
their relationship with physicians, increases the risk of malpractice, improves patient 
safety, breaks their trust with their patients and disrupts the normal workflow (Table 5.1). 
The eight most commonly mentioned behavioral beliefs were used to construct the 
indirect attitude measures. This number is in line with the recommended minimum of five 
to nine belief items (Ajzen & Fishbein, 1980). In addition, information contained in items 
9-11 was likely reflected in other items already included. These items (9-11) did not have 
as much support from the focus groups as the other items.   
 
Table 5.1: Behavioral Belief Items (n = 13 Pharmacists) 
Item Frequency 
Time consuming (to gather facts, to report) 9 
Educates others about drug risks (e.g., increases knowledge and 
information about drugs) 
6 
Little benefit gained from reporting (e.g., reporting is not rewarding, no 
compensation)  
5 
Compromise the relationship one has with physicians and other HCPs  4 
Increase risk of malpractice/legal liability 4 
Improves patient safety 4 
Breaks trust with patient and changes patient care 3 
Disrupts the normal workflow 3 
Make sure that another patient does not have the same experience 2 
Results in call from pharmacy board 1 
To have the information centralized 1 
 
5.1.2 Normative Beliefs 
The main normative beliefs identified from the focus group responses are given in 
Table 5.2. A total of 15 categories of normative beliefs were identified. The pharmacists 
believed that physicians would approve and disapprove of their reporting of serious 
ADEs to the FDA. The other salient social norms were patients, drug manufacturers, 
pharmacy associations, family/spouses, the FDA, pharmacy managers, colleagues, and 
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hospitals or hospital groups. A total of nine most commonly mentioned individuals and 
groups were included as indirect subjective norm measures (Table 5.2).   
 
Table 5.2: Normative Belief Items (n = 13 Pharmacists) 
Item Frequency 
Physicians (physician groups and individual physicians) 10 
Patients 7 
Drug manufacturers 6 
Pharmacy associations (APhA, ASHP, ACCP, CAPA) 4 
My family/spouse/significant others 4 
Food and Drug Administration (FDA) 4 
Pharmacy managers 3 
Other pharmacists 3 
Hospitals and hospital groups 3 
Medicare and Medicaid budget officers 2 
Lawyers 2 
Third party payers (PBMs) 1 
Texas State Board of Pharmacy 1 
Pharmacy technicians 1 
Centers for Medicare and Medicaid Services (CMS) 1 
 
5.1.3 Control Beliefs 
The focus group participants cited many factors that they believed would make it 
easier or more difficult for them to report serious ADEs to the FDA (Table 5.3). 
Pharmacists believed that not having the patient‘s complete medical history made it 
difficult for them to report serious ADEs (n = 12). Also, a majority of the participants (n 
= 10) believed that lack of time made it difficult for them to report serious ADEs. The 
other major control beliefs identified by the participants are pharmacists awareness of 
ADE reporting (e.g., MedWatch program), streamlining the MedWatch form and 
reporting process, lack of employer support of ADE reporting, lack of some form of 
personal benefit (e.g., reward or compensation), ADE reporting not being part of normal 
workflow, increased patient counseling, patient awareness of drug risks, pharmacists 
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being drug experts and lack of clarity on the definition of ADEs to be reported (Table 
5.3). Eleven of the most commonly cited control belief items were used to construct the 
indirect perceived behavioral control (PBC) measure in the instrument. Although this was 
two more than the nine recommended by Ajzen and Fishbein (Ajzen & Fishbein, 1980), 
the focus group participants were passionate about these two extra items. In addition, lack 
of clarity on reportable ADEs has been consistently found to be a barrier to reporting 
ADEs in the literature (Eland et al., 1999; Green et al., 2001; Hasford et al., 2002; Martin 




Table 5.3: Control Belief Items (n = 13 Pharmacists) 
Item Frequency 
I don‘t have the patient‘s complete medical history 12 
Lack of time (busy, no time) 10 
Pharmacists awareness of ADE reporting (e.g., MedWatch program) 7 
Streamlining the MedWatch form and reporting process (having a simpler 
form) 
6 
Lack of employer support of ADE reporting (not a priority in the business 
model) 
5 
Lack of some form of benefit (e.g., reward or compensation) 5 
ADE reporting not part of the normal workflow and routine 4 
Increased patient counseling (spending time with patients, getting better 
information, telling patients what‘s happening) 
4 
Patient awareness of drug risks (e.g., ADEs) and their role in post 
marketing surveillance (PMS) 
4 
Pharmacists being the drug experts 4 
Lack of clarity on the definition of ADEs to be reported 3 
No access to the web at work 3 
Difficulty in pinpointing the drug causing the ADEs 2 
Fear of possible malpractice suit/legal action 2 
We do not see serious ADEs 2 
Apathetic patients 1 
Do not want to have anything to do with ADE reporting 1 
Having the pharmacist accessible to patients 1 
Increased feedback from patients 1 
More pharmacists 1 
My knowledge of the ADE in question 1 
Not going to contribute significantly to the literature 1 
Patient and consumer advocacy of ADE reporting 1 
Perspective of the pharmacist‘s role with respect to reporting 1 
Pharmacist burnout 1 
Prioritize ADE reporting 1 
To publish case reports 1 
The survey instrument was consists of 94 items, 69 of which measure the TPB 




Table 5.4: Number of Survey Items by Each of the TPB Constructs 










Intention  3 3-5 
Attitude – direct  5 6a-e 
Subjective norm - indirect Normative beliefs 





Subjective Norm - direct  3 9-11 
Perceived behavioral 








control – direct 
 2 15-16 
 
5.2 SURVEY RESPONSE RATES 
Data were collected using a self-administered mail survey between May and July 
2009. Surveys together with a cover letter were mailed to 1,500 practicing Texas 
pharmacists. The sample comprised 772 (51.5%) female and 728 (48.5%) male 
pharmacists. A total of 70 letters were returned undeliverable after the first and second 
mail outs. Therefore, 1,430 letters were considered delivered. A total of 399 surveys were 
received via mail by July 31
st
 for a 27.9 percent response rate (399/1,430). Five responses 
received after the 31
st
 July were excluded from the study. In addition, six respondents 
indicated that they had retired, one indicated that he/she was not willing to participate 
(returned an uncompleted survey), one indicated that she was not currently working and 
14 surveys were incomplete (e.g., had more than 20% missing responses). Thus, 377 
usable responses were obtained, yielding a usable response rate of 26.4 percent (377 




5.3 DATA PREPARATION AND CLEANING 
The data were entered into SPSS and prepared and screened for data analysis. 
Data preparation and screening focused on checking the adherence of the data to 
distributional assumptions (normality) and also investigated the existence of outliers and 
missing data.  
 
5.3.1 Non-normality 
Skew and kurtosis values of all variables were calculated and plotted using SPSS. 
Non-normality was defined as having skew > |2| and kurtosis > |7|.   The distributions of 
all the interval level variables did not exceed the skew and kurtosis thresholds of > |2| and 
> |7|, respectively. All the interval level variables were considered normally distributed.  
 
5.3.2 Outliers 
To identify outliers, the z-scores of all the variables were computed and 
examined. All the non-dichotomous variables with a z-score less than -3.29 or greater 
than +3.29 were identified and examined. Some of these values were considered valid 
and thus were retained. However, a total of thirteen univariate outliers that met the 
criteria (z value > 3.29 or < -3.29) were considered to be invalid and thus were 
considered to be outliers. All these outliers pertained to the average number of 
prescriptions/medication orders dispensed per day variable. These values were substituted 
with the median value (average number of prescriptions/medication orders dispensed) for 
similar cases. Similar cases were defined as those cases with similar values on the 
following variables: type of practice setting and area/setting of primary place of 




Table 5.5: Case Numbers, and Old and New Values of the Outliers 
Case Number* Old Value New Value 
387 7200 250 
375 6000 135 
125 3000 200 
19 2100 200 
121 1600 150 
32 1200 234 
182 800 180 
211 800 127.50 
235 700 200 
18 700 150 
353 600 200 
262 600 200 
175 600 123.75 
* All cases pertained to the average number of prescriptions/medication orders dispensed 
variable. 
 
5.3.3 Missing Data 
Data were missing in 150 instances across all 94 variables and all the 377 
respondents. Thus, there were 0.40 missing responses for each respondent. Incomplete 





Table 5.6: Distribution of Missing Responses by Respondents (n = 377) 
Number of Missing 
Responses 
Number of Respondents Percent 
0 303 80.4 
1 51 13.5 
2 7 1.9 
3 5 1.3 
4 4 1.1 
5 3 0.8 
8 1 0.3 
9 2 0.5 
13 1 0.3 
Total 377 100 
 
The variables with the highest frequency of missing values responses were 
―average number of prescriptions/medication orders dispensed‖ (n = 14) and ―year of 
birth‖ (age, n = 11 missing responses).  
We compared data on the key study variables (intention, A, SN, PBC, PRB, and 
PMO) between those with at least one missing response and those without. The analysis 
showed no differences between those with missing information and those without 
missing information. 
 
5.4 INTERNAL CONSISTENCY 
Reliability estimates of all the direct measure scales with at least 3 items were 
computed and examined. The intention scale had a high reliability coefficient of 0.95. 
The attitude (0.75) and subjective norm (0.81) scales were also internally consistent with 




Table 5.7: Reliability Analysis of Direct Measures Study Scales 
Scale Number of Items Cronbach Alpha 
Attitude (direct measure) 5 0.75 
Subjective norm (direct measure) 3 0.81 
Perceived behavioral control (direct measure)
a
 2 0.71 
Intention 3 0.95 
Past reporting behavior
 a
 2 0.37 
Perceived moral obligation
b
 1 - 
Knowledge
c
 9 0.41 
a 
Spearman‘s rho correlation was computed instead of reliability estimates for scales with 
less than 3 items but more than one item. 
b 
No reliability estimates could be calculated. 
c 
Kuder-Richardson‘s ρ was calculated as the items were dichotomous.  
 
5.5 PHARMACISTS’ DEMOGRAPHIC FACTORS AND PRACTICE CHARACTERISTICS 
The pharmacists‘ demographic factors and practice characteristics data were 
computed and examined. A brief description of these results is provided below: 
 
5.5.1 Demographic Factors 
A majority of respondents were male (n = 199, 52.9%), with an average age of 
51.46 (SD = 12.69) years, ranging from 27 to 86 years. A majority of the pharmacists 





Table 5.8: Age, Gender and Ethnicity of the Respondents 
Variable Frequency (%) Mean (SD) 
Age (years; n=366)
 a
  51.46 (12.69) 
Gender (n=376)
 a
   
Male 199 (52.9)  
Female 177 (47.1)  
Race/Ethnicity (n=373)
a
   
Caucasian/non-Hispanic white 262 (70.2)  
Asian-American/Pacific Islander 37 (9.9)  
Mexican-American/Hispanic  33 (8.8)  
African American/non-Hispanic Black 27 (7.2)  
Other
 b
 11 (2.9)  
American-Indian or Alaska native 3 (0.8)  
a
 N is less than 377 because of missing responses. 
b
 The eleven pharmacists who indicated the ‗Other‘ category for their ethnicity were as 
follows: Spanish (1), Anglo-white Caucasian (1), Czech-German (1), and Asian (3). Five 
respondents who checked the ‗Other‘ category did not specify their ethnicity.   
 
5.5.2 Practice Characteristics 
The average number of years of experience of the respondents was 24.98 (SD = 
13.12) years. Pharmacists worked an average of 38.43 (SD = 10.61) hours per week and 
spent an average of 30.79 (SD = 14.80) hours per week dispensing medication/interacting 
with patients (Table 5.9). Pharmacists dispensed an average of 174.67 (SD = 119.72) 
prescriptions/medication orders per day. Respondents were primarily staff pharmacists 
(42.4%) and pharmacy managers (27.1%). One hundred and fifty nine respondents 
practiced in the community-multiple/chain setting (42.2%). Eighty percent of the 
respondents worked in urban and suburban areas while 20 percent worked in rural areas. 
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Years of experience (n=375)  24.98 (13.0) 
Hours worked per week (n=375)  38.43 (10.6) 
Hours per week dispensing medication/interacting 
with patients (n=373) 
 30.79 (14.8) 
Number of prescriptions/medication orders 
dispensed per day (n=363) 
 174.67 (119.7) 
Current job title at primary place of employment 
(n=377) 
  
Staff pharmacist 160 (42.4)  
Pharmacy manager  102 (27.1)  
Pharmacy owner/Partner 44 (11.7)  
Clinical pharmacist 37 (9.8)  
Relief pharmacist 24 (6.4)  
Other
 a
 10 (2.7)  
Area/setting of primary place of employment 
(n=375) 
  
Urban 175 (46.7)  
Suburban 126 (33.6)  
Rural 74 (19.7)  
Practice setting (n=377)   
Community—multiple/chain 159 (42.2)  
Community—independent  74 (19.6)  
Hospital—multiple/chain  58 (15.4)  
Hospital—independent  44 (11.7)  
Other
 b
 42 (11.1)  
a
 Ten pharmacists indicated ‗Other‘ category for their current job title, including 
pharmacy informatics (n = 2), consultancy (n = 2), general manager, clinical pharmacy 
coordinator (n = 2), assistant pharmacy manager, pharmacist-in-charge and vice-
president.  
b 
Forty two pharmacists indicated ‗Other‘ category for their practice setting. Government 
hospital was the most common ‗Other‘ practice setting. Other settings specified by the 
respondents include Veterans Affairs, community health center/clinic, home infusion, 
long term care, army/military, county hospital/clinic, surgery center, city health 
department, mail order, research, worksite pharmacy, home health care and correctional 





5.6 KNOWLEDGE SCORES 
Less than 75 percent of the respondents got items 1, 3 and 6 correct (Table 5.10). 
The lowest pass rate was achieved for the first item with 43.3 percent of pharmacists 
responding that all ADEs irrespective of severity should be reported to the FDA, whereas 
MedWatch stipulates that only serious ADEs should be reported. About 35 percent of 
pharmacists did not know that they could report serious ADEs even if they did not have 
all the details (complete patient history and demographic data) (item 3). Thirty percent of 
the pharmacists did not know that they could anonymously report ADEs to the FDA. The 
highest pass rate was achieved for item four (4) with 361 (96.0%) respondents knowing 
that not all serious ADEs are known before a drug is marketed. None of the items had a 
100 percent pass rate. A majority of the respondents (n = 247, 65.7%) considered 
themselves to have inadequate knowledge about ADE reporting (e.g., what to report and 




Table 5.10: Pharmacists with Correct Responses on Knowledge Items 
Item N Number (%) 
with correct 
responses 
1. All ADEs, irrespective of severity, should be reported to the 
FDA [false]. 
374 212 (56.7) 
2. Pharmacists should report serious ADEs even if they are 
uncertain that the product caused the event [true]. 
376 298 (79.3) 
3. Pharmacists should report serious ADEs even if they do not 
have all the details (e.g., complete patient history and 
demographic data) [true]. 
376 244 (64.9) 
4. All serious ADEs are known before a drug is marketed [false]. 376 361 (96.0) 
5. The FDA does not disclose the ADE reporter‘s identity in 
response to a request from the public [true]. 
370 295 (79.7) 
6. Pharmacists can report ADEs to the FDA anonymously [true] 370 259 (70.0) 
7. Adverse experiences with cosmetics and special nutritional 
products (e.g., dietary supplements, infant formulas) may be 
reported to the FDA [true]. 
374 308 (82.4) 
8. One case reported by a pharmacist does not contribute much 
to knowledge on drug risks [false]. 
375 287 (76.5) 
[=correct answer] 
 
5.7 THEORY OF PLANNED BEHAVIOR CONSTRUCTS 
The study measured the following theory of planned behavior (TPB) constructs: 
A, SN, PBC and intention. The independent variables were measured using both direct 
and indirect measures. In addition, the study measured PRB and PMO.  
 
5.7.1 Intention  
Intention was measured using three items. The means for these items were 5.16 
(SD = 1.51), 5.44 (SD = 1.42) and 5.27 (SD = 1.50) (possible range: 1-7; Table 5.11). 
Two hundred and sixty four (70.0%) pharmacists indicated that they were likely to intend 
to report serious ADEs that they encounter to the FDA, while 49 respondents (13.0%) 
said that they were unlikely to intend to report. Three hundred pharmacists (79.6%) 
agreed that they will try to report serious ADEs that they encounter to the FDA, while 
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276 (73.2%) indicated that they planned to report serious ADEs that they encounter to the 
FDA (Table 5.11). The three items were summed to form an aggregate intention score 
with a mean of 15.87 (SD = 4.22) (possible range: 3 - 21). This score suggests that the 





Table 5.11: Mean and Frequency Distribution of Intention (n = 377) 





























1. I intend to report serious 
ADEs that I will encounter 
to the FDA. 










































2. I will try to report serious 
ADEs that I will encounter 
to the FDA. 














3. I plan to report serious 
ADEs that I will encounter 
to the FDA. 


















5.7.2 Attitude (Direct and Indirect Measures) 
The direct measure of attitude was measured using five (5) items (score: -3 to +3). 
The respondents believed that reporting serious ADEs to the FDA was valuable (mean = 
1.83, SD = 1.26, n = 328), neither pleasant nor unpleasant (mean = 0, SD = 1.41, n = 
148), good (mean = 1.37, SD = 1.49, n = 262), unenjoyable (mean = -0.24, SD = 1.40, n 
= 127) and beneficial (mean = 1.67, SD = 1.45, n = 281) (Table 5.12). Thirty two (8.5%), 
22 (5.9%), and 21 (5.6%) respondents believed that reporting serious ADEs to the FDA 
was worthless, bad, and harmful, respectively. The attitude scores on the five items were 
summed to form a composite attitude score (direct measure). The attitude scores had a 
mean of 4.62 (SD = 4.92, possible range: -15 to +15) and they ranged from -12 to +15. 
Overall, pharmacists had a moderately favorable attitude (direct measure) towards 
reporting serious ADEs to the FDA.  
The indirect attitude construct was measured using eight items (range: 1-7, 4 = 
neutral). On average, pharmacists felt that reporting serious ADEs to the FDA educates 
others about drug risks (mean = 5.53, SD = 1.22), and improves patient safety (mean = 
5.80, SD = 1.12). Pharmacists also believed that reporting was personally 
beneficial/rewarding to the pharmacist (mean = 4.96, SD = 1.56), time consuming (mean 
= 5.06, SD = 1.55) and disrupted the normal workflow (mean = 4.55, SD = 1.65). 
Respondents did not believe that reporting serious ADEs to the FDA increased the risk of 
malpractice (mean = 3.70, SD = 1.62), compromised their relationship with physicians 
(mean = 3.40, SD = 1.49), and broke trust with patients (mean = 2.85, SD = 1.57) (Table 
5.13).  
The pharmacists rated all eight outcomes with three of them being rated as being 
good: educates others about drug risks (mean = 6.02, SD = 1.03), personally 
beneficial/rewarding to the pharmacist (mean = 5.28, SD = 1.30), and improves patient 
safety (mean = 6.07, SD = 0.97). They rated the rest of the outcomes as being bad: 
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increases risk of malpractice (mean = 3.45, SD = 1.53), compromises relationship with 
physicians (mean = 3.33, SD = 1.39), breaks trust with patients (mean = 3.05, SD = 1.53), 
disrupts the normal workflow (mean = 3.60, SD = 1.57) and time consuming to report 
(mean = 3.71, SD = 1.66) (Table 5.14).   
The product of behavioral beliefs and behavioral outcome evaluations was 
computed after reverse coding all the negatively worded items. The means for each 
product item are given in Table 5.15. The product of the item ―Reporting serious ADEs 
to the FDA will improve patient safety‖ and its behavioral outcome evaluation had the 
highest mean (mean = 35.77, SD = 10.57) (Table 5.15). The overall mean for all the eight 
product means was 24.45 (SD = 6.73) ranging from 9 to 46 (possible range: 1 – 49, 
neutral = 16), indicating that pharmacists had marginally favorable A towards reporting 




Table 5.12: Mean and Frequency Distribution of A Direct Measures 
Q. I feel that reporting serious ADEs to the FDA each time I encounter them is: 
    Frequency Distribution of Responses (%) 
























































































































































Table 5.13: Mean and Frequency Distribution of Behavioral Beliefs 
Q. How likely do you think the following outcomes will be if you report serious ADEs to the FDA? 
    Frequency Distribution of Responses (%) 
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Table 5.14: Mean and Frequency Distribution of Behavioral Outcome Evaluations 
Q. How good or bad do you feel each of the following outcomes would be if you reported serious ADEs to the FDA? 
    Frequency Distribution of Responses (%) 
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Table 5.15: Mean and Standard Deviation of the Product of Behavioral Belief and Behavioral Outcome Evaluation Scores  
Behavioral Beliefs and Outcome Evaluation N Mean SD 
1. Reporting serious ADEs to the FDA will educate others about drug risks 
 
 
376 33.98 10.95 
2. Reporting serious ADEs to the FDA is personally beneficial/rewarding to the pharmacist 
 
 
376 27.50 12.87 
3. Reporting serious ADEs to the FDA will improve patient safety 
 
 
376 35.77 10.57 
4. Reporting serious ADEs to the FDA will increase risk of malpractice 
 
 
373 20.72 11.80 
5. Reporting serious ADEs to the FDA will compromise relationship with physicians  
 
 
375 22.53 11.21 
6. Reporting serious ADEs to the FDA will break trust with patients 
 
 
376 26.50 12.69 
7. Reporting serious ADEs to the FDA will disrupt the normal workflow 
 
 
376 15.59 9.90 
8. Reporting serious ADEs to the FDA is time consuming 
 
 
376 13.02 8.85 
Overall mean 376 24.45 6.73 
Note: The belief and behavioral outcome evaluation ratings for items 4 to 8 were first reverse coded before being multiplied. 
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5.7.3 Subjective Norm (Direct and Indirect Measures) 
The direct measure of subjective norm was measured through three (3) items 
(score: -3 to +3). The average SN across these three items was 5.65 (SD = 2.99) ranging 
from -5 to +9. Three hundred and eight (81.9%) pharmacists believed that most people 
who were important to them thought that they should report serious ADEs that they 
encounter to the FDA (mean = 1.83, SD = 1.15), while 64 (17.0%) were neutral. Three 
hundred and forty two (91.0%) pharmacists believed that the people in their lives whose 
opinions they valued would approve their reporting of serious ADEs that they encounter 
to the FDA (mean = 2.19, SD = 0.99). A majority of pharmacists (n = 298, 79.2%) also 
believed that the pharmacists whose opinions they valued report serious ADEs to the 
FDA (mean = 1.62, SD = 1.34) (Table 5.16).  
The indirect measure of SN was measured using nine (9) items (range: 1-7, 4 = 
neutral). On average, pharmacists believed that physicians (mean = 4.97, SD = 1.53), 
patients (mean = 5.76, SD = 1.32), drug manufacturers (mean = 4.37, SD = 1.91), the 
Food and Drug Administration (mean = 6.02, SD = 1.32), pharmacy associations (mean = 
5.71, SD = 1.37), family/spouse/significant others (mean = 5.08, SD = 1.52), pharmacy 
managers/bosses (mean = 5.09, SD = 1.49), hospitals or hospital groups (mean = 5.26, 
SD = 1.37), and other pharmacists (mean = 5.23, SD = 1.30) were likely to think that they 
should report serious ADEs to the FDA (Table 5.17). The largest number of pharmacists 
(n = 320, 85.3%) believed that the FDA was likely to think that they should report serious 
ADEs.  
When it came to reporting ADEs to the FDA, a majority of pharmacists were 
likely to do what physicians (mean = 5.12, SD = 1.43, n = 243), patients (mean = 5.59, 
SD = 1.26, n = 319), drug manufacturers (mean = 4.56, SD = 1.65, n = 190), the FDA 
(mean =5.63, SD = 1.30, n = 320), pharmacy associations (mean = 5.25, SD = 1.26, n = 
306), family/spouses/significant others (mean = 5.13, SD = 1.49, n = 228), pharmacy 
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managers/bosses (mean = 5.43, SD = 1.39, n = 249), hospitals or hospital groups (mean = 
5.12, SD = 1.39, n = 262) and other pharmacists (mean = 5.16, SD = 1.33, n = 274) 
would want them to do (Table 5.18).  
The mean indirect SN scores were high, indicating a favorable subjective norm 
(mean = 28.75, SD = 9.38; range: 2 – 29, possible range: 1 – 49, neutral =16). The FDA 
appeared to be the most influential with respect to reporting serious ADEs (had the 
highest mean of 34.82, SD = 12.16), while drug manufacturers appeared to be the least 
influential with the least mean SN of 21.55 (SD = 13.83) (Table 5.19). The overall mean 
of 28.75 indicates that the referents had moderate influence on the pharmacists‘ when it 








Table 5.16: Mean and Frequency Distribution of SN Direct Measure 
    Frequency Distribution of Responses (%) 
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Table 5.17: Mean and Frequency Distribution of Normative Beliefs 
Q. How likely is it that each of the following groups or individuals would think that you should report serious ADEs to the 
FDA? 
    Frequency Distribution of Responses (%) 












































































































































9. Other pharmacists 
(colleagues/peers) 

















Table 5.18: Mean and Frequency Distribution of Motivation to Comply 
Q. Generally speaking, how likely are you to do what the following individuals or groups would want you to do when it comes 
to ADE reporting? 
 
    Frequency Distribution of Responses (%) 
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Table 5.19: Mean and Standard Deviation of the Product of Normative Beliefs and Motivation to Comply Scores 
Normative Beliefs and Motivation to Comply N Mean SD 
1. Physicians 374 26.43 12.57 
2. Patients 373 32.93 11.99 
3. Drug manufacturers 372 21.55 13.83 
4. Food and Drug Administration 372 34.82 12.16 
5. Pharmacy associations 375 30.98 12.67 
6. Family/spouse/significant others 375 27.31 13.30 
7. Pharmacy managers/bosses 375 28.77 12.71 
8. Hospitals or hospital groups 374 28.07 12.51 
9. Other pharmacists (colleagues/peers) 373 27.94 11.78 




5.7.4 Perceived Behavioral Control (Direct and Indirect Measures) 
The direct PBC construct was measured through two (2) items (score: -3 to +3). A 
majority of pharmacists (n = 319, 85.1%) believed that it was mostly up to them whether 
or not they report serious ADEs to the FDA (mean = 1.83, SD = 1.51) and that they had 
control over reporting serious ADEs that they encounter to the FDA (n = 317, 84.8%, 
mean = 1.71, SD = 1.46) (Table 5.20). The overall mean PBC score was high (mean = 
3.54, SD = 2.69) indicating a positive and high control over reporting serious ADEs 
(possible/actual range: -6 to +6, 0 = neutral) (Table 5.20). 
The indirect PBC construct was measured through eleven (11) items (range = 1-7, 
4 = neutral). Pharmacists believed that a complete patient medical history (n = 204, mean 
= 4.41, SD = 1.92), improved awareness of ADE reporting (n = 269, mean = 5.03, SD = 
1.25), a streamlined MedWatch form and reporting process (n = 319, mean = 5.61, SD = 
1.24), employer support of ADE reporting (n = 291, mean = 5.42, SD = 1.28), some type 
of reward or compensation for reporting serious ADEs (n = 136, mean = 4.54, SD = 
1.31), ADE reporting as a part of the normal workflow (n = 270, mean = 5.14, SD = 
1.47), increased patient counseling (spending more time with patients) (n = 245, mean = 
4.94, SD = 1.56), awareness of drug risks by patients (n = 261, mean = 5.09, SD = 1.25), 
being a drug expert (n = 297, mean = 5.44, SD = 1.17), and clear knowledge of what 
constitutes a reportable ADE (e.g., definition) (n = 319, mean = 5.71, SD = 1.20) will 
make it easy for them to report serious ADEs that they encounter to the FDA. A majority 
of pharmacists (n = 304, mean = 2.55, SD = 1.34) believed that lack of time will make it 
difficult for them to report serious ADEs that they encounter to the FDA (Table 5.21).  
Pharmacists believed that they did not have control over having a complete 
patient medical history (mean = 3.30, SD = 1.81), lack of time (mean = 2.99, SD = 1.49), 
a streamlined MedWatch form and reporting process (mean = 3.42, SD = 1.77), employer 
support of ADE reporting (mean = 3.75, SD = 1.79), some type of reward or 
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compensation (mean = 2.67, SD = 1.61) and having ADE reporting as a part of the 
normal workflow (mean = 3.62, SD = 1.68). Pharmacists however believed that they had 
control over improved awareness of ADE reporting (mean = 4.43, SD = 1.45), increased 
patient counseling (mean = 4.17, SD = 1.67), awareness of drug risks by patients (mean = 
4.27, SD = 1.52), being a drug expert (mean = 5.31, SD = 1.28), and having a clear 
knowledge of what constitutes a reportable ADE (e.g., definition) (mean = 4.85, SD = 
1.54) (Table 5.22).  
The overall mean PBC score (indirect measure) was high (mean = 20.18, SD = 
6.59; range: 5–45) (possible range: 1 – 49, neutral = 16) indicating that pharmacists 




Table 5.20: Mean and Frequency Distribution of PBC Direct Measures 
    Frequency Distribution of Responses (%) 
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Table 5.21: Mean and Frequency Distribution of Control Beliefs 
Q. How easy or difficult will the following factors make it for you to report serious ADEs that you encounter to the FDA? 
    Frequency Distribution of Responses (%) 
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Table 5.21: Mean and Frequency Distribution of Control Beliefs 
Q. How easy or difficult will the following factors make it for you to report serious ADEs that you encounter to the FDA? 
    Frequency Distribution of Responses (%) 
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Table 5.22: Mean and Frequency Distribution of Perceived Power Over Reporting ADEs 
Q. How much control do you feel you have over the following factors when it comes to reporting serious ADEs to the FDA? 
 
    Frequency Distribution of Responses (%) 




























1. a complete patient medical 
history 




























3. improved awareness of 
ADE reporting 














4. a streamlined MedWatch 
form and reporting process  














5. employer support of ADE 
reporting 














6. some type of reward or 
compensation 














7. ADE reporting as a part of 
the normal workflow 














8. increased patient 
counseling  














9. awareness of drug risks by 
patients 


















Table 5.22: Mean and Frequency Distribution of Perceived Power Over Reporting ADEs 
Q. How much control do you feel you have over the following factors when it comes to reporting serious ADEs to the FDA? 
 
    Frequency Distribution of Responses (%) 
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Table 5.23: Mean and Standard Deviation of the Product of Control Belief and Perceived Power Over Reporting ADEs  
Control Beliefs and Perceived Power Over Reporting N Mean SD 
1. a complete patient medical history 374 15.74 12.08 
2. lack of time 376 8.62 7.54 
3. improved awareness of ADE reporting 372 23.02 10.58 
4. a streamlined MedWatch form and reporting process  376 19.44 11.86 
5. employer support of ADE reporting 375 20.88 12.20 
6. some type of reward or compensation 374 12.71 8.90 
7. ADE reporting as a part of the normal workflow 376 19.35 11.85 
8. increased patient counseling (spending more time with patients) 377 21.64 11.94 
9. awareness of drug risks by patients 375 22.49 11.01 
10. being a drug expert 377 29.69 10.96 
11. clear knowledge of what constitutes a reportable ADE (e.g., definition) 375 28.37 11.98 





5.7.5 Correlations Among TPB Constructs 
Tables 5.24 and 5.25 show the correlations among the TPB direct measure 
constructs and indirect measure constructs, respectively. Among the direct and indirect 
measure TPB constructs, SN had the highest correlation with intention.  
 
Table 5.24: Correlations of the TPB Direct Measure Constructs 






Intention Direct     1.000    
Attitude Direct 0.420**     1.000   
Subjective Norm 
Direct 
0.549** 0.455**        1.000  
PBC Direct 0.199** 0.186** 0.293** 1.000 
** Correlation is significant at the 0.01 level 
 
Table 5.25: Correlations of the TPB Belief-Based Constructs 






Intention     1.000    
Attitude Indirect 0.331**     1.000   
Subjective Norm 
Indirect 
0.434** 0.407**        1.000  
PBC Indirect 0.471** 0.416** 0.516** 1.000 
** Correlation is significant at the 0.01 level 
 
A Pearson correlation showed a significant positive correlation of large strength 
between the direct and indirect measures of SN (r = 0.544, n = 375, p < 0.001). There was 
a positive and significant correlation between the direct and indirect measures of A (r = 





Table 5.26: Correlation Between Direct and Indirect TPB Measures  







Attitude (Direct) 0.396**   
Subjective norm (Direct)  0.544**  
Perceived behavioral 
control (Direct) 
  0.288** 
** Statistically significant (p < 0.001).  
 
5.8 PAST REPORTING BEHAVIOR 
A majority of the respondents (n = 256, 67.9%) had never reported any ADEs to 
the FDA through MedWatch, while 352 (93.4%) had not reported any ADEs in the 
previous 12 months. Only 25 respondents (6.6%) had reported ADEs to the FDA through 
MedWatch in the previous 12 months. Many respondents (n = 168, 44.6%) indicated that 
they had encountered reportable ADEs in their practice in the past. One hundred and 
eight respondents (28.6%) indicated that they did not know whether they had encountered 




Table 5.27: Past Reporting Behavior (n = 377) 
Item Frequency 
(%) 
Ever reported an ADE to the FDA through MedWatch   
Yes 121 (32.1) 
No 256 (67.9) 
Reported any ADEs to the FDA through MedWatch in the previous 12 
months 
 
Yes 25 (6.6) 
No 352 (93.4) 
Encountered any reportable ADEs in the past  
Yes 168 (44.6) 
No 101 (26.8) 
Don‘t know 108 (28.6) 
 
5.9 PERCEIVED MORAL OBLIGATION 
Perceived moral obligation (PMO) was measured using a single item on a 1-to-7 
bipolar Likert response scale anchored by strongly disagree and strongly agree. The mean 
PMO score was 5.90 (SD = 1.27). A majority (n = 324; 86.2%) of the respondents agreed 
that they had a moral obligation to report serious ADEs that they encounter to the FDA 
(Table 5.28). 
 
Table 5.28: Perceived Moral Obligation (n = 376) 
Scale Frequency (%) 
7 (strongly agree) 156 (41.2) 
6 111 (29.5) 
5 58 (15.4) 
4 (neither agree nor disagree) 34 (9.0) 
3 10 (2.7) 
2 3 (0.8) 





5.10 HYPOTHESIS TESTING RESULTS 
Data analyses were conducted using multiple regression, t-test, analysis of 
variance (ANOVA) and correlation analysis. A summary of the results of the hypotheses 
tests is provided below.   
 
H1: Favorable attitude (A) is a positive and significant predictor of intention 
to report serious ADEs controlling for SN and PBC. 
Multiple regression analysis was run with A, SN and PBC being the independent 
variables and intention as the dependent variable. Separate models were run for direct 
measure constructs and the belief-based (i.e., indirect) independent constructs. Both the 
direct and indirect measure attitude were (statistically) significant and positive predictors 
of intention to report serious ADEs after controlling for SN and PBC (B = 0.190, p < 
0.001 and B = 0.009, p = 0.030, respectively) (Table 5.29). Therefore, H1 was supported.  
 
Table 5.29: Results of Multiple Regression Analysis for the TPB Constructs 
PREDICTOR VARIABLE B SE Beta (β) t p 
Direct Measures      
Constant 11.302 0.408  27.73 <0.001 
Attitude 0.190 0.041 0.221 4.64 <0.001 
Subjective norm 0.620 0.069 0.438 8.95 <0.001 
PBC 0.044 0.070 0.028 0.64 0.526 
N = 374 pharmacists 
F = 63.60, df = 3, 370, p < 0.001, R = 0.583, R
2
 = 0.340, Adjusted R
2
 = 0.335 
Indirect Measures      
Constant 7.531 0.780  9.66 <0.001 
Attitude 0.009 0.004 0.108 2.18 0.030 
Subjective norm 0.011 0.003 0.227 4.30 <0.001 
PBC 0.017 0.004 0.318 6.00 <0.001 
N = 374 pharmacists 
F = 49.92, df = 3, 370 , p < 0.001, R = 0.537, R
2
 = 0.288, Adjusted R
2
 = 0.282 
Dependent variable = Intention, B = Unstandardized coefficients, Beta = Standardized 




Since the belief-based attitude measure significantly predicted intention to report 
serious ADEs to the FDA, the behavioral beliefs, outcome evaluations and products for 
those who intend to report and those who do not intend to report were compared8 (Tables 
5.30, 5.31, and 5.32). Forty-five respondents were categorized as non-intenders, 35 were 
categorized as neither intenders nor non-intenders (were excluded from analysis), and 
297 were categorized as intenders.  When comparing intenders and non-intenders—using 
indirect measures—intenders had higher mean A (mean = 25.37, SD = 6.52) than non-
intenders (mean = 21.01, SD = 7.13) (t = -4.122, df = 339, p < 0.001). 
Intenders had significantly higher mean A scores than non-intenders on the 
following: educates others about drug risks, personally beneficial/rewarding to the 
pharmacist, and improves patient safety (p < 0.05) (Table 5.30). Non-intenders had 
significantly higher means on the items of reporting serious ADEs ―disrupts the normal 




                                                 
8 As described in Chapter Four (page 130), all the respondents who marked from a one to a three on any of 
the three intention items were considered non-intenders for that item (re-coded with a -1). All responders 
who marked between a five and a seven on any of these three items were considered intenders for that item 
(re-coded with a +1). Those who coded a four on any of the three intention items were considered to be 
neither intenders nor non-intenders (for that item) and were re-coded with a zero. For each respondent, the 
dummy codes (-1s, 0s and +1s) were added together across the three intention items. This composite score 
was then used to categorize respondents into intenders (e.g., positive total score), non-intenders (e.g., had a 
negative total score) and neither intenders nor non-intenders (had a total score of zero). 
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Table 5.30: Behavioral Beliefs About Reporting Serious ADEs by Intenders and Non-
Intenders 
Behavioral Beliefs  Means for 
Non-Intenders 
(SD) 















2. personally beneficial/rewarding to 













































The respondents who were neutral on intention to report serious ADEs were excluded 
from the analysis. 
a
 Equal variances were assumed in the t-test for equality of means. The Levene‘s test of 
equality of variance was not significant (p > 0.05) for all eight items. 
Scale: 1 = very unlikely; 4 = neither unlikely nor likely; 7 = very likely; possible range: 1 
to 7. 
When comparing the mean behavioral outcome evaluations about reporting 
serious ADEs between intenders and non-intenders, intenders were more likely to believe 
that reporting serious ADEs educates others about drug risks, is personally 




Table 5.31: Behavioral Outcome Evaluations About Reporting Serious ADEs by 
Intenders and Non-intenders  


















b. personally beneficial/rewarding to 



























































The respondents who were neutral on intention were excluded from the analysis. 
*Equal variances were not assumed in the t-test for equality of means. The Levene‘s test 
of equality of variance was statistically significant (p < 0.05). 
Scale: 1 = extremely bad; 4 = neither good nor bad; 7 = extremely good; possible mean 
range: 1 to 7. 
When comparing the mean product of behavioral outcome evaluations and 
behavioral beliefs about reporting serious ADEs between intenders and non-intenders, 
intenders were more likely to believe that reporting serious ADEs educates others about 
drug risks, is personally beneficial/rewarding to the pharmacist, and improves patient 




Table 5.32: Product of Behavioral Beliefs and Outcome Evaluations About Reporting 
Serious ADEs by Intenders and Non-Intenders  




















b. personally beneficial/rewarding 



























































*Equal variances were not assumed in the t-test for equality of means. The Levene‘s test 
of equality of variance was statistically significant (p < 0.05). Equal variances were 
assumed for the rest of the items. 
The respondents who were neutral on intention were excluded from the analysis. 




H2: SN supporting ADE reporting is a positive and significant predictor of 
intention to report serious ADEs controlling for A and PBC. 
Table 5.29 indicates that both the direct (B = 0.620, p < 0.001) and indirect (B = 
0.011, p < 0.001) SN measures were positive and significant predictors of intention, after 
controlling for A and PBC. Therefore, H2 was supported. Overall, intenders (mean = 
6.31, SD = 2.67) had higher SN (direct measure) than non-intenders (mean = 2.91, SD = 
2.80) (t = -7.913, df = 339, p < 0.001). Intenders had higher mean SN scores than non-
intenders on all three direct measure items (Table 5.33).  
 
Table 5.33: Mean SN Between Intenders and Non-Intenders 
Direct Measure Items Mean for Non-









1. Most people who are important 
to me think that I should/should not 
report serious ADEs that I 









2. The people in my life whose 
opinions I value would approve/ 
disapprove my reporting of serious 









3. The pharmacists whose opinion I 
value report/do not report serious 















The respondents who were neutral on intention were excluded from the analysis. 
a
 Equal variances were assumed in the t-test for equality of means. The Levene‘s test of 
equality of variance was not statistically significant for all items (p > 0.05). 
Scale: -3 (e.g., disapproave) to +3 (e.g., approave), 0 = neutral.  
Using indirect measures, overall intenders also had higher mean SN (mean = 
30.24, SD = 9.17) than non-intenders (mean = 22.39, SD = 8.03) (t = -5.433, df = 338, p 
< 0.001). When comparing the normative belief mean scores between intenders and non-
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intenders, intenders had significantly higher mean scores than non-intenders on all the 
nine salient referents (Table 5.34).  
 
 Table 5.34: Normative Beliefs About Reporting Serious ADEs by Intenders and Non-
Intenders 


























































6. Family/spouse/significant  





































Respondents who were neutral on intention were excluded from the analysis. 
*
Equal variances were not assumed in the t-test for equality of means. The Levene‘s test 
of equality of variance was significant (p < 0.05). 





When comparing the mean motivation to comply about reporting serious ADEs 
between intenders and non-intenders, intenders were more likely to be motivated to 
comply with physicians, patients, drug manufacturers, FDA, pharmacy associations, 
family/spouses/significant others, hospital or hospital groups, and other pharmacists 
(colleagues/peers) (p < 0.05) (Table 5.35) than non-intenders. There was, however, no 
significant difference in mean motivation to comply between intenders and non-intenders 
on the influence of pharmacy managers/bosses and physicians (p > 0.05) (Table 5.35).  
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Table 5.35: Motivation to Comply With Referents Concerning Reporting Serious ADEs 
by Intenders and Non-intenders  

























































6. Family/spouse/significant  





































Respondents who were neutral on intention were excluded from the analysis. 
a
 Equal variances were assumed in the t-test for equality of means. The Levene‘s test of 
equality of variance was not statistically significant (p > 0.05) for all the items. 
Scale: 1 = extremely unlikely; 4 = neither likely nor unlikely; 7 = extremely likely; 




When comparing the mean product of normative beliefs and motivation to comply 
with referents concerning reporting serious ADEs between intenders and non-intenders, 
intenders were more likely to believe that referents expected them to report serious ADEs 
than did non-intenders (p < 0.05) (Table 5.36). 
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Table 5.36: Product of Normative Beliefs and Motivation to Comply Concerning 
Reporting Serious ADEs by Intenders and Non-Intenders  

























































6. Family/spouse/significant  







































*Equal variances were not assumed in the t-test for equality of means. The Levene‘s test 
of equality of variance was statistically significant (p < 0.05). Equal variances were 
assumed in the rest of the items. 
Respondents who were neutral on intention were excluded from the analysis. 





H3: Strong perceived behavioral control (PBC) is a positive and significant 
predictor of intention to report serious ADEs controlling for A and SN. 
The PBC (indirect measure) was a positive and statistically significant predictor 
of intention (B = 0.017, p< 0.001), but the direct PBC construct was not statistically 
significant (B = 0.044, p = 0.526) (Table 5.29). Therefore, H3 was supported using 
belief-based measures but not supported using direct measures. Using indirect measures, 
intenders (overall) had higher mean PBC (mean = 21.61, SD = 7.12) than non-intenders 
(mean = 14.76, SD = 4.96) (t = -8.094, df = 74.69, p < 0.001). Since the belief-based 
PBC was a statistically significant predictor of intention to report serious ADEs to the 
FDA, Tables 5.37, 5.38, and 5.39 provide a comparison of the control beliefs, perceived 
power and products of control beliefs and perceived power between those who intend to 
report and those who do not intend to report.  
Intenders had statistically significantly higher means than the non-intenders on 
nine of the 11 control beliefs (p < 0.05). The greatest mean difference between intenders 
and non-intenders was on the increased patient counseling item. Intenders were more 
likely to believe that they had control over a complete patient medical history, lack of 
time, a streamlined MedWatch form and reporting process, employer support of ADE 
reporting, ADE reporting as a part of the normal workflow, increased patient counseling, 
awareness of drug risks by patients, being a drug expert, and clear knowledge of what 
constitutes a reportable ADE than non-intenders. There were no statistically significant 
differences in the means for improved awareness of ADE reporting and some type of 
reward or compensation items (p > 0.05) (Table 5.37).  However, intenders had 
significantly higher means on all perceived power items than non-intenders (p < 0.05) 
(Table 5.38).  
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Table 5.37: Control Beliefs About Reporting Serious ADEs by Intenders and Non-
Intenders  




































d. a streamlined MedWatch form and 



































h. increased patient counseling 

























k. clear knowledge of what constitutes 









*Equal variances were not assumed in the t-test for equality of means. The Levine‘s test 
for equality of variances was statistically significant (p < 0.05).  
The respondents who were neutral were excluded from the analysis. 
Scale: 1 = extremely difficult; 4 = neither easy nor difficult; 7 = extremely easy; possible 
mean range: 1 to 7. 
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Table 5.38: Perceived Power About Reporting Serious ADEs by Intenders and Non-
Intenders  




































d. a streamlined MedWatch form 







































h. increased patient counseling 


























k. clear knowledge of what 











*Equal variances assumed in the t-test for equality of means. Equal variances were not 
assumed in the rest of the items. 
The respondents who were neutral were excluded from the analysis. 
Scale: 1 = no control; 4 = neither complete control nor no control; 7 = complete control; 




Intenders had significantly higher means on the products of control beliefs and 
perceived power on 10 of the 11 items (p < 0.05). There was, however, no statistically 
significant difference on the product for the item ―some type of reward or compensation‖ 
(p > 0.05) (Table 5.39).  
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Table 5.39: Product of Control Beliefs and Perceived Power About Reporting Serious 
ADEs by Intenders and Non-Intenders to Report Serious ADEs 








































d. a streamlined MedWatch form 







































h. increased patient counseling 




























k. clear knowledge of what 










*Equal variances were not assumed in the t-test for equality of means. The Levene‘s test 
for equality of variances was statistically significant (p < 0.05).  
The respondents who were neutral on intention were excluded from the analysis.  




H4: A + SN + PBC constructs explain a significant amount of variance in 
pharmacists’ intention to report serious ADEs. 
The direct and indirect A, SN and PBC measures together accounted for 34.0 and 
28.8 percent of the variance in intention to report serious ADEs to the FDA, respectively 
(Table 5.29). Both the direct measure and belief-based models were statistically 
significant (F = 63.60, d.f. = 3, 370, p < 0.001 and F = 49.92, d.f. = 3, 370, p < 0.001). 
Therefore, H4 was supported.  
 
 
H5: PBC significantly increases the explanatory power of the regression 
model compared to only using A + SN to explain pharmacists’ intention. 
The direct A and SN measures together explained 34.0 percent of the variance in 
intention. The addition of PBC (direct measure) did not significantly increase the 
variance in intention explained (R
2
 change = 0.001, F [1, 370] change = 0.404, p = 
0.526). The regression coefficient for PBC (direct measure) was not statistically 
significant (B = 0.044, p = 0.526).  
Using indirect measures, A and SN together statistically significantly explained 
21.9 percent of the variance in intention [F (2, 371) = 51.99, p < 0.001]. The addition of 
an indirect measure PBC significantly added to the prediction of intention (R
2
 change = 
0.069, F [1, 370] change = 35.99, p < 0.001). The regression weight for the PBC indirect 
measure was statistically significant (B = 0.017, p < 0.001). Therefore, H5 was supported 




H6: PRB significantly increases the explanatory power of the regression 
model compared to only using the A + SN + PBC to explain pharmacists’ 
intention to report serious ADEs. 
The addition of PRB to direct measure constructs increased the proportion of 
variance in intention explained from 34.0 percent to 35.0 percent (R
2
 change= 0.009, F 
[1, 369] change = 5.39, p = 0.021). The regression weight of the PRB construct was 
significant (B = 0.698, p = 0.021) (Table 5.40). The addition of PRB to the indirect A, SN 
and PBC measures also significantly increased the proportion of variance in intention 
explained from 28.8 percent to 30.1 percent (R
2
 change = 0.013, F [1, 369] change = 
6.93, p = 0.013). The regression coefficient of the PRB was also statistically significant 
(B = 0.823, p = 0.009). After the addition of PRB in the model, A became statistically 
insignificant (B = 0.007, p = 0.069). Therefore, H6 was supported. 
 
Table 5.40: Regression Coefficients After Adding the PRB to the TPB Constructs  
PREDICTOR VARIABLE B SE Beta (β) t p 
Direct Measures      
(Constant) 14.015 1.237 - 11.33 <0.001 
Attitude  0.184 0.041 0.215 4.53 <0.001 
Subjective norm  0.600 0.069 0.424 8.65 <0.001 
Perceived behavioral control 0.030 0.069 0.019 0.43 0.666 
Past reporting behavior 0.698 0.301 0.100 2.32 0.021 
N = 374, F = 49.61, df = 4, 369, p < 0.001, R = 0.591, R
2
 = 0.350, Adjusted R
2
 = 0.343 
Indirect Measures      
(Constant) 6.000 0.968 - 6.20 <0.001 
Attitude  0.007 0.004 0.091 1.83 0.069 
Subjective norm  0.011 0.003 0.229 4.36 <0.001 
Perceived behavioral control 0.016 0.003 0.303 5.71 <0.001 
Past reporting behavior 0.823 0.313 0.118 2.63 0.009 
N = 374, F = 39.78, df = 4, 369, p < 0.001, R = 0.549, R
2
 = 0.301, Adjusted R
2
 = 0.294 
Dependent variable = Intention, B = Unstandardized coefficients, Beta (β) = Standardized 




H7: PMO significantly increases the explanatory power of the regression 
model compared to only using the A + SN + PBC to explain pharmacists’ 
intention to report serious ADEs. 
The addition of the PMO construct to the TPB constructs (A, SN and PBC) direct 
measures increased the proportion of variance in intention explained by the model from 
34.0 percent to 37.6 percent. The change in R-squared was statistically significant (R
2
 
change = 0.036, F [1, 369] change = 21.21, p < 0.001). The regression coefficient of the 
PMO construct was statistically significant (B = 0.809, p < 0.001) (Table 5.41).  
The addition of the PMO construct to indirect A + SN + PBC measures increased 
the proportion of variance in intention explained by the model from 28.8 percent to 36.9 
percent. The change in R-squared was statistically significant (R
2
 change= 0.081, F [1, 
369] change = 47.17, p < 0.001). The PMO construct became the largest single predictor 
of intention and its regression coefficient was statistically significant (B = 1.074, p < 
0.001) (Table 5.41). After the addition of PMO in the model, A became statistically 
insignificant (B = 0.005, p = 0.163). Therefore, H7 was supported.  
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Table 5.41: Regression Coefficients After Adding the PMO to the TPB Constructs 
PREDICTOR VARIABLE B SE Beta t p 
Direct Measures      
(Constant) 7.742 0.869  8.908 <0.001 
Attitude  0.166 0.040 0.193 4.127 <0.001 
Subjective norm  0.424 0.080 0.300 5.314 <0.001 
Perceived behavioral control 0.045 0.068 0.029 0.671 0.503 
Perceived moral obligation 0.809 0.176 0.244 4.605 <0.001 
N = 374, F = 55.61, df = 4, 369, p < 0.001, R = 0.613, R
2
 = 0.376, Adjusted R
2
 = 0.369 
Indirect Measures      
(Constant) 3.697 0.923  4.005 <0.001  
Attitude 0.005 0.004 0.066 1.396 0.163 
Subjective norm  0.008 0.003 0.160 3.149 0.002 
Perceived behavioral control 0.012 0.003 0.234 4.539 <0.001 
Perceived moral obligation 1.074 0.156 0.324 6.868 <0.001 
N = 374, F = 53.91, df = 4, 369, p < 0.001, R = 0.607, R
2
 = 0.369, Adjusted R
2
 = 0.362 
Dependent variable = Intention, B = Unstandardized coefficients, Beta = Standardized 
coefficients, SE = Standard error. 
 
H08: There is no significant difference in A to report serious ADEs by 
gender. 
An independent groups t-test showed no statistically significant difference in 
mean attitude scores (direct measures) between male (mean = 4.24, SD = 5.09, n = 199) 
and female (mean = 5.07, SD = 4.69, n = 177) pharmacists (t = -1.642, df = 374, p = 
0.101). There was also no statistically significant difference in mean attitude scores 
(indirect measures) between male (mean = 24.02, SD = 6.90, n = 199) and female (mean 
= 24.96, SD = 6.52, n = 176) pharmacists (t = -1.349, df = 373, p = 0.178).  Therefore, 






H09: There is no significant difference in SN regarding reporting serious 
ADEs by gender. 
An independent groups t-test showed no statistically significant difference in 
mean SN scores (direct measures) between male (mean = 5.57, SD = 3.0, n = 198) and 
female (mean = 5.78, SD = 2.96, n = 177) pharmacists (t = 0.694, df = 373, p = 0.488). 
However, using indirect measures, female pharmacists (mean = 29.85, SD = 9.32, n = 
177) had significantly higher mean SN scores than male (mean = 27.83, SD = 9.35, n = 
197) (t = -2.097, df = 372, p = 0.037). Therefore, H09 was supported using direct 
measures but not supported using indirect measures.   
 
H010: There is no significant difference in PBC over reporting serious ADEs 
by gender. 
An independent groups t-test showed no statistically significant difference in 
mean PBC scores (direct measures) between male (mean = 3.43, SD = 2.64) and female 
(mean = 3.67, SD = 2.75) pharmacists (t = 0.865, df = 372, p = 0.388). In addition, using 
indirect measures, female pharmacists (mean = 20.91, SD = 7.11) had significantly 
higher mean PBC scores than male pharmacists (mean = 19.52, SD = 7.47) (t = -1.844, df 
= 374, p = 0.066). Therefore, H010 was supported using both direct and indirect 
measures.  
 
H011: There is no significant relationship between A to report serious ADEs 
and pharmacists’ years of experience. 
Attitude (direct measure) was not significantly correlated with the pharmacists‘ 
years of experience (r = -0.080, n = 375, p = 0.123). However, the indirect measure of 
attitude was significantly negatively correlated with the pharmacists‘ years of experience 
(r = -0.136, n = 374, p = 0.008). Pharmacists who had more years of experience had a less 
favorable attitude (indirect measures) towards reporting serious ADEs than those with 
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fewer years of experience. Therefore, H011 was confirmed with direct measures but not 
confirmed with the indirect measures.   
 
H012: There is no significant relationship between SN to report serious ADEs 
and pharmacists’ years of experience. 
A Pearson correlation showed no statistically significant correlation between SN 
(direct measures) and the pharmacists‘ years of experience (r = -0.044, n = 374, p = 
0.398). However, the indirect SN measures was negatively and significantly correlated 
with the pharmacists‘ years of experience (r = -0.164, n = 373, p = 0.001). Pharmacists 
who had been in practice longer were more likely to think that the important others 
(indirect measures) did not support ADE reporting than those who had been in practice 
for fewer years. Therefore, H012 was confirmed with the direct measures but not 
confirmed with the indirect measures.   
 
H013: There is no significant relationship between PBC to report serious 
ADEs and pharmacists’ years of experience. 
A Pearson correlation showed no statistically significant relationship between 
PBC (direct measures) and the pharmacists‘ years of experience (r = -0.012, n = 373, p = 
0.821). However, the indirect measures of PBC was negatively and significantly 
correlated with the pharmacists‘ years of experience (r = -0.106, n = 375, p = 0.040). 
Pharmacists with more years in practice perceived more constraints (indirect measures) to 
reporting serious ADEs than those with fewer years of practice. Therefore, H013 was 





H014. There is no significant difference in A toward ADE reporting by 
pharmacists’ primary practice setting (community-independent, community-
multiple/chain, hospital-independent, hospital-multiple/chain, and other). 
A one-way ANOVA showed no significant difference in mean direct A towards 
reporting ADEs among pharmacists practicing in the five practice settings (F = 1.932, df 
= 4, 372; p = 0.105). However, using indirect measures, a one-way ANOVA showed a 
significant difference in mean A towards reporting serious ADEs among pharmacists 
practicing in the five practice settings (F = 2.538, df = 4, 371; p = 0.04). A Tukey‘s post 
hoc test showed that the mean for the hospital-multiple/chain group (mean = 26.72, SD = 
7.10) was significantly higher than the mean for the community-independent group 
(mean = 23.23, SD = 7.30) at an alpha level of p < 0.05. No other between groups mean 
A scores were statistically significant. The means (SDs) and group sizes for the five 
groups are provided in Table 5.42. Therefore, H014 was confirmed with direct measures 
but not with indirect measures.  
 
Table 5.42: Mean Indirect A Scores by Type of Primary Practice Setting 
Type of Primary Practice 
Setting 
N Mean Standard 
Deviation 
Hospital-Multiple/Chain 58 26.72 7.10 
Hospital-Independent 44 25.07 6.06 
Community-Multiple/Chain 158 24.10 6.21 
Other 42 24.10 7.18 
Community-Independent 74 23.23 7.30 





H015: There is no significant difference in SN regarding ADE reporting by 
pharmacists’ primary practice setting (community-independent, community-
multiple/chain, hospital-independent, hospital-multiple/chain, and other). 
A one-way ANOVA showed no significant difference in mean direct SN (F = 
0.650, df = 4, 371; p = 0.627) and indirect SN (F = 1.685, df = 4, 370; p = 0.153) toward 
reporting serious ADEs among pharmacists practicing in the five practice settings. 
Therefore, H015 was confirmed.  
 
H016: There is no significant difference in PBC over ADE reporting by 
pharmacists’ primary practice setting (community-independent, community-
multiple/chain, hospital-independent, hospital-multiple/chain, and other). 
A one-way ANOVA showed no significant difference in mean direct (F = 0.103, 
df = 4, 370; p = 0.981) and indirect PBC over reporting serious ADEs (F = 0.690, df = 4, 
372; p = 0.599) among pharmacists practicing in the five practice settings. Therefore, 
H016 was confirmed.  
 
H017. There is no significant relationship between the pharmacists’ number 
of hours worked and A toward ADE reporting. 
A Pearson correlation showed no significant relationship between A (direct 
measures) and the number of hours worked by the pharmacist per week (r = 0.068, n = 
375, p = 0.189). However, for indirect measures, a Pearson correlation showed a 
statistically significant positive relationship between A and the number of hours worked 
by the pharmacist per week (r = 0.157, n = 374, p = 0.002). Thus, pharmacists who 
worked longer hours were more likely to have a favorable A toward reporting serious 
ADEs than those who worked less. Therefore, H017 was supported using direct measures 




H018: There is no significant relationship between the pharmacists’ number 
of hours worked and SN regarding ADE reporting.  
Using direct measures, a Pearson correlation showed a statistically significant 
positive relationship between the number of hours worked by pharmacists and SN 
regarding ADE reporting (r = 0.104, n = 374, p = 0.044). Pharmacists who worked longer 
hours tended to have a more favorable SN towards ADE reporting than those who 
worked less hours. However, using indirect measures, a Pearson correlation showed no 
statistically significant relationship between the pharmacists‘ number of hours worked 
and SN regarding ADE reporting (r = 0.045, n = 373, p = 0.390). Therefore, H018 was 
supported using indirect measures but not supported using direct measures.  
 
H019: There is no significant relationship between the pharmacists’ number 
of hours worked and PBC over ADE reporting. 
A Pearson correlation showed no significant relationship between pharmacists‘ 
number of hours worked and PBC over ADE reporting using both direct (r = 0.096, n = 
373, p = 0.063) and indirect (r = 0.086, n = 375, p = 0.096) measures. The number of 
hours worked was not related to the constraints that the pharmacists perceived. Therefore, 
H019 was supported.  
 
H020: There is no significant difference in A toward reporting serious ADEs 
by the pharmacists’ ethnicity. 
A one-way analysis of variance (ANOVA) showed a significant difference in 
mean direct A towards reporting serious ADEs by pharmacists‘ ethnicity (F = 3.675, df = 
5, 367, p = 0.003). A Tukey‘s post-hoc test showed that the A for African American/non-
Hispanic black group (mean = 7.04, SD = 5.77) was significantly more favorable than 
that of the Caucasian/non-Hispanic white group (mean = 4.10, SD = 4.84) at an alpha 
level of p < 0.05. There were no statistically significant differences between the means 
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for the American Indian or Alaska Native (mean = 1.67, SD = 1.35), Asian 
American/Pacific Islander (mean = 6.49, SD = 4.29), Mexican American/Hispanic (mean 
= 5.36, SD = 3.60) and other (mean = 2.91, SD = 4.81) groups.  
However, using indirect measures, a one-way ANOVA showed no statistically 
significant difference in mean A towards reporting serious ADEs by the pharmacists‘ 
ethnicity (F = 0.560, df = 5, 366, p = 0.731). Therefore, H020 was confirmed using 
indirect measures but not confirmed using direct measures.  
 
H021: There is no significant difference in SN regarding reporting serious 
ADEs by the pharmacists’ ethnicity. 
A one-way ANOVA showed no statistically significant difference in mean direct 
SN (F = 2.050, df = 5, 366, p = 0.071) and indirect SN (F = 2.152, df = 5, 365, p = 0.059) 
regarding reporting serious ADEs by pharmacists‘ ethnicity. Therefore, H021 was 
confirmed for both direct and indirect measures. 
 
H022: There is no significant difference in PBC over reporting serious ADEs 
by the pharmacists’ ethnicity. 
A one-way ANOVA showed no statistically significant difference in mean direct 
PBC over reporting serious ADEs ratings by pharmacists‘ ethnicity (F = 1.431, df = 5, 
365, p = 0.212). However, using indirect measures, a one-way ANOVA showed a 
statistically significant difference in mean PBC ratings toward reporting serious ADEs by 
pharmacists‘ ethnicity (F = 4.437, df = 5, 367, p = 0.001). A Tukey‘s post-hoc test 
showed that the African American/non Hispanic black group (mean = 24.53, SD = 9.47) 
had significantly higher perceived control than the Caucasian/non-Hispanic white group 
(mean = 19.24, SD = 6.57) at an alpha level of p < 0.05. The means for the American 
Indian or Alaska Native (mean = 26.97, SD = 17.66), Asian American/Pacific Islander 
(mean = 21.46, SD = 6.92) and the Mexican American/Hispanic (mean = 22.75, SD = 
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8.19) groups were not significantly different. Therefore, H022 was confirmed using direct 
measures but not confirmed using indirect measures.  
 
H023: There is no significant relationship between the pharmacists’ 
knowledge of ADE reporting and A toward ADE reporting. 
A Pearson correlation showed a statistically significant positive relationship 
between A toward ADE reporting and pharmacists‘ knowledge of ADE reporting for both 
direct (r = 0.274, n = 376, p < 0.001) and indirect (r = 0.293, n = 375, p < 0.001) 
measures. Pharmacists who had higher knowledge on ADE reporting had a more 
favorable A towards reporting serious ADEs to the FDA than those who had lower 
knowledge. Therefore, H023 was not confirmed.  
 
H024: There is no significant relationship between the pharmacists’ 
knowledge of ADE reporting and SN regarding ADE reporting. 
A Pearson correlation showed a statistically significant positive relationship 
between pharmacists‘ knowledge of ADE reporting and SN regarding ADE reporting for 
both direct (r = 0.254, n = 375, p < 0.001) and indirect (r = 0.200, n = 374, p < 0.001) 
measures. Pharmacists with higher knowledge of ADE reporting had higher SN than 
those with lower knowledge. Therefore, H024 was not confirmed.  
 
H025: There is no significant relationship between the pharmacists’ 
knowledge of ADE reporting and PBC over ADE reporting. 
A Pearson correlation showed a statistically significant positive relationship 
between the pharmacists‘ knowledge of ADE reporting and PBC over ADE reporting for 
both direct (r = 0.220, n = 374, p < 0.001) and indirect (r = 0.343, n = 376, p < 0.001) 
measures. Pharmacists with higher knowledge of ADE reporting had higher perceived 
control than those with lower knowledge. Therefore, H025 was not confirmed. 
205 
 
5.11 ASSUMPTIONS OF MULTIPLE (LINEAR) REGRESSION ANALYSIS 
 The study examined the data to determine if it satisfied the assumptions for 
multiple (linear) regression analysis. Specifically, the investigation looked at the 
following four criteria: normality, homoscedasticity, linearity, and multicollinearity.  
The normality of the distribution of errors was assessed by inspecting the 
histograms of residuals from the regression analysis (direct and indirect TPB constructs) 
(see Appendix G). The assumption was also assessed by inspecting and evaluating the 
normal probability plots (see Appendix H). The histograms show that the standardized 
residuals of the regression analysis had a normal distribution. The sample data was from 
a normal distribution given that most standardized residuals fell along the reference line 
on the normal probability plot (Appendix H). The plots showed that A, SN, and PBC 
(direct and indirect measures) were normally distributed (Appendix H). 
The homoscedasticity of errors assumption was assessed by inspecting the 
scatterplot of standardized residuals against the regression standardized predicted values 
of the dependent variable (direct and indirect TPB constructs) (see Appendix I). The 
sample data did not violate the assumption of homoscedasticity of errors because the 
residuals were evenly scattered around zero (Appendix I). 
The scatterplots of regression standardized residuals versus regression 
standardized predicted values (direct TPB and indirect TPB) were evaluated to assess the 
linearity of the data (see Appendix J). Visual examination of the partial regression plots 
did not indicate a curvature in the relationships between the dependent and independent 
variables for both direct and indirect measures models. The assumption of linearity was 
not violated.  
 Multicollinearity was assessed by evaluating the values of correlation coefficients 
of the variables, tolerance, and variance inflation factors (Tables 5.43, 5.44, and 5.45). 
Using direct measures, the correlations among the constructs ranged from 0.14 to 0.55. 
Using indirect measures, the correlations among the constructs ranged from 0.12 to 0.52. 
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Multicollinearity does not seem to be high or problematic in the data because none of the 
correlations between the variables were greater than 0.75.   
 
Table 5.43: Correlation Matrix for the Direct Measures Variables 


























































































Intention 1.00      
Attitude (direct) 0.42 1.00     
Subjective norm (direct) 0.55 0.46 1.00    
Perceived behavioral control (direct) 0.20 0.19 0.29 1.00   
Past reporting behavior 0.22 0.14 0.20 0.15 1.00  






































































































Intention 1.00      
Attitude (indirect) 0.33 1.00     
Subjective norm (indirect) 0.43 0.41 1.00    
Perceived behavioral control (indirect) 0.47 0.42 0.52 1.00   
Past reporting behavior 0.22 0.20 0.12 0.19 1.00  
Perceived moral obligation 0.51 0.32 0.39 0.42 0.18 1.00 
 
Table 5.45 shows tolerance and variance inflation factors (VIF). The VIF values 
ranged from 1.057 to 1.888. Tolerance values were high (range: 0.530 – 0.904) (see 
Table 5.45). Multicollinearity does not appear to be a problem because none of the VIF 




Table 5.45: Tolerance and Variance Inflation Factors (VIF) of Independent Variables 
Independent Variables  Tolerance Variance Inflation Factors 
Direct Measures   
Attitude  0.770 1.298 
Subjective norm 0.530 1.888 
Perceived behavioral control 0.904 1.057 
Perceived moral obligation 0.602 1.662 
Past reporting behavior 0.946 1.057 
Indirect Measures   
Attitude  0.752 1.329 
Subjective norm 0.662 1.510 
Perceived behavioral control 0.639 1.565 
Perceived moral obligation 0.759 1.318 
Past reporting behavior 0.938 1.066 
 
5.12 SUMMARY OF TESTS OF HYPOTHESES 
Table 5.46 shows the summary of hypotheses test results. Eighteen of the 25 
hypotheses were supported using direct measures and 15 hypotheses were supported 
using indirect measures. The decision reached (supported or not) was different using 





Table 5.46: Summary of Hypotheses Test Results 
Hypothesis Direct Measures Indirect Measures 
H1: Favorable A is a positive and significant predictor of intention to report serious 
ADEs controlling for SN and PBC. 
Supported Supported 
H2: SN supporting ADE reporting is a positive and significant predictor of intention to 
report serious ADEs controlling for A and PBC. 
Supported Supported 
H3: Strong PBC is a positive and significant predictor of intention to report serious 
ADEs controlling for A and SN. 
Not supported Supported 
H4: A + SN + PBC constructs explain a significant amount of variance in pharmacists‘ 
intention to report serious ADEs. 
Supported Supported 
H5: PBC significantly increases the explanatory power of the regression model compared 
to only using A + SN to explain pharmacists‘ intention. 
Not supported Supported 
H6: PRB significantly increases the explanatory power of the regression model compared 
to only using the A + SN + PBC to explain pharmacists‘ intention to report serious 
ADEs. 
Supported Supported 
H7: PMO significantly increases the explanatory power of the regression model 
compared to only using the A + SN + PBC to explain pharmacists‘ intention to report 
serious ADEs. 
Supported Supported 
H08: There is no significant difference in A to report serious ADEs by gender. Supported Supported 
H09: There is no significant difference in SN regarding reporting serious ADEs by 
gender. 
Supported Not supported 
H010: There is no significant difference in PBC over reporting serious ADEs by gender. Supported Supported 
H011: There is no significant relationship between A to report serious ADEs and 
pharmacists‘ years of experience. 
Supported Not supported 
H012: There is no significant relationship between SN to report serious ADEs and 
pharmacists‘ years of experience. 
Supported Not supported 
H013: There is no significant relationship between PBC to report serious ADEs and 
pharmacists‘ years of experience. 
Supported Not supported 
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Table 5.46: Summary of Hypotheses Test Results Continued 
Hypothesis Direct Measures Indirect Measures 
H014. There is no significant difference in A toward ADE reporting by pharmacists‘ 
primary setting (community-independent, community-multiple/chain, community-
government, hospital-non-government, hospital-government, and other). 
Supported Not supported 
H015: There is no significant difference in SN regarding ADE reporting by pharmacists‘ 
primary setting (community-independent, community-multiple/chain, community-
government, hospital-non-government, hospital-government, and other). 
Supported Supported 
H016: There is no significant difference in PBC over ADE reporting by pharmacists‘ 
primary setting (community-independent, community-multiple/chain, community-
government, hospital-non-government, hospital-government, and other). 
Supported Supported 
H017. There is no significant relationship between the pharmacists‘ number of hours 
worked and A toward ADE reporting. 
Supported Not supported 
H018: There is no significant relationship between the pharmacists‘ number of hours 
worked and SN regarding ADE reporting. 
Not supported Supported 
H019: There is no significant relationship between the pharmacists‘ number of hours 
worked and PBC over ADE reporting. 
Supported Supported 
H020: There is no significant difference in A toward reporting serious ADEs by the 
pharmacists‘ ethnicity. 
Not supported Supported 
H021: There is no significant difference in SN regarding reporting serious ADEs by the 
pharmacists‘ ethnicity. 
Supported Supported 
H022: There is no significant difference in PBC over reporting serious ADEs by the 
pharmacists‘ ethnicity. 
Supported Not supported 
H023. There is no significant relationship between the pharmacists‘ knowledge of ADE 
reporting and A toward ADE reporting. 
Not supported Not supported 
H024: There is no significant relationship between the pharmacists‘ knowledge of ADE 
reporting and SN regarding ADE reporting. 
Not supported Not supported 
H025: There is no significant relationship between the pharmacists‘ knowledge of ADE 
reporting and PBC over ADE reporting. 
Not supported Not supported 
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CHAPTER SIX: DISCUSSION 
 
This study investigated the predictive utility of the theory of planned behavior 
(TPB) in understanding Texas pharmacists‘ intentions to report serious adverse drug 
events (ADEs). The factors affecting Texas pharmacists‘ attitude (A), subjective norm 
(SN), and perceived behavioral control (PBC) toward ADE reporting were identified 
using the TPB model. In addition, the relative importance of past reporting behavior 
(PRB) and perceived moral obligation (PMO) in the prediction of Texas pharmacists‘ 
intention to report ADEs were assessed. The study also examined the roles of 
pharmacists‘ knowledge, demographic factors and practice characteristics in ADE 
reporting.  
This chapter provides a discussion of the study results. The first section discusses 
the results of the hypothesis tests of the study, evaluates the study model, proposes 
possible explanations for the findings, and suggests institutional and organizational 
changes for improving ADE reporting. The second section discusses the implications and 
directions for future research. The final section addresses the main limitations of the 
study and conclusions.   
 
6.1 FOCUS GROUP  
Several important aspects were gleaned from the focus group participants. First, 
the focus group participants seemed to strongly agree that lack of time was a major 
constraint to reporting serious ADEs to the FDA. Participants felt that pharmacists did 
not have time to report ADEs. In addition, pharmacists often do not consider reporting 
ADEs. During the focus group, one pharmacist said, ―It just does not occur to me that I 
should fill out a MedWatch form for the ADEs that I see.‖ Also, it seemed apparent that 
participants had notable misconceptions on ADE reporting in general and MedWatch 
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specifically. For example, pharmacists were suggesting things that are already being 
implemented by the FDA and some asked questions that indicated their ignorance of 
MedWatch. Pharmacists‘ misconceptions were also reflected in the findings of the 
knowledge scores.  
 
6.2 RESPONSE RATE  
This study‘s response rate of 26.4 percent is comparable to one other mail survey 
involving pharmacists in Texas (27.0%) (Brown, Barner, & Shah, 2005). However, this 
study‘s response rate was low compared to other studies involving pharmacists in Texas 
that reported response rates ranging from 35.1 percent to 58.4 percent (Brown, 1998; 
Brown et al., 2007; Griggs & Brown, 2007; Mashburn et al., 2003; O'Donnell, Brown, & 
Dastani, 2006; Olson & Lawson, 1996), but comparable or higher to response rates in 
studies of healthcare professionals (HCPs): 21 percent (Herbert et al., 2006), 25 percent 
(Pradel, Obeidat, & Tsoukleris, 2007), and 19.7 percent (Belton & The European 
Pharmacovigilance Research Group, 1997). 
 
 
6.3 SAMPLE CHARACTERISTICS 
The study used a sample of Texas practicing pharmacists (n = 1,500). The sample 
was drawn from a Texas State Board of Pharmacy list (population/census) which contains 
information on all licensed pharmacists in Texas (N = 25,177). Although the sample and 
population of Texas pharmacists were similar on gender and ethnicity (Table 6.1), the 
African American and Mexican American groups seem to have been oversampled. 
However, overall the (study) sample was fairly representative of Texas pharmacists in 




Table 6.1: Gender and Ethnicity of Texas Pharmacists, Study Sample and Respondents 
Characteristic  Census of Licensed 
Texas Pharmacists 
in 2008 (Frequency, 
%)  









%) (n = 377) 
Gender    
Female 12,646 (50.2) 772 (51.5) 177 (47.1) 
Male 12,531 (49.8) 728 (48.5) 199 (52.9) 
Ethnicity    
Caucasian/non-Hispanic white 15448 (61.4) 881 (58.7) 262 (70.2) 
Asian American/Pacific 
Islander 
3912 (15.5) 220 (14.7) 37 (9.9) 
African American/non-
Hispanic black 
3127 (12.4) 214 (14.3) 27 (7.2) 
Mexican American/Hispanic 1879 (7.5) 141 (9.4) 33 (8.8) 
Other 401 (1.6) 23 (1.5) 11 (2.9) 
American Indian or Alaska 
Native 
195 (0.8) 8 (0.5) 3 (0.8) 
Not specified/Other 215 (0.9) 13 (0.9) 11 (2.9) 
 
The mean age of respondents in this study of 51.46 (SD = 12.69) years shows that 
pharmacists who responded to this study were middle-aged, and had been practicing 
pharmacy for an average of 25 years.  In other studies involving pharmacists, the 
respondents were younger: 45 (SD = 12.0) years (Pradel, Obeidat, & Tsoukleris, 2007), 
48.6 (SD = 12.46) years (Mashburn et al., 2003), 49.45 (SD = 14.35) years (Griggs & 
Brown, 2007), 44.8 (SD = 12.5) years (Brown et al., 2007); and had fewer years of 
experience: 11.0 (SD = 9.9) years (Farris & Schopflocher, 1999), 18 (SD = 12.4) years 
(Coleman, 2003), and 24.3 (SD = 13.2) years (O'Donnell, Brown, & Dastani, 2006).  
 
6.4 INTENTION TO REPORT SERIOUS ADES 
The overall mean intention score was high (mean = 5.29, SD = 1.41; possible 
range: 1 – 7, neutral = 4), suggesting that pharmacists intended to report serious ADEs to 
the FDA. This finding is positive, encouraging and was expected given that reporting 
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serious ADEs promotes drug and patient safety, which is a key responsibility of 
pharmacists (Beard & Lee, 2006). ADE reporting fits in well with pharmacists‘ 
responsibility of ensuring the safe use of medicines, and has become standard practice for 
pharmacists in many countries (Griffin, 1986). Previous research studies using theoretical 
models found that pharmacists have moderate intentions to provide services that help 
patients and contribute towards the safe use of medicines such as the provision of 
MTMS, pharmaceutical care and medication counseling (Farris & Schopflocher, 1999; 
Herbert et al., 2006; Mason, 1983; Pradel, Obeidat, & Tsoukleris, 2007).  
In the literature, behavioral intention has been found to be a valid proxy measure 
for behavior; there is good correspondence between measures of health professionals‘ 
intentions and their subsequent behavior (Eccles et al., 2006; Farris & Schopflocher, 
1999; Godin & Kok, 1996; Godin, Naccache, Morel, & Ebacher, 2000; Millstein, 1996; 
O'Boyle, Henly, & Larson, 2001; Renfroe, O'Sullivan, & McGee, 1990; Sheeran, Conner, 
& Norman, 2001). Intention is the most important predictor of subsequent behavior 
(Godin & Kok, 1996). A recent systematic review reported that on average, intentions 
account for 28 percent (range: 0.15 – 0.40%) of the variance in subsequent behavior 
(Eccles et al., 2006). Thus, pharmacists‘ participation in ADE reporting can be increased 
by targeting their intentions and the predictors of intentions.  
Intention was positively and significantly related with pharmacists‘ knowledge. 
Pharmacists who knew more about how to report serious ADEs intended to report more 
than those who knew less on how to report. As expected, intenders had significantly more 
favorable A, higher SN, and higher PBC (indirect measures only) than non-intenders. 
This suggests that pharmacists‘ salient beliefs and knowledge were key factors in 




6.5 EVALUATION OF THE STUDY MODEL 
The hypothesis that the TPB model would predict a significant amount of 
variance in ADE reporting intentions was supported by the data. Using direct and indirect 
measures, the combination of A, SN and PBC explained 34.0 and 28.8 percent of the 
variance in intent to report serious ADEs to the FDA, respectively. Explaining 34 or 29 
percent of the variance in pharmacists‘ reporting of serious ADEs may be extremely 
worthwhile from a practical point of view, given the small number of predictors. In the 
literature, explaining 10 percent or more of the variance in the dependent variable is 
considered worthwhile from a practical viewpoint particularly if a small number of 
predictors are used (Sutton, 1998).   
The proportion of variance in intention explained in this study (direct measures - 
34.0%) is comparable to those obtained by Conner and Sparks (33.7%) and Godin and 
Kok (40%) (Conner & Sparks, 2005; Godin et al., 2008). One study involving 
pharmacists reported that the TPB constructs explained 19 percent of the variance in 
intention (Walker et al., 2004). Elsewhere, the TPB constructs explained a higher 
proportion of variance in intention (belief-based measures - 37.1%; direct measures - 
73.5%) (Mashburn et al., 2003). A systematic review of studies on HCPs‘ intentions and 
behaviors based on social cognitive theories found an overall frequency-weighted mean 
R
2
 of 0.31 and 0.59 for prediction of behavior and intention, respectively (Godin et al., 
2008).  
The TPB appears to be an appropriate theoretical model and a useful framework 
for studying pharmacists‘ reporting of serious ADEs. This corroborates previous research 
studies involving HCPs (Godin et al., 2008; Millstein, 1996; Sheeran, Conner, & 




Theory of Planned Behavior Constructs 
Direct Measures: As hypothesized, favorable A and SN supporting ADE 
reporting were positive and significant predictors of intention to report serious ADEs. 
The study results show that SN was the most important and significant predictor of 
intention. However, the hypothesis that PBC was a positive and significant predictor of 
intention to report serious ADEs controlling for A and SN was not supported by the data.  
 Indirect Measures: The hypotheses that favorable A, SN supporting ADE 
reporting and strong PBC were positive and significant predictors of intention after 
controlling for other variables in the model were supported. PBC significantly increased 
the explanatory power of the regression model compared to only using A and SN to 
explain pharmacists‘ intention. PBC was the strongest predictor of intention. 
In general, the data were consistent with the predicted relationships among the 
TPB model components (A, SN, PBC, and BI). As expected, there were positive 
correlations between direct and indirect measures of the TPB predictors (Ajzen, 2002; 
Montano & Kasprzyk, 2002). Although direct and indirect measures9 have different 
assumptions about the underlying cognitive structures (Francis et al., 2004), they are 
expected to be correlated because they are indicators of the same underlying construct 
(Ajzen, 2002). Based on Cohen‘s classification,10 there was a small correlation11 between 
PBC direct and PBC indirect measures, moderate correlation between direct and indirect 
                                                 
9 ―Briefly, indirect measures are based on responses to items about specific beliefs and scores are then 
combined by the researcher. The assumptions are that the method used for combining responses (weighting 
and then averaging the scores) reflects the methods that individuals use when forming, for example, an 
attitude, and that all relevant beliefs have been represented among the questionnaire items. Direct 
measurement effectively asks individuals themselves to combine the separate beliefs. It does not rely on the 
assumption that all relevant beliefs have been represented in the questionnaire but assumes that people can 
accurately combine and report a global attitude, subjective norm, and perceived level of control over the 
behavior in question‖ (Francis et al., 2008). 
 
10 Jacob Cohen classified correlations into three: large (> 0.5), moderate (0.3 – 0.5) and small (0.1 – 0.3). 
Correlations smaller than 0.1 are considered trivial and not substantial (Cohen, 1998). 
 
11 The small correlation between PBC direct and PBC indirect measures may have resulted from problems 




A measures, and large correlations between direct and indirect SN measures. In addition, 
our findings were consistent with Montano and Kasprzyk (2002) who reported that the 
TPB direct measures (taken together) were stronger predictors of intention than indirect 
measures.  
 
Past Reporting Behavior 
As expected, PRB significantly increased the explanatory power of the regression 
models (direct and indirect measures models) compared to only using A, SN, and PBC to 
explain pharmacists‘ intention to report serious ADEs (p < 0.05).  The R
2 
change 
associated with the addition of PRB for both the direct and indirect measures models 
were significant (p < 0.05). These findings confirm the results from previous studies that 
reported that past behavior significantly improved the prediction of intention over and 
above the TRA and TPB constructs (Albarracin et al., 2001; Bagozzi, 1981; Leone, 
Perugini, & Ercolani, 1999; Mashburn et al., 2003; Quine & Rubin, 1997; Schaalma, 
Kok, & Peters, 1993; Walker, Grimshaw, & Armstrong, 2001). Taken together, these 
findings indicate that past behavior is an important predictor and, thus, should be 
included in models of ADE reporting intentions among pharmacists. 
 
Perceived Moral Obligation 
As hypothesized, PMO significantly increased the explanatory power of the 
regression models (direct and indirect measures models) compared to only using A, SN 
and PBC to explain pharmacists‘ intention to report serious ADEs (p < 0.05). The R
2 
change associated with the addition of PMO for both the direct and indirect measures 
models were significant (p < 0.05). This finding corroborates previous research that 
reported that PMO is an important predictor of HCPs‘ intention especially in moral 
situations (Fazekas, Senn, & Ledgerwood, 2001; Godin et al., 2008; Gorsuch & Ortberg, 
1983; Randall & Gibson, 1991; Werner & Mendelsson, 2001). This study confirms the 
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importance of PMO with respect to reporting serious ADEs. This finding suggests that 
ADE reporting is a moral imperative for pharmacists.  
In summary, the TPB is a useful model and appropriate framework for predicting 
pharmacists‘ reporting intentions and behavior. Intention to report serious ADEs was 
predictable from the TPB constructs. SN (direct measures) and PBC (indirect measures) 
were the strongest TPB predictors of intention. The study data are consistent with the 
predicted relationships among the TPB model components. PRB and PMO had a strong 
effect on intention beyond the TPB constructs.  
 
6.6 ATTITUDES TOWARD REPORTING SERIOUS ADES 
As hypothesized, favorable A was a significant and positive predictor of intention 
to report serious ADEs after controlling for SN and PBC. Thus, an understanding of the 
factors affecting pharmacists‘ A can provide insight into how to increase ADE reporting 
by pharmacists. Implementation strategies aimed at increasing ADE reporting should 
address pharmacists‘ A toward ADE reporting. The overall mean A (direct measure) 
score was positive (mean = 0.92, SD = 0.98; possible range: -3 to +3, 0 = neutral), 
suggesting that respondents had a positive A toward reporting serious ADEs. Pharmacists 
believed that ADE reporting was valuable, good and beneficial. However, pharmacists 
did not exhibit very strong support for these outcomes, with most responses falling 
around zero. The mean A (indirect measures) score was high (mean = 24.45, SD = 6.73; 
possible range: 1-49, 16 = neutral) signifying that Texas pharmacists held a favorable A 
towards reporting serious ADEs to the FDA. The finding that pharmacists had a favorable 
A toward ADE reporting is consistent with previous studies (Bawazir, 2006; Irujo et al., 
2007; van Grootheest, Mes, & de Jong-van den Berg, 2002). In other studies involving 
pharmacists‘ A toward patient safety and patient care, pharmacists have been reported to 
hold a favorable A towards correcting drug therapy problems, providing MTMS and 
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asthma counseling (Farris & Schopflocher, 1999; Herbert et al., 2006; Pradel, Obeidat, & 
Tsoukleris, 2007).  
 
Primary Drivers of Attitude 
The strongest positive beliefs driving A towards reporting serious ADEs to the 
FDA were to improve patient safety, and educate others about drug risks. In addition, the 
beliefs with the strongest negative influence were that reporting will increase the risk of 
malpractice, break trust with patients and compromise the relationship with physicians.  
The beliefs that reporting serious ADEs to the FDA will improve patient safety 
and educate others about drug risks were the strongest beliefs (i.e., had highest mean 
product of behavioral belief and outcome evaluation scores).  At the time of approval, 
little is known about the safety of a drug. Inevitably, more is learned as the drug is widely 
used on the market. Rare, serious, uncommon and unpredictable events that may surface 
after approval are identified through voluntary ADE reporting (Meadows, 2002). These 
events enhance and improve understanding of the drug‘s risk profile. Voluntary ADE 
reports are an important source of information concerning drug risks to the FDA, HCPs 
and patients (e.g., educates other HCPs and patients about drug risks). New drug risks 
identified through serious ADE reports are added to the drug‘s label and the information 
is communicated to doctors (Meadows, 2002). This information further contributes to 
patient safety through informing better and safer methods of using medicines and, in rare 
cases when evidence suggests that the drug is unsafe, the drug may be withdrawn from 
the market. It is encouraging that pharmacists‘ beliefs were in line with the primary 
advantages of ADE reporting—to improve patient safety and to educate others about drug 
risks. Similar findings have been reported elsewhere (Irujo et al., 2007; Vessal, Mardani, 
& Mollai, 2009). Physicians have been reported to believe that reporting ADEs informs 
their colleagues of the adverse experiences they have encountered (Inman, 1985). 
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Although Texas pharmacists believed that increased risk of malpractice was a bad 
outcome, they did not believe that reporting serious ADEs to the FDA increased the risk 
of malpractice. This finding is contrary to previous research findings that reported that 
ADE reporting or self-identification could result in repercussions, investigation and 
malpractice suits (Ashcroft et al., 2006; Bateman, Sanders, & Rawlins, 1992). In the 
literature, open reporting of ADEs is reported to be deterred by the threat of litigation, 
professional disciplinary action, investigation or reprisal (Institute of Medicine Report, 
2004; Kaufman, Stoukides, & Campbell, 1994; Vincent et al., 2006). For example, in a 
classic study, Inman identified fear of possible involvement in litigation or investigation 
of prescribing costs by health departments as one of the seven main reasons why medical 
doctors did not report suspected ADRs (Inman, 1978). This study‘s finding is, however, 
consistent with other studies (Belton & The European Pharmacovigilance Research 
Group, 1997; Granas, Buajordet, Stenberg-Nilsen, Harg, & Horn, 2007; Hasford et al., 
2002; Herdeiro et al., 2006; Lopez-Gonzalez, Herdeiro, & Figueiras, 2009; Sweis & 
Wong, 2000). The passage of the Patient Safety and Quality Improvement Act of 2005 
(P.L. 109-41), which grants ―peer review protection from report disclosure during legal 
proceedings, and protection of providers who report from professional retaliation‖ 
(Institute of Medicine of the National Academies, 2007b, p. 91), together with the 
confidentiality and anonymity of reporting accorded by MedWatch may explain our 
findings. 
Pharmacists also believed that reporting serious ADEs to the FDA did not break 
trust with patients and did not compromise their relationship with physicians. Similarly, 
elsewhere ADR reporting was found to build rather than destroy patient trust (Bawazir, 
2006). Furthermore, ADR reporting was reported to show that pharmacists took patients‘ 
complaints seriously (Bawazir, 2006) and that they took greater responsibility for patient 
care (Biriell & Edwards, 1997). 
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In addition, pharmacists believed that reporting serious ADEs to the FDA is 
personally beneficial/rewarding to the pharmacist, time consuming and disrupted the 
normal workflow. However, they did not exhibit very strong support for these advantages 
and disadvantages (outcomes) with most of the responses to these items falling around 4 
(neither agree nor disagree) on a scale of 1 to 7. The beliefs that ADE reporting disrupted 
the normal workflow, though not strong, are consistent with previous findings (Sweis & 
Wong, 2000). Similar to previous findings, it may be that pharmacists consider reporting 
ADEs as an additional duty or not to be an integral part of their professional duties 
(Sweis & Wong, 2000). Pharmacists could submit more reports if they considered 
reporting to be an integral part of their duties, as is the case in the Netherlands (van 
Grootheest, Mes, & de Jong-van den Berg, 2002). 
 
Attitude Differences Between Intenders and Non-Intenders 
Results showed that those pharmacists who were intending to report serious 
ADEs to the FDA were more likely to believe that reporting serious ADEs educates 
others about drug risks, is personally beneficial/rewarding to the pharmacist, and 
improves patient safety (p < 0.05) than those who did not intend to report. As a result, 
interventions that increase pharmacists‘ awareness of the benefits of ADE reporting could 
be valuable. Pharmacists ought to be educated on the benefits of reporting serious ADEs 
(see Section 6.8).  
 
Factors Associated with Attitude 
Using direct measures, the study found that pharmacists practicing in the hospital-
multiple chain group had a significantly more favorable A than those practicing in the 
community-independent group. This is consistent with previous studies that found that 
hospital pharmacists are more likely to report ADRs than community pharmacists 
(Herdeiro et al., 2006; Taras-Zasowski & Einarson, 1989). Practice setting was also 
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reported to be associated with reporting among medical practitioners (Belton & The 
European Pharmacovigilance Research Group, 1997; Eland et al., 1999; Figueiras et al., 
1999; Herdeiro et al., 2005). Hospital pharmacists have a more favorable A than 
community pharmacists because they are more knowledgeable about clinical pharmacy 
and pharmacovigilance, have access to patient medical records and tend to see more 
patients with serious ADEs (Calvert, 1999; Pirmohamed et al., 2004; Rawlins, 1995; van 
Grootheest & de Jong-van den Berg, 2005). In addition, hospital pharmacists are more 
directly involved in patient care, and have access to state of the art computer systems 
which may not be available in the community setting (Dormann et al., 2000; Emerson et 
al., 2001). These factors increase their chances of detecting serious ADEs compared to 
community pharmacists.  
Using indirect measures, A was negatively associated with the pharmacists‘ years 
of experience. Pharmacists with more years in pharmacy practice were likely to have a 
less favorable A than those who had fewer years of experience.  This is in contrast with 
other studies in Europe that reported a positive association between tendency to report 
ADRs and years of experience (seniority) (Generali, Danish, & Rosenbaum, 1995; Irujo 
et al., 2007; Kelley & Tucci, 2001; McGettigan, Golden, Conroy, Arthur, & Feely, 1997; 
Sweis & Wong, 2000). 
Pharmacists‘ A (indirect measures) was positively correlated with the number of 
hours worked. As observed by Sweis and Wong (2000), pharmacists who worked more 
hours tended to have a more favorable A than those who worked less hours. In addition, 
pharmacists who were younger had a more favorable A towards reporting ADEs than 
other pharmacists. Focus should be given to the needs of the more experienced 
pharmacists, those pharmacists practicing in community independent settings and those 
who work less hours when implementing activities aimed at positively increasing 
pharmacists‘ A.  
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6.7 SUBJECTIVE NORM REGARDING ADE REPORTING 
The hypothesis that SN supporting ADE reporting is a positive and significant 
predictor of intention to report serious ADEs controlling for A and PBC was supported 
by the data. The direct SN measure was positive (mean = 1.88, SD = 1.0; range: -3 to +3, 
neutral = 0) and the mean ‗normative beliefs‘ by ‗motivation to comply‘ product (indirect 
measures) score was high (mean = 28.75, SD = 9.38; possible range: 1-49, neutral = 16), 
indicating that pharmacists felt social pressure to report serious ADEs to the FDA. Using 
direct measures, SN was the best TPB predictor of intention to report serious ADEs after 
controlling for A and PBC. SN has also been found to be the most important predictor of 
intention in pharmacy research (Herbert et al., 2006). As noted in the literature review, 
SN is stronger than A in the prediction of behaviors that affect others compared to 
behaviors that do not (Quine, Rutter, & Arnold, 1998).  In other words, when an 
individual forms an intention about a behavior that carries implications for others, the 
perceived views of significant others are of greater importance (Quine, Rutter, & Arnold, 
1998). Thus, SN may have played a greater role in the formulation of intentions to report 
serious ADEs because ADE reporting is seen to have implications for other people (e.g., 
doctors, patients, and workmates) too. For example, pharmacists may believe that 
reporting ADEs will affect the safe use of medicines by their patients.   
Professional campaigns that use role models, peer educators and patient advocates 
to encourage reporting may be effective. The use of peer-led educational interventions 
(led by peer educators or role models) has been reported to be effective in improving 
participants‘ attitude and knowledge (Gibson, Shah, & Mamoon, 1998; Kirby, Obasi, & 
Laris, 2006; Li et al., 2010; Shah et al., 2001; Tobler, 1992); however, such programs 
have not been tested empirically for the promotion of ADE reporting. Pharmacists may 
be more likely to change if the message is presented by someone they can relate to or 
perceive as important to this reporting decision. Interventions that incorporate such 
important others to enhance or promote positive social norms may be effective in 
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changing ADE reporting. The finding that SN predicts intention is consistent with prior 
research supporting the TPB (Ajzen, 1991; Feng & Wu, 2005; Godin et al., 2008; Herbert 
et al., 2006; Randall & Gibson, 1991). 
 
Primary Drivers of Subjective Norm 
The most important salient referents were the FDA, patients, pharmacy 
associations, pharmacy managers/bosses and hospitals and hospital groups. Pharmacists 
believed that these salient referents were interested in whether or not they report serious 
ADEs to the FDA. The study results also show that pharmacists were likely to comply 
with what all nine groups included in the study wanted them to do concerning ADE 
reporting. These referents could be used to communicate with pharmacists the need to 
report serious ADEs to the FDA. 
The FDA was the most salient referent. A close look at the results shows that 85.3 
percent of the respondents believed that the FDA likely wanted them to report serious 
ADEs and 80.7 percent of the respondents were likely to do what the FDA would want 
them to do when it comes to reporting ADEs. This result is not surprising and is in 
agreement with opinion poll results that show that the FDA commands the respect of 
more than two-thirds of the American adult population (Harris Interactive, 2007). The 
FDA is responsible for protecting the public health by assuring the efficacy and safety of 
all drugs sold within the U.S. borders. Drug safety is an essential component of the 
FDA‘s mission. In line with its mission, the FDA expects all pharmacists to report serious 
ADEs that they encounter. Most pharmacists seem to accept the role of the FDA in drug 
safety. However, a few pharmacists had negative perceptions of the FDA‘s conduct of 
postmarketing surveillance (PMS) activities and seven made negative comments12 at the 
end of the survey.  
                                                 
12
 Some of the comments made by the pharmacists at the end of the survey are as follows: ―I think the FDA 
looks the other way on a large number of adverse drug events. Personally, I feel the FDA is just an 
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The patients also emerged as important referents for pharmacists‘ intent to report 
serious ADEs to the FDA. A majority of respondents were likely to comply with what 
their patients wanted them to when it comes to reporting serious ADEs. Direct to 
consumer advertising and the widespread availability of health information on the 
internet and other sources makes patients more knowledgeable and engaged in their 
treatment, and in reporting serious ADEs to the FDA. About 15 percent of the 422,889 
ADE reports submitted to the FDA in 2004 were submitted directly by consumers. 
Studies have found that patients respect pharmacists and respond favorably to pharmacist 
services in the community setting (Ukens, 1998; Whitley, Jones, & Peal, 1996). 
Pharmacists, especially community pharmacists, mostly obtain information about serious 
ADEs directly from patients (Herbert et al., 2006). 
In addition, the study results indicate that physicians also influenced pharmacists‘ 
intent to report serious ADEs. A majority of respondents (65.7%) were likely to comply 
with what physicians would want them to do when it comes to reporting serious ADEs. 
Physicians have varied reactions to pharmacists‘ reporting of serious ADEs to the FDA. 
A study in Utah found that physicians were less willing to having pharmacists help 
patients manage ADRs or suggest alterations in patients‘ drug regimens (Bradshaw & 
Doucette, 1998). The study also found a negative correlation between a physician‘s 
attitude toward community pharmacists acting as patient advocates on drug-related 
matters and age (Bradshaw & Doucette, 1998). The negative attitude of physicians 
towards pharmacists‘ drug therapy recommendations, and difficulty in making direct 
contact with physicians (Amsler et al., 2001; Hughes & McCann, 2003) may limit the 
interprofessional liaison between pharmacists and physicians (Herbert et al., 2006). 
                                                                                                                                                 
extension of the drug companies.‖ ―The FDA is slow to respond and is reluctant to confront PMA 
members.‖ ―I am well aware that the FDA is greatly understaffed and unable to adequately perform its 
duties.‖ ―I am not convinced that the FDA bureaucracy is efficient enough to manage the information that 
is reported‖ and ―Previous FDA response has been none.‖ 
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Similar to Cosentino and colleagues (1997) and Irujo and colleagues (2007), drug 
manufacturers were found to have a weak but positive influence on pharmacists‘ 
reporting of serious ADEs to the FDA  Irujo and colleagues (2007) reported that few 
pharmacists communicated the occurrence of ADRs to drug manufacturers. 
Pharmaceutical companies did not appear to have much influence on pharmacists‘ 
reporting of serious ADEs, perhaps because pharmacists find them not to be trustworthy 
about drug safety. This may be explained by the fact that drug companies do not always 
reveal all they know about their products‘ safety profiles to the FDA, HCPs and the 
public (Caplovitz & The New Jersey Public Intrest Research Group Law and Policy 
Center, 2006; Psaty, Furberg, & Ray, 2004; Topol, 2004) and have little economic 
incentive to search and publicize information about ADEs associated with their products 
(Stern, 2003). In addition, the sponsoring of false and misleading drug advertisements 
(making unsubstantiated claims and misrepresenting drug risks) by drug manufacturers 
may also play a role (Caplovitz & The New Jersey Public Intrest Research Group Law 
and Policy Center, 2006). However, drug manufacturing companies are required by law 
to forward to the FDA all the ADEs that are reported to them by HCPs or patients. 
 
SN Differences Between Intenders and Non-Intenders 
Pharmacists who intended to report (mean = 5.91, SD = 1.26) had significantly 
higher mean normative beliefs than those who did not intend to report (mean = 5.02, SD 
= 1.43, p < 0.001). Higher SN for ADE reporting predicted higher intention to report 
serious ADEs in the future. Pharmacists intending to report ADEs (mean = 5.15, SD = 
1.47) were more likely to believe that physicians would like them to report serious ADEs 
than those not intending to report (mean = 4.22, SD = 1.72, p < 0.001). The differences in 
normative beliefs between intenders and non-intenders may be explained by differential 





Factors Associated with Subjective Norm 
SN (indirect measures) was negatively associated with years of experience and 
was associated with gender—female respondents had significantly higher SN than males. 
Other studies found a similar association between gender and ADE reporting (Kurz, Van 
Ermen, Roisin, & Belton, 1996; Lee, Chan, Raymond, & Critchley, 1994). Another study 
conducted in Spain however, found male physicians to be more likely to report ADEs 
than female physicians (Figueiras et al., 1999). Using direct measures, this study found 
that the number of hours worked per week was significantly and positively correlated 
with pharmacists‘ SN. The pharmacists who worked less hours were likely to have less 
SN than those who worked more hours. These factors (gender, years of experience, and 
hours worked) should be considered in designing interventions aimed at enhancing the 
SN.  
 
6.8 PERCEIVED BEHAVIORAL CONTROL OVER REPORTING SERIOUS ADES 
As hypothesized, after controlling for A and SN, the belief-based PBC measure 
was a significant and the strongest predictor of intent. This finding implies that 
pharmacists do not have complete volitional control over reporting serious ADEs to the 
FDA and that reporting depends on skills, resources, opportunities, information and 
availability of time. This finding is consistent with other pharmacy-related studies (Farris 
& Schopflocher, 1999; Herbert et al., 2006; Pradel, Obeidat, & Tsoukleris, 2007). The 
findings confirm the importance of PBC in explaining HCPs‘ behavior (Godin et al., 
2008; Godin & Kok, 1996). A meta-analysis found that PBC significantly added to the 
prediction of intention in 65 of the 76 analyses reported in the studies (Godin & Kok, 
1996). In the literature PBC is a stronger predictor of intention and behavior when 
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perceived control is low (Madden, Ellen, & Ajzen, 1992). Thus, interventions are needed 
to increase the self-efficacy and perceived control of pharmacists.  
The results show that pharmacists perceived themselves as having some control 
over reporting and believed that it was mostly up to them whether or not they reported 
serious ADEs to the FDA. However, PBC (direct measure) was not a significant predictor 
of intent to report. This finding should be reviewed with caution given the problems 
associated with directly measuring the PBC construct reported in the literature (Conner & 
Sparks, 1996; Courneya, Conner, & Rhodes, 2006; Kraft, Rise, Sutton, & Roysamb, 
2005) and the small number of items (n = 2) used to measure the construct. The problems 
associated with directly measuring the PBC may explain the non-significance of PBC 
among other studies involving pharmacists (Mashburn et al., 2003; Saengcharoen et al., 
2008; Walker et al., 2004). 
 
Primary Drivers of Perceived Behavioral Control 
Some of the strongest beliefs driving PBC of reporting serious ADEs to the FDA 
were: being a drug expert, a clear knowledge of what constitutes a reportable ADE, 
improved awareness of ADE reporting, and awareness of drug risks by patients. A 
majority of respondents indicated that having a clear knowledge of what constitutes a 
reportable ADE (85.1%), being a drug expert (78.8%) and having improved awareness of 
ADE reporting (71.9%) would enhance their control over reporting. In addition, the 
results of the eight-item knowledge scale showed that many pharmacists (43.3%) were 
not clear on reportable ADEs and how to report ADEs.  Furthermore, a majority of 
respondents (65.7%) considered themselves to have inadequate knowledge concerning 
ADE reporting, a finding corroborated by anecdotal comments made by (some) 
respondents on their questionnaires. Taken together, these findings suggest a substantial 
lack of knowledge of ADE reporting and they (the findings) corroborate previous 
research that suggest that medical professionals (Bateman, Sanders, & Rawlins, 1992; 
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Eland et al., 1999; Hasford et al., 2002; Martin et al., 1998) and pharmacists (Backstrom, 
Mjorndal, & Dahlqvist, 2002; Granas et al., 2007; Green et al., 2001; Sweis & Wong, 
2000) have deficient ADE reporting knowledge. Knowledge of ADE reporting is a major 
driver of PBC, which in turn is associated with intent to report. This study‘s finding 
improves our understanding of how knowledge works in shaping intentions with respect 
to reporting serious ADEs. The positive association between knowledge and ADE 
reporting (who, what, how and where) and the number of ADE reports submitted by 
HCPs has been observed in the literature (Irujo et al., 2007; Lopez-Gonzalez, Herdeiro, & 
Figueiras, 2009).   
Educational interventions have been found to be effective in increasing reporting 
and improving the quality of reports (Backstrom, Mjorndal, & Dahlqvist, 2002; 
Figueiras, Herdeiro, Polonia, & Gestal-Otero, 2006; Green et al., 2001; Hazell & Shakir, 
2006). More training and educational programs (CEs, seminars, undergraduate and post 
graduate pharmacy training) should be offered to pharmacists in order to increase their 
knowledge concerning reporting. Several pharmacists recommended (anecdotal 
comments13) continuing education and training on ADE reporting. In line with the study 
findings, the training and education should cover the types of ADEs that should be 
reported, definition of serious ADEs, how to detect and report ADEs, the operations of 
MedWatch and the benefits/value of pharmacovigilance. All the relevant stakeholders 
(e.g., FDA, employers, and managers/bosses) should prioritize and support the provision 
of ADE reporting education and training to pharmacists. 
A majority of pharmacists believed that increased patient counseling (65.0%) 
would make it easier to report serious ADEs to the FDA. Before pharmacists can report 
                                                 
13 Some of the comments made by the pharmacists include: ―I would like a refresher on ADE reporting‖, 
―There should be continuing education on ADE and reporting‖, ―I would like to know more details on this 





serious ADEs, they need to first identify them. Through spending more time counseling 
patients (e.g., interviewing and advising patients, encouraging patients to ask questions, 
and reconciling medications), pharmacists increase their potential to identify serious 
ADEs (Kuyper, 1993; Nolan, 2000; Viktil & Blix, 2008). The role of patient counseling 
in aiding ADE reporting and improving patient outcomes is established in the literature 
(Nolan, 2000; Viktil & Blix, 2008). However, pharmacists are not adequately devoting 
time to counseling their patients (Farris & Schopflocher, 1999; Pradel, Obeidat, & 
Tsoukleris, 2007; Suh et al., 2001), which can be explained by various factors including 
lack of time, lack of private counseling space, and limited access to relevant patient-
specific clinical data (Amsler et al., 2001).  
Interestingly, a majority of respondents indicated that employer support for ADE 
reporting (78.2%) would make it easier to report serious ADEs. Similarly, Green and 
colleagues (2001) reported that encouragement from managers and departments would 
improve reporting. However, due to commercial pressures in pharmacy practice and the 
high prescription volumes, ADE reporting may not be prioritized by employers and 
managers. Employers and managers should be sensitized to the importance of 
pharmacovigilance and should be encouraged to support pharmacists in their quest to 
report serious ADEs.  
The results of this study also indicate that a majority of pharmacists believed that 
having a complete patient medical history (54.3%) would make it easier to report serious 
ADEs to the FDA. Community pharmacists do not have access to complete patient 
medical histories and some considered this to be an impediment to ADE reporting. 
Without patient medical histories, pharmacists may find it difficult to establish an 
association between a drug and the adverse event. Having access to patients‘ medical 
history may enhance pharmacists‘ confidence in iatrogenic diagnosis and patient 
counseling (Kuyper, 1993) and thus foster reporting. This is particularly relevant given 
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that many pharmacists (35.1%) were not aware that they could report serious ADEs even 
if they did not have all the details (e.g., complete patient history and demographic data).  
Offering financial compensation or some other form of incentive (e.g., lottery 
tickets, educational bulletin linked to educational credits and free advice) has been 
associated with an increased number and improved quality of ADE reports (Bäckström & 
Mjörndal, 2006; Bracchi et al., 2005; Feely, Moriarty, & O'Connor, 1990; Jankovic, 
2003). Direct economic inducements may offset or compensate for the inconveniences 
involved in submitting ADE reports. However, most respondents in other studies did not 
think that economic inducements (e.g., fees or lottery tickets) were an incentive to report 
ADRs (Bäckström & Mjörndal, 2006; Bawazir, 2006; Green et al., 2001). Our findings 
show that most of the respondents (55.1%) indicated that having some type of reward or 
compensation neither made it easier nor more difficult to report serious ADEs. Only 
about a third of respondents indicated that having some type of reward or compensation 
(36.1%) would make it easier to report serious ADEs. 
Most pharmacists believed that lack of time (80.7%) made it more difficult for 
them to report serious ADEs to the FDA. Lack of time is a deterrent to ADE reporting. 
This finding corroborates previous research that suggested that lack of time to fill a report 
or to look for ADEs limits ADE reporting (Bateman, Sanders, & Rawlins, 1992; Bawazir, 
2006; Belton et al., 1995; Granas et al., 2007; Green et al., 2001; Herdeiro et al., 2006; 
Nita, Batty, & Plumridge, 2005; Sweis & Wong, 2000; Vallano et al., 2005; van 
Grootheest, Mes, & de Jong-van den Berg, 2002). The pharmacists‘ working conditions 
and other workplace issues may make it difficult for pharmacists to devote time to 
reporting. These include increased workload (Bateman, Sanders, & Rawlins, 1992; 
Belton et al., 1995), high turnover, shortage of pharmacists, too much time spent on 
insurance-related problems, hectic pace of practice, and increased prescription volumes 
(Amsler et al., 2001; Anonymous, 1999; Gidman, Hassell, Day, & Payne, 2007; Knapp, 
Quist, Walton, & Miller, 2005). Previous studies show that lack of time also affects 
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pharmacists‘ participation in other clinical activities (Coleman, 2003; Janke & 
Plamondon, 1997; Pradel, Obeidat, & Tsoukleris, 2007; Venkataraman, Madhavan, & 
Bone, 1997). There is an urgent need to address these organizational factors so that 
pharmacists can find more time to submit reports. One suggestion is to incorporate ADE 
reporting into the daily routines of pharmacists through linking the dispensing computer 
software to the online MedWatch reporting form. Such convergence will allow 
pharmacists to submit ADE reports as part of dispensing or through a touch of a button. 
Furthermore, the software can be designed to automatically populate patient and drug 
information on the MedWatch form. If implemented, this measure will reduce the time 
needed to submit a report and also make reporting more convenient than at present. 
Information gathered during focus groups shows that pharmacists think that such 
computerized support would be valuable. In addition, the time required to report can be 
reduced through further simplifying the MedWatch form and streamlining the reporting 
process, which have been reported to increase ADE reporting rates (Brewer & Colditz, 
1999). 
 
Factors Associated with Perceived Behavioral Control 
Pharmacists who were in practice for a longer time were likely to have lower PBC 
over reporting than those who had fewer years of experience.  In addition, using indirect 
measures, there was a significant difference in mean PBC ratings toward reporting 
serious ADEs by pharmacists‘ ethnicity with the African American/non Hispanic black 
group having higher perceived control than the Caucasian/non-Hispanic white group. 
Knowledge levels were positively correlated with PBC over reporting serious ADEs, 
indicating that pharmacists who had more knowledge of ADE reporting perceived 
themselves to have more control over reporting serious ADEs. Personal factors may be 
playing a role in shaping reporting decision-making and should be targeted in behavior 
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change strategies. The pharmacists with more years of practice experience, Caucasians, 
and those who are less knowledgeable of ADE reporting should be prioritized.  
 
 
6.9 PAST REPORTING BEHAVIOR 
As expected, the addition of past reporting behavior (PRB) construct to the TPB 
model significantly increased the power of the regression model in explaining intention to 
report serious ADEs to the FDA. The R
2 
change for both the direct and indirect measures 
models were significant (p < 0.05). Pharmacists who had reported serious ADEs in the 
past had higher intentions to report serious ADEs than those who had never reported. The 
results of this study confirm the findings of previous studies that reported that the 
addition of past behavior significantly improved the prediction of intention over and 
above the TPB constructs (Albarracin et al., 2001; Bagozzi, 1981; Hart & Morris, 2008; 
Leone, Perugini, & Ercolani, 1999; Mashburn et al., 2003; Quine & Rubin, 1997; Walker, 
Grimshaw, & Armstrong, 2001). Taken together, these findings indicate that past 
behavior is an important predictor and, thus, should be included in models of ADE 
reporting intentions among pharmacists.  
The study results show that seven percent of the respondents had reported ADEs 
in the previous 12 months and 32 percent had reported ADEs to the FDA in the past, 
although about 45 percent of pharmacists indicated that they had encountered reportable 
ADEs in their practice in the past. The proportion of pharmacists who had ever reported 
ADEs (32%) in this study is comparable to the proportion of reporters found in previous 
studies: 33.2 percent obtained among Dutch doctors (Belton & The European 
Pharmacovigilance Research Group, 1997) and 33.7 percent obtained among Swedish 
general practitioners and hospital pharmacists (Bäckström et al., 2000). Other studies 
found lower percentages of healthcare professionals (HCPs) who had ever reported 
ADRs: 25.6 percent (Green et al., 2001), 23.3 percent (Irujo et al., 2007), and 19.4 
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percent (Belton & The European Pharmacovigilance Research Group, 1997). However, 
other studies reported higher percentages of HCPs who had ever reported ADRs (Belton 
et al., 1995; Eland et al., 1999).   
The study results show that a large proportion of respondents are not fully 
engaged in reporting ADEs to the FDA, despite them having favorable BI, A, SN and 
PBC toward reporting. Similar findings were reported in the non-pharmacy (Fried, 
DeVore, & Dailey, 2001; Meyer, Battles, Hart, & Tang, 2003), and pharmacy (Granas et 
al., 2007; Lee et al., 1994; Pradel, Obeidat, & Tsoukleris, 2007) literature. In these 
studies, a majority of pharmacists had a favorable A towards the behavior yet most of 
them were not performing the behavior. Lee (1994) reported that 93 percent of 
pharmacists agreed that ADR reporting was important, yet only 14.7 percent had done so 
in the previous year. These results may mean that pharmacists viewed intention and 
performance as being mutually exclusive (Meyer et al., 2003), or indicate existence of 
challenges that impede the translation of intentions into behavior. There are several 
factors that may moderate the intention-behavior link and consistency (Eccles et al., 
2006; Sheeran, 2002; Sutton, 1998; Webb & Sheeran, 2006). Some of the factors include 
the presence of facilitating conditions, (perceived) control over the behavior, the extent to 
which the behavior is habitual, stability and context of performance, frequency of 
behavior performance, coping appraisals (e.g., perceptions of the efficacy and costs), 
strength of the respective intentions, time interval between intention and behavior, type of 
behavior measure (objective vs. self-report) and type of sample (Armitage, Sheeran, 
Conner, & Arden, 2004; Randall & Wolff, 1994; Sheeran & Orbell, 1998; Sheeran, 
Trafimow, & Armitage, 2003; Triandis, 1980; Wood & Quinn, 2005). Owing to the 
above factors, BI may prove to be a poor predictor of behavior.  
Studies of healthcare professionals on reporting show that low reporting may be 
due to several factors including lack of motivation, cues to action and not prioritizing 
ADE reporting (Giraldo-Matamoros, Alvarez-Díaz, & Ramos-Aceitero, 2007; Irujo et al., 
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2007; WHO Collaborating Centre for International Drug Monitoring and The Uppsala 
Monitoring Centre, 2002). It has been established that cues to action are necessary to 
trigger action or behavioral change (Gasparotto, 2007; Rosenstock, 1974). ―Cues to 
action are external events that prompt a desire to make a health change… A cue to action 
is something that helps move someone from wanting to make a health change to actually 
making a change‖ (Boskey, 2009, p. no page number). Cues to action can be anything 
(e.g., a person or event) that can trigger action or behavior change. Without appropriate 
cues to action, busy pharmacists tend to forget to report ADEs (Irujo et al., 2007; 
Kingston, Evans, Smith, & Berry, 2004). Thus, they may need to be periodically 
prompted to report ADEs (Figueiras et al., 2006). Appropriate cues to action not only 
trigger action/reporting but may also rekindle the pharmacists‘ motivation to report ADEs 
(Simon, 2002). Reporting cues that can be implemented include: a) promotion of the 
professional and public health benefits of ADE reporting; b) sending out drug safety 
bulletins to all pharmacists by the FDA; c) publishing more journal articles on ADE 
reporting; d) television advertisements and programs; e) provision of specific and 
detailed feedback to all who report serious ADEs; and f) provision of education and 
training. Cues to action are effective in increasing reporting rates among HCPs. For 
example, in New Zealand, ―The use of especially designed prescription pads which 
prompted doctors to report on new drugs separately increased the reporting rate 14-fold‖ 
(Edwards, 1999, p. 140).  
 
6.10 PERCEIVED MORAL OBLIGATION  
The addition of the PMO construct to the TPB constructs (direct and indirect 
measures) significantly improved the prediction of intention; the change in R-squared 
was significant. This finding corroborates previous research that found that PMO is an 
important predictor of intention especially in moral situations (Fazekas, Senn, & 
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Ledgerwood, 2001; Gorsuch & Ortberg, 1983; Randall & Gibson, 1991; Werner & 
Mendelsson, 2001). A systematic review of studies based on social cognitive theories 
among HCPs‘ intentions and behavior found moral norm to be a consistently significant 
cognitive factor explaining intention (Godin et al., 2008). Moral norm (equivalent of 
PMO) was significant (p < 0.05) in 10 of the 14 studies assessed (Godin et al., 2008). 
This study was the first to examine the direct path from moral norm to intention to report 
serious ADEs by pharmacists.  
The results show that a large number of pharmacists believed that they had a 
moral obligation to report serious ADEs that they encounter to the FDA. This finding 
may suggest that ADE reporting is a moral issue or a professional responsibility for 
pharmacists. Pharmacists in other countries also feel that they have a professional 
obligation to report ADRs (Green et al., 2001; Herdeiro et al., 2006; Vessal, Mardani, & 
Mollai, 2009) and ADE reporting is their professional duty (Figueiras et al., 1999). 
Physicians also believe that reporting ADEs is their professional duty and the WHO 
consider ADE reporting as a part of HCPs‘ duties (Figueiras et al., 1999; World Health 
Organization, 2002a).  
 
6.11 INSTITUTIONAL AND ORGANIZATIONAL CHANGES 
The continued occurrence of serious ADE underreporting may suggest an 
existence of inadequacies and shortcomings in the current institutional and organizational 
arrangements for addressing postmarketing surveillance (PMS) activities. As noted in 
Chapter Two, the licensing and labeling of all medicines and their PMS are conducted14 
by the FDA‘s Center for Drug Evaluation and Research (CDER). The FDA seems to pay 
more attention to evaluating new drugs than to PMS, as fewer resources (e.g., staff and 
                                                 
14
 There is a potential conflict between these roles as data from PMS activities often result in labeling 
changes or reversal of previous approval decisions or provide evidence to prove the initial approval 
decision was incorrect (Fontanarosa, Rennie, & DeAngelis, 2004; Wood, Stein, & Woosley, 1998). 
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funds) are channeled toward PMS activities. PMS activities at the FDA are also 
hampered by limited capacity, high attrition, lack of analytical sophistication, low staff 
morale, the existence of multiple competing priorities and limited regulatory authority 
over enforcement (Griffin, Stein, & Ray, 2004; Institute of Medicine of the National 
Academies, 2007a; Schmit, 2007; United States General Accounting Office, 2003; Wood, 
Stein, & Woosley, 1998). As a result, the FDA takes a long time to recognize and address 
safety signals, and to inform the public about safety problems. Little is being done to 
stimulate pharmacists and other HCPs to report ADEs (Institute of Medicine of the 
National Academies, 2007a). Furthermore, PMS is not comprehensive or systematic and 
is sub-optimal (Institute of Medicine of the National Academies, 2007a, p. 108; Moore, 
Psaty, & Furberg, 1998; Strom, 2006; Wood, Stein, & Woosley, 1998), thereby further 
exacerbating underreporting of serious ADEs.  
Several long-term solutions have been suggested to enhance PMS or to increase 
ADE reporting including reforming and restructuring the FDA, and increasing resources 
to the FDA. Suggestions for restructuring and reforming the FDA that are relevant to 
PMS include decentralizing the FDAs PMS activities and establishing an independent 
drug safety board, respectively. These are briefly discussed below.  
One suggestion for decentralizing the FDA‘s PMS activities includes establishing 
MedWatch regional reporting centers, similar to the New York Patient Occurrence and 
Tracking System (NYPORTS) (Motl, Timpe, & Eichner, 2004). The proposed regional 
centers can collect and evaluate serious ADEs, provide feedback to reporters, encourage 
HCPs to report, forward reported ADEs to MedWatch and provide targeted outreach 
support to HCPs including pharmacists. The proposed regional reporting centers can be 
integrated into the existing drug information centers (DICs) and poison control centers 
that most HCPs are already familiar and comfortable with (Motl, Timpe, & Eichner, 
2004). The establishment of regional centers in the Netherlands, United Kingdom, 
France, and Spain helped bring the centers closer to reporters and resulted in more and 
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better quality ADE reports (Clarkson, Ingleby, Choonara, Bryan, & Arlett, 2001; Motl, 
Timpe, & Eichner, 2004). 
The current institutional setup can be improved through the establishment of a 
drug safety board, that is independent of both the FDA and drug manufacturers, to 
oversee drug PMS activities (Griffin, Stein, & Ray, 2004; Moore, Psaty, & Furberg, 
1998; Okie, 2005; Psaty & Furberg, 2005; Wood, Stein, & Woosley, 1998). The board 
may oversee the management of drug safety-related issues and make recommendations to 
improve drug safety to the FDA and the medical community. The establishment of such 
an agency would minimize conflicts of interests (separate post-marketing from new drug 
approval functions), separate powers, and ensure objectivity in the investigation of ADEs 
(Fontanarosa, Rennie, & DeAngelis, 2004; Psaty & Furberg, 2005; Wood, Stein, & 
Woosley, 1998). In 2005, the FDA established a Drug Safety Oversight Board to:  
Improve public knowledge of emerging important drug safety concerns; 
strengthen internal drug safety management; foster practical policy development 
to improve consistency and timely resolution of important drug safety concerns; 
and provide a standing venue for resolution of CDER organizational disputes 
(Cummins, 2006, p. 1). 
The board consists of FDA staff (n = 10) and medical officers from other U.S. 
Department of Health and Human Services agencies (n = 2). This board falls short of the 
independent external oversight of drug safety that many have recommended (Wood, 
Stein, & Woosley, 1998). The effectiveness of the current board is compromised by the 
lack of resources, authority, and most importantly independence from the FDA (Harris, 
2005).  
The implementation of the above changes needs to be complemented with the 
provision of increased resources (e.g., staff and information technology) to the FDA to 
carry out drug safety work. The following recommendations have been forwarded for 
increasing FDA resources for PMS:  
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 Increase appropriations from Congress: Many have called for Congress to increase 
the resources appropriated to the FDA for carrying out PMS activities (Institute of 
Medicine of the National Academies, 2007a). Public funding is considered the best 
way to support the FDA‘s PMS activities (Institute of Medicine of the National 
Academies, 2007a). 
 Reduce restrictions on the Prescription Drug User Fees Act (PDUFA) funds: 
Currently, only a small portion (5%) of the user fees (fees paid by pharmaceutical 
companies to the FDA) collected can be used for PMS activities. The FDA can raise 
more funds for PMS activities, if the current restrictions on the use of fees raised 
under PDUFA are relaxed (Zelenay, 2005). 
 Introduce a tax: A small tax on prescriptions has been suggested as a way to raise 
funds for PMS activities. For example, ―a tax of ten cents on every prescription would 
generate more than $100 million for the FDA budget‖ (Institute of Medicine of the 
National Academies, 2007a, p. 198). Others have suggested a tax on direct-to-
consumer advertisements for new drugs (Institute of Medicine of the National 
Academies, 2007a). 
 
6.12 IMPLICATIONS AND DIRECTIONS FOR FUTURE RESEARCH 
There is an urgent need to increase ADE reporting rates by pharmacists. Although 
all pharmacists are responsible for ensuring the safe use of medicines, of which ADE 
reporting is an integral part, low ADE reporting rates among pharmacists persists. The 
failure to report serious ADEs that pharmacists encounter is a missed opportunity for 
preventing unnecessary and avoidable patient harm from drug use. Although most of our 
sample encountered reportable ADEs, only seven (7) percent reported submitting ADE 
reports to the FDA in the previous 12 months. There is an urgent need to boost ADE 
reporting rates among pharmacists. 
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All three TPB constructs (A, SN and PBC) were associated with an increased 
likelihood of intent to report serious ADEs. Pharmacists‘ overall evaluation of reporting 
serious ADEs, their perceived expectation of important others with respect to their 
reporting of serious ADEs and their beliefs about the degree of control they had over 
reporting serious ADEs are important and positive influences on intention. Interventions 
may need to focus on increasing pharmacists‘ A, SN and PBC. The application of the 
TPB holds promise for Texas pharmacists by identifying potentially modifiable factors 
for increasing intention and actual reporting of serious ADEs to the FDA. More serious 
ADE reports (safety signals) will facilitate the identification of unsafe products, facilitate 
the education and training of HCPs on the safe use of medicines and inform better and 
safer ways to use the available medicines. In the long term, improved reporting will 
minimize the potential for patient exposure to avoidable drug risks.  
An understanding of the factors affecting pharmacists‘ A provides insight into 
strategies to increase ADE reporting by pharmacists. The most salient beliefs of the 
pharmacists were: (reporting) improves patient safety, educates others about drug risks, 
reduces the risk of malpractice, and builds trust with patients. Strategies to increase ADE 
reporting should address these beliefs to enhance pharmacists‘ A. The pharmacists‘ 
positive A can be enhanced through various ways including providing incentives for 
reporting, providing verbal expression of support for ADE reporting by the FDA and 
managers/bosses, among others, and educating pharmacists on the value/benefits of ADE 
reporting to the profession.  
SN plays an important role in the formulation of intentions to report serious 
ADEs. This may imply that ADE reporting is influenced by others more than by the 
pharmacists‘ individual choices and that the opinions of others are of great importance in 
pharmacists‘ decision making. Interventions that enhance pharmacists‘ positive social 
norms may be effective in changing ADE reporting behavior. The most salient referents 
driving SN were the FDA, patients, pharmacy associations, pharmacy managers/bosses 
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and hospitals/hospital groups. Using the FDA, patients, pharmacy associations and 
pharmacy managers/bosses to communicate with pharmacists the need to report serious 
ADEs may be effective and worthwhile.   
Because PBC (indirect measures) emerged as the strongest predictor of intention 
to report serious ADEs, interventions would be most beneficial if they targeted 
pharmacists‘ perceived barriers towards ADE reporting. The most important barriers 
perceived by the pharmacists include not being a drug expert, lack of knowledge of what 
constitutes a reportable ADE, limited awareness of ADE reporting, limited awareness of 
drug risks by patients and limited patient counseling. Interventions may need to focus on 
increasing the self-efficacy and perceived control of pharmacists through education (e.g., 
CEs) on ADE reporting and ADEs and through professional campaigns that use role 
models or peer educators to encourage ADE reporting. In addition, pharmacy managers 
and the FDA need to ensure that pharmacists have sufficient resources and psychological 
support for reporting and to make reporting as convenient as possible.  
The findings of this study show that PRB and PMO enhanced the prediction of 
intentions to report serious ADEs to the FDA over and above the TPB constructs (A, SN 
and PBC). Similarly, other studies found that the inclusion of PRB and PMO increased 
the proportion of explained variance in intention (Albarracin et al., 2001; Bagozzi, 1981; 
Fazekas, Senn, & Ledgerwood, 2001; Gorsuch & Ortberg, 1983; Hart & Morris, 2008; 
Leone, Perugini, & Ercolani, 1999; Mashburn et al., 2003; Nwokeji, 2007; Quine & 
Rubin, 1997; Randall & Gibson, 1991; Walker, Grimshaw, & Armstrong, 2001; Werner 
& Mendelsson, 2001). Taken together, these findings indicate that PRB and PMO are 
important predictors and, thus, should be included in models of ADE reporting intentions 
among pharmacists. Interventions to increase ADE reporting should enhance 
pharmacists‘ perception of their moral norms concerning ADE reporting. This can be 
done through portraying ADE reporting as promoting the wellbeing of others, and 
avoiding harm and distress to others (beneficence and nonmaleficience). In addition, to 
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enhance the PRB, interventions should give pharmacists an opportunity to practice 
reporting serious ADEs.  
There are several issues that need further investigation. First, the study population 
consists of Texas practicing pharmacists, and therefore, the results cannot be extrapolated 
to non-practicing pharmacists or to pharmacists in other states. More empirical research 
should be conducted to confirm the study findings using a different population.  
Second, more experimental designs (use of a control group) that can offer an 
insight on causality of predictors should be conducted. This could be set up through 
having intervention and control groups. Using longitudinal data would provide 
conclusive evidence of the causal relationships among the constructs. 
Third, this study focused on pharmacists‘ intention to report serious ADEs to the 
FDA.  More research should be conducted to investigate the link between intention to 
report serious ADEs and actual behavior and also between PBC and behavior. Typically, 
A, SN, PBC and intention should be measured and then behavior measured after a time 
interval (Montano & Kasprzyk, 2002). The intention-behavior relationship is an 
important component of the TPB. The resulting information could provide further 
opportunities for influencing behavior.  
Fourth, the frequency and consistency of ADE reporting by pharmacists was not 
investigated in this study and is largely unknown. The TPB is primarily a model of 
intention formation and does not effectively distinguish regular and consistent reporters 
from one-time reporters nor is it effective in predicting the maintenance of behavior over 
time (Sheeran, Conner, & Norman, 2001). Future studies should be conducted to predict 
the frequency (never reported, reported once, and reported multiple times) and 
consistency of ADE reporting by pharmacists.  Processes of change  based on the 
transtheoretical model (Prochaska, DiClemente, & Norcross, 1992) may provide valuable 
insights on the differences between consistent reporters and non-consistent reporters. 
Understanding these processes and differences could further enhance the prediction of 
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pharmacists‘ intention to report serious ADEs to the FDA and actual subsequent 
behavior.  
Finally, future research should pay more attention to the reporting context. The 
use of vignettes or hypothetical serious ADEs could help contextualize the performance 
of ADE reporting. Vignettes and hypothetical ADEs have been successfully used to 
predict physician prescribing and reporting behavior (Eland et al., 1999; Harrell & 
Bennett, 1974) and pharmacists‘ reporting behavior (Green et al., 2001). Vignettes and 
hypothetical cases may be effective in predicting pharmacists‘ reporting of serious ADEs.  
 
6.13 LIMITATIONS 
Findings of this study should be interpreted in light of its limitations as discussed 
below. First, this study used a cross-sectional study design and the findings provide a 
snapshot picture only. The study does not unequivocally demonstrate the causal nature of 
the structural relationships and these relationships may change over time. 
Second, the study used self-reports from pharmacists which are prone to 
inaccurate responses. The study could not verify the pharmacists‘ responses since the 
responses were anonymous. The pharmacists‘ responses could have been influenced by 
response bias, poor recall or social desirability factors associated with an expected 
behavior. It has been reported that physicians overestimate their adherence to guidelines 
in their self-reports by as much as 20 percent (Adams, Soumerai, Lomas, & Ross-
Degnan, 1999). Some pharmacists may have provided socially desirable responses to 
questions especially pertaining to A, SN, PBC and intentions. This leads to difficulties in 
interpreting the findings, especially if people differentially overestimate their 
performance. However, responses in this study were anonymous and a majority of those 
who responded admitted that they had never reported ADEs. Although, this is no 
guarantee of accuracy of the data, it seems there was no incentive to be deceptive.   
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Third, despite using a second mailing to improve the survey response rate, only 
26.4 percent of the selected sample returned complete survey responses. Since the study 
was anonymous, non-responders and responders could not be compared. Selection bias 
may be a problem; it is possible that the study mainly attracted pharmacists with high 
intentions and favorable attitudes toward ADE reporting.  This low response rate may 
limit the generalizability of the results from this study.  
Fourth, the length of the survey may have discouraged some potential responders. 
The survey, designed following TPB guidelines, was 6 pages long and consisted of 94 
items. Some respondents may have found the survey instrument used in this study to be 
too long. In addition, some items in the questionnaire had similar wording. Some 
respondents may have considered some similarly worded questions to be the same, thus 
leading them to doubt their own responses (Young, Lierman, Powell-Cope, Kasprzyk, & 
Benoliel, 1991), or to pay less attention to these questions, resulting in response set bias 
(Meyer et al., 2003). 
Fifth, PBC (direct measure) and PRB were each measured using only two (2) 
items. A measure with more than two (2) items is likely to have higher internal 
consistency. However, at the time of this study, the author was unaware of other 
measures that had undergone methodological testing for construct validity.  
Sixth, the correlations among variables and constructs in this study may have 
been artificially inflated owing to shared method and shared sources (e.g., self-report 
measures). It was not feasible to collect data through other methods and from other 
sources given the anonymity of the ADE reporting process.  
Seventh, the items used to measure intentions were not precise on the time frame 
of the intentions. This was due to the difficulty in predicting the timing of pharmacists‘ 
next encounter with serious ADEs. It was assumed that the time pertained to the next 
time pharmacists will encounter serious ADEs. Similar challenges have been encountered 
in coming up with operational definitions of intention in studies of physician samples, 
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given the complexity of clinical-related behaviors (Godin et al., 2008). The fact that the 
intention measure did not specify the time frame could have inflated the intention scores 
and may reduce the accuracy of intention in predicting future behavior. However, it 
seems unlikely this consideration seriously threatens the validity of the present analyses, 




The study findings indicated that a majority of pharmacists held favorable 
behavioral, normative and control beliefs concerning reporting of serious ADEs. 
Pharmacists intended to report serious ADEs that they encounter to the FDA. The study 
data supported the TPB model: A, SN and PBC predicted pharmacists‘ intentions to 
report serious ADEs, explaining 34.0 percent (direct measures) and 28.8 percent (indirect 
measures) of the variance in intention. In general, the data were consistent with the 
predicted relationships among the TPB model components (A, SN, PBC, and BI). 
Although the PBC (direct measure) was not a significant predictor of intent to report, but 
as hypothesized, after controlling for A and SN, the belief-based PBC measure was a 
positive and the strongest predictor of intent. The TPB appears to be an appropriate 
theoretical model and a useful framework for studying pharmacists‘ reporting of serious 
ADEs.  
PRB and PMO increased the explanatory power of the regression model 
compared to only using the A + SN + PBC to explain pharmacists‘ intention to report 
serious ADEs. PRB and PMO had a strong effect on intention beyond the TPB 
constructs. The fit of the model on pharmacist ADE reporting intentions may be 
improved through the addition of PRB and PMO constructs to the TPB. 
The pharmacists‘ A, SN, and PBC toward reporting serious ADEs were mostly 
unrelated to practice characteristics and demographic factors. Pharmacists‘ knowledge of 
ADE reporting was the only characteristic that was significantly related with all the TPB 
constructs using both direct and indirect measures. Pharmacists‘ A, SN, PBC may be 
modified through increasing their knowledge concerning reporting. Modifying 
pharmacists‘ beliefs through educational interventions and breaking down the barriers to 
reporting are likely to be successful in increasing pharmacists‘ reporting of serious ADEs 
to the FDA. More training and educational programs (CEs, seminars, undergraduate and 
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post graduate pharmacy training) related to ADE reporting should be offered to 
pharmacists. All the relevant stakeholders (e.g., FDA, employers, and managers/bosses) 
should prioritize and support the provision of ADE reporting education and training to 
pharmacists. 
This study is the first to use a theoretical model to examine pharmacists‘ intention 
to report serious ADEs. Based on the TPB, this study identified the predictors of Texas 
pharmacists‘ intention to report serious ADEs to the FDA through MedWatch. The study 
findings offer a theoretically-based understanding of individual factors that influence 
pharmacists‘ intention to report serious ADEs. Public health officials, drug safety experts 
and pharmacy educators can gain insight from these findings in developing strategies to 
increase ADE reporting by pharmacists. Pharmacy educators need to further examine the 
results of this study and use them to direct teaching strategies. Solving the problem of 






















We are interested in factors that influence your willingness to report serious adverse drug events 
(ADEs) to the U.S. Food and Drug Administration (FDA) through the MedWatch program. 
Please answer the following questions to the best of your knowledge of ADE reporting.  
 
First, we would like to determine your beliefs about pharmacists reporting serious ADEs to the 
FDA. Please circle the number that corresponds to your choice using the scales listed below. 
 
1. How likely do you think the 
following outcomes will be if you 






unlikely   
Extremely  
likely 
a. educates others about drug risks 1 2 3 4 5 6 7 
b. personally beneficial/rewarding to 
the pharmacist  
1 2 3 4 5 6 7 
c. improves patient safety 1 2 3 4 5 6 7 
d. increases risk of malpractice 1 2 3 4 5 6 7 
e. compromises relationship with 
physicians  
1 2 3 4 5 6 7 
f. breaks trust with patients 1 2 3 4 5 6 7 
g. disrupts the normal workflow 1 2 3 4 5 6 7 
h. time consuming to report   1 2 3 4 5 6 7 
 
 
Even though you may not agree with the outcomes listed, how good or bad do you feel each of the     
following outcomes would be if you reported serious ADEs to the FDA?  
 
2. How good or bad do you feel each 
of the following outcomes would 




  Neither  
bad  
nor good 
  Extremely 
good 
a. educates others about drug risks 1 2 3 4 5 6 7 
b. personally beneficial/rewarding to 
the pharmacist 
1 2 3 4 5 6 7 
c. improves patient safety 1 2 3 4 5 6 7 
d. increases risk of malpractice 1 2 3 4 5 6 7 
e. compromises relationship with 
physicians  
1 2 3 4 5 6 7 
f. breaks trust with patients 1 2 3 4 5 6 7 
g. disrupts the normal workflow 1 2 3 4 5 6 7 




Next, please circle the number that corresponds to your level of intention with the following statements. 
 
3. I intend to report serious ADEs that I will encounter to the FDA. 
extremely unlikely 1 2 3 4 5 6 7 extremely likely 
 
4. I will try to report serious ADEs that I will encounter to the FDA. 
strongly disagree 1 2 3 4 5 6 7 strongly agree 
 
5. I plan to report serious ADEs that I will encounter to the FDA. 
strongly disagree 1 2 3 4 5 6 7 strongly agree 
 
Next, we would like to know how you feel about reporting ADEs. Please complete the following 
statement based on each of the following adjectives. 
 
 
6. I feel that reporting serious ADEs to the FDA each time I encounter them is: 
 
Worthless -3 -2 -1 0 1 2 3 Valuable 
Unpleasant  -3 -2 -1 0 1 2 3 Pleasant 
Bad -3 -2 -1 0 1 2 3 Good 
Unenjoyable -3 -2 -1 0 1 2 3 Enjoyable 
Harmful -3 -2 -1 0 1 2 3 Beneficial 
 
Next, we are interested in what groups or individuals would influence your willingness to report serious 
ADEs to the FDA. Please circle the number that corresponds to your choice using the scales listed below. 
 
7. How likely is it that each of the 
following groups or individuals 
would think that you should report 
serious ADEs to the FDA? 
Very 
unlikely 
  Neither  
likely nor 
unlikely 
  Very  
likely 
a. Physicians 1 2 3 4 5 6 7 
b. Patients 1 2 3 4 5 6 7 
c. Drug manufacturers 1 2 3 4 5 6 7 
d. Food and Drug Administration 1 2 3 4 5 6 7 
e. Pharmacy associations 1 2 3 4 5 6 7 
f. Family/spouse/significant others 1 2 3 4 5 6 7 
g. Pharmacy managers/bosses 1 2 3 4 5 6 7 
h. Hospitals or hospital groups 1 2 3 4 5 6 7 




8. Generally speaking, how likely are 
you to do what the following 
individuals or groups would want 




  Neither  
likely nor 
unlikely 
  Very  
likely 
a. Physicians 1 2 3 4 5 6 7 
b. Patients 1 2 3 4 5 6 7 
c. Drug manufacturers 1 2 3 4 5 6 7 
d. Food and Drug Administration 1 2 3 4 5 6 7 
e. Pharmacy associations 1 2 3 4 5 6 7 
f. Family/spouse/significant others 1 2 3 4 5 6 7 
g. Pharmacy managers/bosses 1 2 3 4 5 6 7 
h. Hospitals or hospital groups 1 2 3 4 5 6 7 
i. Other pharmacists (colleagues/peers) 1 2 3 4 5 6 7 
 
 
9. Most people who are important to me think that 
I should not -3 -2 -1 0 1 2 3 I should 
report serious ADEs that I encounter to the FDA. 
 
10. The people in my life whose opinions I value would 
Disapprove -3 -2 -1 0 1 2 3 Approve 
my reporting of serious ADEs that I encounter to the FDA. 
 
11. The pharmacists whose opinions I value 
Do not report  -3 -2 -1 0 1 2 3 Report  
serious ADEs to the FDA. 
 
 
12. I believe I have a moral obligation to report serious ADEs that I will encounter to the FDA. 




Next, we are interested in the extent to which the following factors would make it easy or difficult for you 
to report serious ADEs to the FDA. Please circle the number that corresponds to your choice using the 
scales below.  
 
13. How easy or difficult will the 
following factors make it for 
you to report serious ADEs 








  Extremely  
easy 
a. a complete patient medical history 1 2 3 4 5 6 7 
b. lack of time 1 2 3 4 5 6 7 
c. improved awareness of ADE 
reporting 
1 2 3 4 5 6 7 
d. a streamlined MedWatch form and 
reporting process  
1 2 3 4 5 6 7 
e. employer support of ADE    
reporting 
1 2 3 4 5 6 7 
f. some type of reward or 
compensation 
1 2 3 4 5 6 7 
g. ADE reporting as a part of the 
normal workflow 
1 2 3 4 5 6 7 
h. increased patient counseling 
(spending more time with 
patients) 
1 2 3 4 5 6 7 
i. awareness of drug risks by patients 1 2 3 4 5 6 7 
j. being a drug expert 1 2 3 4 5 6 7 
k. clear knowledge of what 
constitutes a reportable ADE (e.g., 
definition) 





14. How much control do you feel 
you have over the following 
factors when it comes to 




  Neither  
complete  




  Complete 
control 
a. a complete patient medical history 1 2 3 4 5 6 7 
b. lack of time 1 2 3 4 5 6 7 
c. awareness of ADE reporting 1 2 3 4 5 6 7 
d. a streamlined MedWatch form and 
reporting process  
1 2 3 4 5 6 7 
e. employer support of ADE reporting 1 2 3 4 5 6 7 
f. some type of reward or 
compensation 
1 2 3 4 5 6 7 
g. ADE reporting as a part of the 
normal workflow 
1 2 3 4 5 6 7 
h. increased patient counseling 
(spending more time with patients) 
1 2 3 4 5 6 7 
i. awareness of drug risks by patients 1 2 3 4 5 6 7 
j. being a drug expert  1 2 3 4 5 6 7 
k. clear knowledge of what constitutes 
a reportable ADE (e.g., definition) 
1 2 3 4 5 6 7 
 
Next, we would like you to answer the following two statements in a general sense. Please circle the 
number that corresponds to your choice using the scales listed below.  
 
15. It is mostly up to me whether or not I report serious ADEs to the FDA.  
strongly disagree -3 -2 -1 0 1 2 3 strongly agree 
 
16. How much control do you believe you have over reporting serious ADEs that you encounter to the 
FDA? 
no control -3 -2 -1 0 1 2 3 complete control 
       
Next, we would like to know about your past behavior regarding the reporting of ADEs. Please check the 
appropriate response or circle the number where appropriate.  
 











19. Have you encountered any reportable ADEs in your practice in the past? 
__________(1) Yes 
__________(2) No 
__________(3) Don‘t know 
 
Now, we would like to know a little about you and your practice setting so that we can better understand 
your responses. Please check the appropriate response or write in your responses where appropriate.  
 
20. Which of the following best describes your ethnic/racial background? 
________(1) African American/non-Hispanic black 
________(2) American Indian or Alaska Native 
________(3) Asian American/Pacific Islander 
________(4) Caucasian/non-Hispanic white 
________(5) Mexican American/Hispanic 
________(6) Other (please specify)_______________________________________ 
 
21. Please indicate your type of practice setting at your primary place of employment. 
________(1) Community-Independent 
________(2) Community-Multiple/Chain (3 or more pharmacies under common ownership) 
________(3) Hospital-Independent 
________(4) Hospital-Multiple/Chain (3 or more pharmacies under common ownership) 
________(5) Other (please specify)__________________________________________ 
 
22. What is your current job title at your primary place of employment? 
________(1) Pharmacy Owner/Partner 
________(2) Pharmacy Manager/Supervisor 
________(3) Clinical Pharmacist 
________(4) Staff Pharmacist 
________(5) Relief Pharmacist 
________(6) Other (please specify)_________________________________________ 
 
23. What is your gender? 
________ (1) Male 
________ (2) Female 
 
24. In what year where you born?  19________ 
 





26. How many years have you been practicing pharmacy? ________years 
 
27. On average, how many hours per week do you work at your primary place of employment? 
________hours/week 
 
28. On average, how many hours per week do you dispense medication and/or interact with patients at 








30. Based on your knowledge, please circle the number that corresponds 
with your answer.   
True False 
a. All ADEs, irrespective of severity, should be reported to the FDA.  1 0 
b. Pharmacists should report serious ADEs even if they are uncertain that the 
product caused the event. 
1 0 
c. Pharmacists should report serious ADEs even if they do not have all the 
details (e.g., complete patient history and demographic data). 
1 0 
d. All serious ADEs are known before a drug is marketed. 1 0 
e. The FDA does not disclose the ADE reporter‘s identity in response to a 
request from the public. 
1 0 
f. Pharmacists can report ADEs to the FDA anonymously. 1 0 
g. Adverse experiences with cosmetics and special nutritional products (e.g., 
dietary supplements, infant formulas) may be reported to the FDA. 
1 0 
h. One case reported by a pharmacist does not contribute much to knowledge 
on drug risks. 
1 0 
i. I have adequate knowledge on ADE reporting  (e.g., what to report and 
how to report) 
1 0 
 



















Focus Group Invite 
 
Dear Pharmacist Colleague,  
 
You have been selected to participate in a focus group conducted as part of research study 
entitled: A qualitative analysis of the attitudes and beliefs of Texas pharmacists toward reporting 
serious adverse drug events (ADEs). As you may be aware, the Food and Drug Administration 
allows you as a pharmacist to report ADEs that you come across through MedWatch. To date, no 
research has focused on how Texas pharmacists’ beliefs and attitudes toward ADE reporting 
relate to their intent to report ADEs. This focus group is part of a dissertation research project 
being conducted in the Division of Pharmacy Administration at the University of Texas at Austin. 
Up to 12 pharmacists will participate in this focus group. This focus group will determine the 
advantages and disadvantages of reporting ADEs by pharmacists, the factors that would make it 
easier or difficult for pharmacists to report ADEs as well as the individuals or groups who would 
approve or would not approve pharmacists reporting ADEs.  
 
Because you are one of a small group of people selected for this study, we hope that you will 
participate so that our results will be a good representation of Texas pharmacists. Your decision 
to participate or not will not affect your present or future relationship with the University of 
Texas at Austin. Your participation in this study is voluntary. The focus group is expected to last 
approximately 1 – 1 
1
/2 hours. The focus will be conducted at [venue, address] at [time] on the 
[date]. Risks to participants are considered minimal. Sessions will be audio-taped;  
 tapes will be coded so that no personally identifying information is visible on them;  
 tapes will be kept in a secure place (e.g., a locked file cabinet in the investigator’s office);  
 tapes will be heard or viewed only for research purposes by the investigator and his or her 
associates; and 
 tapes will be destroyed after they are transcribed or coded.  
 
If you have any questions, please do not hesitate to contact us by phone at (512) 961-1692 and 
(512) 471-2374 or e-mail pgavaza@mail.utexas.edu and cmbrown@mail.utexas.edu. If you have 
questions about your rights as a research participant, complaints, concerns, or questions about the 
research please contact Jody Jensen, Ph.D., Chair, The University of Texas at Austin Institutional 
Review Board for the Protection of Human Subjects at (512) 232-2685 or the Office of Research 
Support at (512) 471-8871 or email: orsc@uts.cc.utexas.edu. Thank you in advance for your time 
and cooperation in participating in this important study.  
 





Paul Gavaza, M.S.    Carolyn M. Brown, R.Ph., Ph.D. 
Ph.D. Candidate    Professor and Dissertation Advisor 




Appendix D: Focus Group Informed Consent 
IRB Approved on: (ORSC Use Only)   Expires on:  
 
Protocol Title:   
A qualitative analysis of the attitudes and beliefs of Texas pharmacists toward reporting 
serious adverse drug events (ADEs)  
 
Conducted by:  
Paul Gavaza, MS., (pgavaza@mail.utexas.edu), The University of Texas at Austin, College 
of Pharmacy; 512-961-1692 and Carolyn Brown, Ph.D., (cmbrown@mail.utexas.edu), The 
University of Texas at Austin, College of Pharmacy; 512-471-2374.  
 
You are being asked to participate in a research study.  This form provides you with 
information about the study.  The person in charge of this research will also describe this 
study to you and answer all of your questions. Please read the information below and ask any 
questions you might have before deciding whether or not to take part.  Your participation is 
entirely voluntary.  You can refuse to participate without penalty or loss of benefits to which 
you are otherwise entitled.  You can stop your participation at any time and your refusal will 
not impact current or future relationships with UT Austin or participating sites.  To do so 
simply tell the researcher you wish to stop participation.  The researcher will provide you 
with a copy of this consent for your records. 
 
Purpose of the research study:  
This purpose of the study is to identify the advantages and disadvantages of reporting ADEs 
by pharmacists as well as the individuals or groups who would approve or would not approve 
pharmacists reporting ADEs. The study will also discuss the factors that would make it easier 
or difficult for pharmacists to report ADEs.  
 
What you will be asked to do in the study:  
This meeting could have up to 11 other pharmacists.  If you agree to participate in this study, 
we will ask you to do the following things: 
 Participate in a focus group discussion; and  
 Respect and protect the confidentiality of the other participants in this focus group.  
 
Time required:  
1 - 11/2 hours  
 
Risks: 
Loss of confidentiality 
 The researchers will protect the confidentiality of all participants in this focus group by 
using pseudonyms when transcribing.  The tapes will be kept locked in the principal 
investigator‘s office.  After they have been transcribed, the tapes will be destroyed. 
 This study may involve risks that are currently unforeseeable. If you wish to discuss the 
information above or any other risks you may experience, you may ask questions now or 




Benefits of being in the study are to identify advantages, disadvantages, factors that would 
make it easier or difficult to report ADEs and the individuals and groups who would approve 
of pharmacists reporting ADEs.  
 
Compensation: 
 There is $25.00 compensation for participation. 
 
Confidentiality and Privacy Protections: 
 Sessions will be audio-taped;  
o tapes will be coded so that no personally identifying information is visible on them;  
o tapes will be kept in a secure place (e.g., a locked file cabinet in the investigator‘s 
office);  
o tapes will be heard or viewed only for research purposes by the investigator and his 
or her associates; and 
o tapes will be destroyed after they are transcribed or coded.  
 
The records of this study will be stored securely and kept confidential.  Authorized persons 
from The University of Texas at Austin, members of the Institutional Review Board, and (study 
sponsors, if any) have the legal right to review your research records and will protect the 
confidentiality of those records to the extent permitted by law.  All publications will exclude 
any information that will make it possible to identify you as a subject.  Throughout the study, 
the researchers will notify you of new information that may become available and that might 
affect your decision to remain in the study. 
 
Contact and questions: 
If you have any questions about the study please ask now.  If you have questions 
later, want additional information, or wish to withdraw your participation call the researchers 
conducting the study.  Their names, phone numbers, and e-mail addresses are at the top of 
this page.  If you have questions about your rights as a research participant, complaints, 
concerns, or questions about the research please contact Jody Jensen, Ph.D., Chair, The 
University of Texas at Austin Institutional Review Board for the Protection of Human 
Subjects at (512) 232-2685 or the Office of Research Support and Compliance at (512) 471-
8871 or email: orsc@uts.cc.utexas.edu. 
  
You will be given a copy of this information to keep for your records. 
 
Agreement: 
I have read the above information and have sufficient information to make a decision about 
participating in this study.  I consent to participate in the study. 
 
Signature:________________________________________ Date: __________________ 
 
________________________________________________ Date: ___________________ 
Signature of Person Obtaining Consent 
 
Signature of Investigator:__________________________ Date: __________________ 
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My name is Paul Gavaza and I will be the moderator for this focus group session. The 
purpose of this focus group session is to identify the advantages, disadvantages of 
reporting ADEs, the factors that make it easier or difficult to report ADEs and the 
individuals or groups who would or would not approve pharmacists reporting ADEs. The 
information obtained from this focus group session will be used to develop a survey 
instrument that will be administered to a larger group of Texas pharmacists.  
 
This session will be audio (tape) recorded. However, no names will be used for any 
portion of the larger study. Information obtained from this focus session will not be 
associated with any specific focus group participant. The audio recording of the focus 
group session ensures that all the important information is captured and available for 
inclusion in the survey instrument. The audio tapes will be stored in a locked file cabinet 
and will be used only by research personnel. This session is expected to last one to one 




As the moderator, I will ask the questions and keep everyone on track. I will keep track 
of time, and therefore, I may need to interrupt the discussion and move forward if I see 
we are getting short on time. It is important that everyone feels comfortable and easy 
going during the discussion. There are no right and wrong answers. Everyone‘s input is 




1. Briefly tell me what you think about when you think of the reporting of ADEs to 




1. What do you think are some of the advantages associated with pharmacists 
reporting ADEs to the FDA? 
 
2. What do you think are some of the disadvantages associated with pharmacists 
reporting ADEs to the FDA? 
 
3. Are there any other advantages and disadvantages associated with pharmacists 
reporting ADEs to the FDA? 
 
4. Are there any individuals or groups who would approve pharmacists reporting 
ADEs to the FDA? 
 
5. Are there any individuals or groups who would not approve pharmacists reporting 




6. Are there any other individuals or groups who would or would not approve 
pharmacists reporting ADEs to the FDA? 
 
7. What do you think would make it easier to report ADEs to the FDA? 
 
8. What do you think would make it difficult to report ADEs to the FDA? 
 









Survey Cover Letter 
 
Dear Pharmacist Colleague,  
 
You have been selected to participate in a state-wide research study entitled: Using the 
theory of planned behavior to predict Texas pharmacists‘ intention to report adverse drug 
events (ADEs). As you may be aware, the Food and Drug Administration allows you as a 
pharmacist to report ADEs that you come across through MedWatch. To date, no 
research has focused on how Texas pharmacists‘ beliefs and attitudes toward ADE 
reporting relate to their intent to report ADEs. This questionnaire is part of a dissertation 
research project being conducted in the Division of Pharmacy Administration at The 
University of Texas at Austin. This study questionnaire measures your attitudes and 
beliefs about ADE reporting. Your responses to the study questionnaire will be a great 
help to us in improving our understanding of what factors help explain ADE reporting.  
 
Because you are one of a small group of people randomly selected for this study, we hope 
that you will participate so that our results will be a good representation of the entire 
population of Texas pharmacists. Your decision to participate or not will not affect your 
present or future relationship with The University of Texas at Austin. Although 
participation is voluntary, we feel that it is important that you make yourself heard on an 
issue that may affect your practice.  
 
The survey takes approximately 10 minutes to complete. All your responses will be kept 
confidential and the records of this study will be stored securely. Reponses will only be 
reported in aggregated form and results can in no way be linked to you. Completing the 
mail survey will serve as your consent to participate in the study. After completing the 
survey, please fold it with the business reply on the outside, secure it with tape, and mail 
it back to us by May 28, 2009. No postage is necessary.  
 
If you have any questions, please do not hesitate to contact us by phone at (512) 961-
1692 and (512) 471-2374 or e-mail pgavaza@mail.utexas.edu and 
cmbrown@mail.utexas.edu. If you have questions about your rights as a research 
participant, complaints, concerns, or questions about the research please contact Jody 
Jensen, Ph.D., Chair, The University of Texas at Austin Institutional Review Board for 
the Protection of Human Subjects at (512) 232-2685 or the Office of Research Support at 
(512) 471-8871 or email: orsc@uts.cc.utexas.edu. Thank you in advance for your time 
and cooperation in participating in this important study.  
 
Sincerely, 
     
Paul Gavaza, M.S.    Carolyn M. Brown, R.Ph., Ph.D. 
Ph.D. Candidate    Professor and Dissertation Advisor 




Follow up Cover Letter 
 
Dear Pharmacist Colleague,  
 
About three weeks ago, you were contacted regarding a questionnaire asking about your 
perceptions and attitudes toward ADE reporting. If you have already completed the 
questionnaire, please accept our sincere thanks. If you have not yet completed the 
questionnaire, we kindly ask for your assistance by completing it as soon as possible. 
 
Again, this questionnaire is part of a dissertation research project being conducted in the 
Division of Pharmacy Administration at The University of Texas at Austin. This study 
questionnaire measures your attitudes and beliefs about ADE reporting. Your responses 
to the study questionnaire will be a great help to us in improving our understanding of 
what factors help explain ADE reporting. Because you are one of a small group of people 
randomly selected for this study, we hope that you will participate so that our results will 
be a good representation of the entire population of Texas pharmacists. Your decision to 
participate or not will not affect your present or future relationship with The University of 
Texas at Austin. Although participation is voluntary, we feel that it is important that you 
make yourself heard on an issue that may affect your practice.  
 
The survey takes approximately 10 minutes to complete. All your responses will be kept 
confidential and the records of this study will be stored securely. Reponses will only be 
reported in aggregated form and results can in no way be linked to you. Completing the 
mail survey will serve as your consent to participate in the study. After completing the 
survey, please fold it with the business reply on the outside, secure it with tape, and mail 
it back to us by July 6, 2009. No postage is necessary.  
 
If you have any questions, please do not hesitate to contact us by phone at (512) 758-
1845 and (512) 471-2374 or e-mail pgavaza@mail.utexas.edu and 
cmbrown@mail.utexas.edu.  If you have questions about your rights as a research 
participant, complaints, concerns, or questions about the research please contact Jody 
Jensen, Ph.D., Chair, The University of Texas at Austin Institutional Review Board for 
the Protection of Human Subjects at (512) 232-2685 or the Office of Research Support at 
(512) 471-8871 or email: orsc@uts.cc.utexas.edu. Thank you in advance for your time 




     
Paul Gavaza, M.S.    Carolyn M. Brown, R.Ph., Ph.D. 
Ph.D. Candidate    Professor and Dissertation Advisor 
Pharmacy Administration Division  Pharmacy Administration Division 
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Figure G.1: Histogram of Standardized Residual from Regression of TPB Direct 
Measures Constructs 
 
Figure G.2: Histogram of Standardized Residual from Regression of TPB Indirect 
Measures Constructs 
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Figure H.1: Normal P-P Plot of Regression Standardized Residuals—Direct Measures 
 
















































Figure I.1: Scatter Plots of Residuals for the TPB Direct Measures 
 





































































PARTIAL REGRESSION PLOTS FOR DIRECT TPB MEASURES 
 




















Dependent Variable: Intention 
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Figure J.3: Partial Regression Plot for Intention and Direct Measure PBC  
 


















Partial Regression Plot: Intention vs. Perceived Moral Obligation
Dependent Variable: Intention
















Dependent Variable: Intention 
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PARTIAL REGRESSION PLOTS FOR INDIRECT TPB MEASURES 




















Dependent Variable: Intention 
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Partial Regression Plot: Intention vs. Perceived Moral Obligation
Dependent Variable: Intention
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